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I.Introduction 
I.A. Malaria 
I.A.1. Prevalence and Progress 
In 2010, 3.3 billion people worldwide were at risk of malaria according to the World Health 
Organization’s (WHO) estimations. There were 216 million cases of malaria, 81% of them were found 
in Africa. An estimated 655 000 people, of which 86% were children under 5 years old, died of 
malaria in 2010. Generally, 91% of malaria deaths occurred in Africa1.  
Table I.1: Estimated malaria cases and deaths by WHO Region, 20101 
Region Estimated Cases Estimated Deaths 
Africa 174 million 596 000 
Americas 1 million 1 000 
Eastern Mediterranean 10 million 15 000 
Europe 2 000 0 
South-East Asia 28 million 38 000 
Western Pacific 2 million 5 000 
 
Still according to the WHO, malaria mortality rates are declining: a 5% reduction was seen 
between 2010 (655 000 malaria deaths) and 2009 (691 000 malaria deaths). During the last decade, 
malaria mortality rates have fallen by more than 25%, with the largest reductions seen in the 
European (99%), American (55%) and Western Pacific (42%) and African Regions (33%)1. 
Important factors that mediated this trend are the increased availability of longlasting insecticidal 
nets, indoor residual spraying, and better access to diagnostic testing and effective treatment with 
artemisinin-based combination therapies (ACTs). In sub-Saharan Africa, improvements in the socio-
economic situation in many countries have contributed to the decreased number of deaths among 
children under 5 from all causes, including malaria1. Although this represents a nice progress, 
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mortality numbers are still disturbingly high bearing in mind that malaria is entirely preventable and 
treatable. 
I.A.2. Plasmodium 
Malaria is a life-threatening tropical disease caused in humans by four species of the genus 
Plasmodium, namely: 
P. falciparum which causes malaria tropica 
P. malariae which causes malaria tertiana 
P. ovale which causes malaria quartana 
P. vivax which causes malaria tertiana 
Of highest relevance are P. falciparum for it causes the highest mortality rates, and P. vivax for its 
ability to form dormant liver stages (hypnozoites) in infected patients. Plasmodium species belong to 
the phylum apicomplexa: eukaryotic unicellular organisms (protists) named after their apical 
complex or apicoplast, an intracellular structure required for invasion of host cells which is composed 
of cytoskeletal elements combined with specific secretory organelles. Almost all apicomplexan 
parasites bear a unique apicomplexan plastid that has no photosynthetic function. This apicoplast 
was most probably acquired through secondary endosymbiosis of a plastid-containing red alga and is 
consequently surrounded by four membranes: two ‘inner’ membranes from the initial plastid 
envelope, a periplastid membrane originating from the plasma membrane of the engulfed alga and 
an outer membrane formed by the initial phagotrophic membrane. This is important because a 
number of targets for antimalarial drugs are located inside the apicoplast, drugs that therefore have 
to cross many membrane barriers before reaching their target2. 
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Illustration I.1: Apicoplast of P. falciparum: a relict nonphotosynthetic plastid involved in 
essential metabolic functions. (A) Schematic drawing of P. falciparum, a unicellular 
eukaryote belonging to the Apicomplexa phylum, showing the  three DNA-containing 
organelles, i.e., the nucleus, the mitochondrion, and the apicoplast. (B) Electron microscopic 
image showing the location of the apicoplast in P. falciparum. The apicoplast is basically a 
plastid (Pl) surrounded by four membranes (arrow). (C) Four major biosynthetic pathways 
located in the apicoplast: a fatty acid synthesis pathway (FASII), the nonmevalonate pathway 
or DOXP pathway (see below), a heme synthesis pathway, and an iron/sulfur (FeS) cluster 
synthesis pathway. The apicoplast possesses a 35 kilobase genomic DNA which is replicated, 
transcribed into RNA, and translated into proteins via its own machineries of prokaryotic 
origin. Figure from: Chemical Reviews (2012), 112, 1269–1283 
 
The vector for malaria transmission is the female Anopheles mosquito, which transmits the parasites 
by biting humans in search of a blood meal. In the gut of the mosquito, Plasmodium undergoes its 
sexual reproductive cycle, whereas in the mammalian host it undergoes cycles of asexual divisions 
known as schizogony. These cycles, which take place first in the liver cells but in a later stage 
continue in the red blood cells, cause the often deadly symptoms of malaria3. 
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I.A.3. Current therapies 
In general, for malaria prophylaxis established drugs from the quinine family (quinine, 
chloroquine, mefloquine, halofantrine) are still of frequent use. Also atovaquone (an inhibitor of the 
mitochondrial electron transport) combined with proguanil (an antifolate), or the antibiotic doxycylin 
are mainstream malaria prophylactics4. 
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Figure I.1: Mainstream antimalarials (and their target, in parentheses) used for 
prophylaxis and therapy 
 
Concerning the treatment of malaria infections, on the other hand, chemotherapy should never 
be based on the same drugs the patient used for prophylaxis before he got infected. Nowadays, 
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artemisinin-based combination therapies (ACTs) are recommended as the first-line treatment for 
malaria caused by P. falciparum, but they are also in use for infections by other Plasmodium species. 
For uncomplicated falciparum malaria, the following combinations are used: artemether-
lumefantrine, atovaquone-proguanil or quinine plus doxycycline or clindamycin. For vivax malaria, 
radical cure (treatment of both blood and liver stages, preventing recrudescence and relapse) is 
obtained with chloroquine-primaquine. In case of chloroquine resistance, amodiaquine-primaquine 
or lumefantrine plus quinine or artemether are used. In mixed infections (falciparum-vivax), 
treatment of the P. falciparum malaria will usually also cure the vivax part. Primaquine is added to 
achieve radical cure (see above)4. In 2010, 181 million courses of ACTs were procured worldwide in 
the public sector, up from 158 million in 2009, and just 11 million in 20051. 
I.A.4. Resistance 
Continuous exposure of a Plasmodium parasite population to a drug may lead to the 
development of resistance against that drug through natural selection, but it may also cause the 
selection of genetic traits that favor initiation of resistance to novel, unrelated antimalarials5. Several 
factors are of importance in the acquisition of drug resistance: 
• Mechanism of action: resistance can be generated by a single mutation in the case of drugs 
which act against a single target, such as an enzyme (monogenetic resistance); 
• Pharmacokinetics: when low plasma concentrations of an antimalarial are present, parasites 
are not killed, although selective pressure will result in the selection of resistant parasite strains6; 
• Drug efficiency: if a drug is not sufficiently effective, it will leave a surviving part of the 
parasite population behind, thus stimulating the development of resistance; 
• Population immunity: antimalarial chemotherapy may be more efficient in populations with a 
high immune response, because the opportunity for the parasite to spread and infect the host is 
decreased. 
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Of all Plasmodium species, P. falciparum shows the highest potential to develop (multi)drug 
resistance7. The first case of resistance was discovered around 1910 for quinine, and resistance 
against almost all mainstream antimalarials has emerged since then with an increasing speed: 
whereas the quinine resistance took 280 years to develop, resistance against artemisinin was already 
reported a few years after its introduction. 
Table I.2: Chronology of resistance against common antimalarials 
Antimalarial Introduced in First case of resistance 
Quinine 1632 1910 
Chloroquine 1945 1957 
Proguanil 1948 1949 
Sulfadoxine-Pyrimethamine 1967 1967 
Mefloquine 1977 1982 
Atovaquone 1996 1996 
 
Because of the importance of ACTs as first-line therapy for uncomplicated P. falciparum malaria8, 
9, development of resistance against artemisinin is a major concern. It was first confirmed on the 
Cambodia-Thailand border in 2009 but is now suspected in parts of Myanmar and Vietnam as well. 
Fortunately, ACTs remain effective in most settings as long as the combination partner drug is 
effective. 
Ongoing efforts by the WHO to limit the spread of artemisinin-resistant parasites by means of 
containment zones has resulted in a strongly diminished falciparum malaria burden within these 
zones. However, the proportion of patients with resistant parasites has increased. Therefore, it is 
necessary to eliminate all parasites in areas with documented resistance, an endeavor for which the 
WHO started the Global Plan for Artemisinin Resistance Containment (GPARC) in 2010. Additionally, 
the marketing of oral artemisinin-based monotherapies, which has been one of the major causes of 
emerging drug resistance, is discouraged1. 
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I.A.5. Vaccine  
An effective vaccine against malaria has long been envisaged as a valuable addition to the 
available tools for malaria control, although there are some important issues concerning the 
development of such a vaccine. First of all, it takes about 5 years for children in endemic areas to 
develop full immunity against malaria. Hence the high mortality rate for malaria in children under 5. 
Furthermore, this immunity seems to disappear over time, suggesting that a continuous exposure to 
the parasite is necessary in order to keep the immunity at a high level. Immunity against Plasmodium 
can thus be considered incomplete, making lifelong protection hard to realize. Nevertheless, malaria 
vaccines have been the subject of intensive research over the past years10-17. The WHO declared that, 
if the development of a vaccine that prevents malaria infection would prove unrealistic, the concept 
of a vaccine that could interrupt malaria transmission is also of interest1. 
There are currently no licensed malaria vaccines but over 20 research projects are in clinical trials. 
The most advanced of these is a vaccine called RTS,S/AS01 developed by a GlaxoSmithKline 
partnership, which is currently in Phase 3 clinical trials and at least 5-10 years ahead of other 
candidate malaria vaccines18-20. It is a P. falciparum vaccine, with no protection expected against P. 
vivax. Phase 3 trial results are still being collected, but in the first interim report an efficacy of 55% 
reduction in frequency of malaria episodes during the 12 months follow-up was communicated. 
I.A.6. The Need for New Antimalarials Acting onto New Targets  
Several reasons for the development of new antimalarials can be recited. 
First of all there is the issue of resistance against virtually all antimalarials currently in clinical use as 
described above. Secondly, most –if not all- of nowadays antimalarials show a significant toxicity, 
translating in sometimes severe adverse effects while they often have to be used in pregnant women 
and young children. Furthermore, with ACTs being todays number one treatment choice, the price of 
antimalarial treatment has also become an issue as artemisinin, a natural product of limited supply, is 
quite expensive. As also stated above, a vaccine offering broad spectrum and long term protection 
against malaria is not to be expected soon. Besides all this, there is already a need to extend the 
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portfolio of antimalarial drugs for the treatment of pregnant women and in regions of multidrug 
resistance21. All these reasons underscore the importance of antimalarial chemotherapy and the 
continuing need of research for new classes of antimalarial agents. 
New drug candidates that are based on line-extension of already used antimalarials risk the fast 
induction of resistance through their lack of structural diversity with their predecessors, or by 
targeting the same enzyme or pathway.21 Hence the need for new drugs that are structurally 
unrelated to drugs used before, in order to avoid fast development of resistance. This might imply 
also drugs acting against new, unsourced, targets. In general an ideal antimalarial should have the 
following PK/PD properties: 
 good bioavailability to cure sufficient parasite exposure, preferably also after oral 
administration in order to facilitate use in non-hospital settings; 
 low inter-individual pharmacokinetic variability; 
 well tolerated by the patient, low toxicity; 
 a pharmacokinetic profile which allows for shorter duration of treatment with fewer 
doses (a 3-day maximum therapy for cure with once or twice a day dosing is desirable for 
concern about patient compliance); 
 predictable pharmacokinetic profile such that the drug is retained for sufficient length of 
time (adequately long half-life) to ensure that it kills the parasites, but does not 
accumulate to any extent to cause damage to the host22. 
Concerning the half-life of antimalarials, two issues are important. On the one hand, 
antimalarials with a long half-life are useful for chemoprophylaxis since longer maintained plasma 
levels allow for longer dosage intervals, and for directly observed chemotherapy (with observed 
compliance). However, they are also particularly vulnerable to the development of resistance as they 
  Chapter I: Introduction 
I.9 
 
may produce subtherapeutic plasma levels for significant periods of time, thus providing selection 
pressure. Drugs with a short half-life, on the other hand, will not pose such problems of inducing 
resistance but these need frequent administration, thus creating the risk of low compliance23-30. In 
general, antimalarials for treatment in endemic areas are preferred to have a short plasma half-life26, 
31. 
Over the past few years, considerable efforts have also been made through public-private 
partnerships, resulting in the progression of several drugs and drug combinations to various stages of 
clinical development3. The development of new antimalarials has unfortunately been of very low 
interest to the pharmaceutical industry due to the increased costs of developing and registering of 
pharmaceuticals, combined with the prospect of low commercial returns.21  Currently, mainly 
academic groups have identified a large number of potentially new targets, and target validation, 
drug discovery and lead optimization are in progress3.  
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I.B. The Non-Mevalonate Pathway 
I.B.1. Isoprenoids 
Isoprenoids form the largest class of natural products with more than 35000 compounds known 
so far, comprising a heterogeneous group of biologically important primary and secondary 
metabolites32. They are found in all living organisms33, 34 where they carry out vital biological 
functions such as: modulation of membrane properties in archaebacteria35, eubacteria and 
eukaryotes36, electron transport carriers (e.g. ubiquinone)37, light harvesting and photoprotection 
(carotenoids, chlorophyll side chains), growth and development regulation (steroid hormones, 
cytokinins)38, signal transduction (prenylation of proteins)39, but also pollination, seed dispersion and 
repelling of herbivores (toxins) in plants40, 41. In contrast to their huge diversity, all isoprenoids are 
formed from the same two common five-carbon building blocks isopentenyl diphosphate (IPP) and 
its isomer dimethylallyl diphosphate (DMAPP) as described by Ruzicka’s isoprene rule42, 43. Until the 
late 1980’s it was believed that in all organisms IPP and DMAPP were formed exclusively by the 
mevalonate pathway that was known since the early 1950s44-46. The mevalonate pathway, as 
depicted in scheme I.1, starts with the condensation of two molecules of acetyl-CoA to form 
acetoacetyl-CoA, which is then converted to 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA). In the next 
step, HMG-CoA is reduced to mevalonic acid (MVA) by HMG-CoA reductase, an extensively studied 
key enzyme in this pathway47 and also the target of the statins, a class of human cholesterol-reducing 
drugs. Subsequently, MVA undergoes two phosphorylation steps, yielding mevalonic-5-diphosphate 
(MVA-PP), which is finally converted by an ATP-dependent decarboxylation into IPP. IPP and its 
isomer DMAPP are interconverted by IPP isomerase48. 
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Scheme I.1: Mevalonate versus Non-mevalonate Pathway 
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I.B.2. The Non-Mevalonate Pathway as a Drug Target 
In the early 1990’s the groups of Arigoni and Rohmer independently established the existence of 
a second pathway for the biosynthesis of isoprenoid building blocks, starting from the triose pool of 
intermediary metabolism49. The history of the discovery of this so-called non-mevalonate pathway 
has been reviewed50. The pathway is also known as the 1-deoxy-D-xylulose-5-phosphate (DOXP) 
pathway, the Rohmer pathway or the 2C-methyl-D-erythritol-4-phosphate (MEP) pathway48 and 
comprises seven enzymatic steps as depicted in Scheme I.1. First, glyceraldehyde-3-phosphate is 
condensed with pyruvate in a transketolase-type reaction catalyzed by DOXP synthase (DXS) to 
produce DOXP51. Next, DOXP is transformed into MEP by DOXP-reductoisomerase (DXR, IspC) in a 
single step comprising an intramolecular rearrangement and an NADPH-mediated reduction52. The 
mechanism of this step is still a matter of debate and will be handled in more detail below, but 
nevertheless it is also the most relevant and most studied step of the non-mevalonate pathway. In 
the following step, MEP is transformed into 4-diphosphocytidyl-2C-methyl-D-erythritol or CDP-ME by 
the CTP-dependent action of CDP-ME synthase (YgbP, IspD)53. CDP-ME is then phosphorylated at the 
2-hydroxy position by CDP-ME kinase (YchB, IspE), using ATP as a cofactor with the formation of 4-
diphosphocytidyl-2C-methyl-D-erythritol-2-phosphate (CDP-ME2P)54. This CDP-ME2P is converted by 
MECP synthase (YgbB, IspF) into 2-C-methyl-D-erythritol-2,4-cyclodiphosphate (MECP) using CTP as a 
cofactor55, and then transformed into 1-hydroxy-2-methyl-2-(E)-butenyl-4-diphosphate (HMBPP) by 
HMBPP synthase (GcpE, IspG)56, 57. Finally, HMBPP reductase (IPP/DMAPP synthase, LytB, IspH) 
catalyzes the conversion of HMBPP into a mixture of IPP and DMAPP58. HMBPP synthase seemingly 
replicates the activity of IPP isomerase from the mevalonate pathway59. 
The mevalonate pathway is the only pathway for isoprenoid biosynthesis in mammals. It is also 
present in the cytoplasm of higher plants and in some bacteria. The non-mevalonate pathway, on the 
other hand, is present in the chloroplast of plants and is found widespread in bacteria, sometimes 
together with the mevalonate pathway60, 61. In some important pathogenic bacteria, and also in 
Mycobacterium tuberculosis and in Plasmodium (where it is located in the apicoplast), it is the only 
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biosynthetic route to vital isoprenoids48. Together with the fact that all enzymes of the non-
mevalonate pathway are absent in humans (as well as in yeasts and funghi), this makes it an 
interesting target for antimalarial drugs48. 
I.B.3. DXR  
I.B.3.a. Structure 
As stated above, DXR is currently the most studied62 and also clinically the most relevant enzyme 
of the non-mevalonate pathway. Several NMR- and X-ray studies have been conducted to unravel its 
structure and function63-70. Most of these studies are performed on the E. coli isozyme67, 69-71 for it is 
easier to handle than, for instance, the Plasmodium isozyme. Fortunately, X-ray structures of both 
the M. tuberculosis65, 66 as well as the P. falciparum72 isozymes have been published, the latter both 
in the absence and in the presence of fosmidomycin, the lead structure for DXR inhibitor 
development (see below). PfDXR, in its active form (that is: Lys75 to Ser488), is a homodimer with an 
approximate mass of 47 kDa consisting of two subunits that each contain an NADPH molecule and a 
divalent metal cation (usually Mg2+, Mn2+ or Co2+). The overall structure of PfDXR is essentially similar 
to those of DXRs from other species63, 66-73. Each DXR subunit consists of two large domains separated 
by a cleft containing a deep pocket, a linker region and a small C-terminal domain. One of the large 
domains holds the groups necessary for catalysis (metal and substrate binding, residues 231 to 369) 
while the other one (residues 77 to 230) is involved in the binding of NADPH. The catalytic domain is 
an α/β-type structure consisting of five α-helices and four β-strands in which a crevice is found with 
the bound divalent metal cation at the bottom. A phosphate binding site is also present, relying 
mostly on H-bridge interactions with serine, asparagine and lysine residues. Upon binding of the 
substrate or an inhibitor, the enzyme undergoes an induced fit and the active site is covered by a 
flexible loop. This flexible loop complicates the acquisition of representative X-ray structures and 
thus DXR ligand design. 
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I.B.3.B. Function 
DXR catalyzes the second step in the non-mevalonate pathway: the conversion of DOXP into 
MEP, consisting of an isomerization followed by an NADPH-mediated reduction. Two mechanisms 
have been proposed for the isomerization step: a stepwise fragmentation-reassembly via retro-
aldol/aldol-mechanism or a concerted α-ketol rearrangement (Figure I.2)74-78. 
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Figure I.2: Two alternative mechanisms for the isomerization of DOXP in DXR 
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 The retro-aldol/aldol mechanism involves the cleavage of the C3-C4 bond in DOXP with the 
formation of two intermediates: glycolaldehyde and hydroxyacetone. So far, the involvement of 
neither of these intermediates in the reaction could be proven, so the logical conclusion would be 
that the isomerization goes via the α-ketol rearrangement75. On the other hand, experiments based 
on the kinetic isotope effect support the retro-aldol/aldol route76, 77. Support for this mechanism has 
also been gathered by Fox and Poulter79 and by the group of Liu80 by using fluorinated substrate 
analogues. After the aldehyde intermediate is formed by isomerization, it is reduced by transfer of 
the pro-S hydride ion of NADPH to its RE face. 
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I.C. Fosmidomycin 
I.C.1. Fosmidomycin as a DXR Inhibitor 
Fosmidomycin, also known as FR31564 or 3-(N-formyl-N-hydroxyamino)propylphosphonic acid, 
was discovered in the late 1970s by Fujisawa Company as a natural antibiotic from Streptomyces 
lavendulae together with its congeners FR900098 (the N-acetyl congener of fosmidomycin), FR33289 
(the β-OH congener of FR900098) and FR32863 or α,β-unsaturated fosmidomycin81-84. In many 
assays, FR900098 has shown to be more potent than fosmidomycin and these two analogues are the 
most studied ones of this series. 
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Figure I.3: Structures of fosmidomycin congeners originally discovered by Fujisawa 
Company 
 
 Fosmidomycin was also found to show herbicidal activity. After its discovery it was tested in a 
Phase II clinical trial for the treatment of urinary tract infections but due to the availability of more 
potent antibiotics at that time, further development of fosmidomycin and its congeners was 
discontinued. In 1998, Kuzuyama et al. identified fosmidomycin as a putative pathway-specific 
inhibitor that was active against most Gram-negative and some Gram-positive bacteria through a 
database search to identify specific inhibitors of the non-mevalonate pathway. Further work then 
showed that fosmidomycin was an astonishingly non-toxic specific inhibitor of DXR78, 85. In an in vitro 
experiment, fosmidomycin inhibited purified recombinant EcDXR in a dose-dependent manner with 
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an IC50 of 8.2 nM
78. Furthermore, the inhibitory effect of fosmidomycin in an E. coli growth assay was 
overcome by the addition of 2-C-methylerythritol (the free alcohol of MEP). These results, together 
with studies of isoprenoid biosynthesis in plants, led to the conclusion that fosmidomycin is a specific 
inhibitor of DXR activity56, 85. 
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Figure I.4: Structure and binding analogy between DOXP and Fosmidomycin/FR900098 
 
X-ray crystal structures of DXR-metal-fosmidomycin/FR900098 complexes with both EcDXR73 and 
PfDXR72 as well as MtDXR65 reveal a substrate-like binding mode of the inhibitor: the phosphonate 
functionality occupies the phosphate binding site, while the hydroxamate chelates the catalytic 
divalent cation. The three-carbon spacer interacts with a methionine residue and is covered by the 
indole ring of a tryptophane residue of the flexible loop. In EcDXR, the phosphonate forms hydrogen 
bonds to Ser185, Ser221 and Lys227. The three-carbon spacer interacts with Met213, while the 
hydroxamate chelates the catalytic divalent cation that is bound by residues Asp149, Glu151 and 
Glu230 (Diagram I.1). 
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Diagram I.1: Simplified diagram of Fosmidomycin (“Fom 1001”) binding to EcDXR86 
 
 
Diagram I.2: Fosmidomycin complex with PfDXR. The carbon atoms of fosmidomycin, the 
four buried water molecules, and the bound Mg2+ ion are shown in yellow, cyan, and green, 
respectively. Figure from Scientific Reports 2011, 1. 
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In PfDXR, the phosphonate is anchored in the phosphate binding site by a hydrogen bond 
network with Ser270, Asn311, two water molecules and His293. The three-carbon spacer lies parallel 
to the indole ring of Trp296 and also interacts with Met298, while the hydroxamate chelates the 
catalytic divalent cation that is bound by residues Asp231, Glu233 and Glu31572(Diagram I.2). It is 
necessary that both oxygen atoms of the retrohydroxamate functionality adopt a cis (Z) 
conformation. Fosmidomycin has been described both as a mixed-type inhibitor (both competitive 
and non-competitive)56 and as a slow, tight-binding competitive inhibitor of DXR67.  
I.C.2. Fosmidomycin as an Antimalarial 
In 1999, Jomaa et al. showed that fosmidomycin and its acetyl congener FR900098 inhibit PfDXR 
in a dose-dependent manner. They also revealed its in vitro antimalarial effect on P. falciparum 
infected erythrocytes as well as its in vivo effect in P. berghei infected mice. Furthermore, they 
provided evidence for the presence of the non-mevalonate pathway in the apicoplast of 
P. falciparum, thus opening the way for the use and development of fosmidomycin as an 
antimalarial87. Shortly after, fosmidomycin was tested in humans and cured uncomplicated 
P. falciparum malaria88, 89 , albeit with a high rate of recrudescence. This precluded its use in 
monotherapy, leading to the successful combination with clindamycin90, 91 or artesunate92. 
The major advantage of fosmidomycin/FR900098 is its very low toxicity, and also its low serum half-
life93 (see I.A.6.). The latter can be seen both as an advantage and as a disadvantage as described 
above. Unfortunately, both compounds also show poor oral bioavailability of around 20-40%, 
probably due to the very polar nature of both the phosphonic acid and the retrohydroxamate 
structure94. 
Although fosmidomycin shows a very attractive antimalarial potential, acting on a new, hitherto 
unsourced target, it certainly also has some shortcomings. Optimization efforts directed at improving 
fosmidomycin’s potency as well as reducing its polarity could lead to new, promising antimalarials. 
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I.D. SAR of Fosmidomycin Analogues 
Since the potential of inhibitors of the non-mevalonate pathway as new antimicrobial or 
antiparasitic drugs became clear61, 95, and Kuzuyama et al. identified fosmidomycin as a DXR 
inhibitor78 a lot of research has been dedicated to the structural modification of this lead in search of 
more potent antibacterial and herbicidal96 analogues. The establishment of fosmidomycin as an 
antimalarial by Jomaa et al.87 gave this research a new twist and since then, many fosmidomycin 
analogues have been synthesized and tested specifically for their antiplasmodial properties. Here, we 
will give an overview of the structural modifications of fosmidomycin that have been published and 
try to derive some structure-(antimalarial) activity relationship. Generally, fosmidomycines are 
evaluated in three different ways: in vitro enzyme kinetics, in vitro Plasmodium growth inhibition and 
in vivo experiments in mice infected with P.berghei. The former method is applied on different 
enzymes, usually EcDXR or (recombinant) PfDXR but also Synechocystis-DXR. Moreover, inhibitory 
activities are reported in various ways: as percentual inhibition for a given concentration of inhibitor, 
as a Ki-value or as an IC50-value. Because fosmidomycin, and expectedly also its structural analogues, 
are slow tight-binding inhibitors of DXR, measured DXR inhibition values (Ki’s) may vary strongly 
depending on whether the inhibitor was added to an enzyme-substrate mixture or rather was pre-
equilibrated with DXR before addition of substrate and activity measurement. Often it is not clearly 
mentioned which conditions were applied. Moreover, also the concentration of enzyme, substrate 
and inhibitor used in testing can significantly influence measured Ki values, thus complicating the 
comparison of Ki values measured by different groups or in different experiments
97. Concerning the 
in vitro Plasmodium growth inhibition: large variability in measured results is often seen, due to the 
use of different strains of P. falciparum for this test. Depending on the origin of the strain used, its 
sensitivity for different antimalarials, hence also the tested ones, may vary significantly. Finally, also 
the communication of in vivo results is not unambiguous: percentage survival after certain time 
intervals, relative reduction in infected red blood cells or graphic representations of mice survival 
have all been used. 
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These facts make the strict comparison of activity among different groups of published fosmidomycin 
analogues a very ambiguous task. In the best case reported results include the activity of a reference 
substance (usually fosmidomycin and/or FR900098), but often they don’t. Therefore, we will restrict 
the next part to a description of trends in fosmidomycin SAR rather than trying to elaborate 
numerical data. More recently, also the search for antimycobacterial fosmidomycine analogues has 
received considerable interest98-102, although it seems that penetration of the mycobacterial cell wall 
by such polar compounds is still a major hurdle103. Note that in Plasmodium and some other species, 
so-called parasite-induced new permeability pathways appear to facilitate the uptake of these 
indeed very polar molecules104. Some trends in fosmidomycin SAR, albeit not strictly for antimalarial 
activity, can also be deduced from these data. 
Fosmidomycin is composed of three main structural parts: a phosphonic acid group, the three-
carbon spacer and the retrohydroxamate. The following review will divide modifications according to 
this structural division, and will focus mainly on modifications from a medicinal point of view. We will 
not include all substrate-, transition-state- and product-analogues that have been mainly synthesized 
as tools to unravel DXR’s mode of action. Although some of these analogues showed a moderate DXR 
inhibitory effect, most featured a phosphate functionality, precluding their use as drugs because of 
chemical and enzymatic instability. Therefore, these analogues will not separately be discussed but 
may be mentioned among other modifications where appropriate. 
 
I.D.1. Modifications of the phosphonate functionality 
The phosphonate functionality in fosmidomycin acts as an isostere for the phosphate group of 
DOXP (Phosphate isosteres are discussed in more detail in Chapter II), thus securing its binding in the 
phosphate binding site of DXR72. In many cases, enzyme phosphate binding sites are mainly 
composed of glycine residues without specific recognition motifs for the charged phosphate group105, 
106. Such binding sites can usually be targeted by neutral heterocyclic groups bearing suitable H-bond 
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acceptors. Unfortunately, as is described above, the phosphate binding site of DXR is formed by polar 
amino acid side chains (for EcDXR: Ser 186, Ser222, Asn227 and Lys22873) acting as H-bond donors 
and relies heavily on an H-bond network with the charged phosphate group acting as an acceptor. 
The presence of a phosphate or phosphonate group has thus turned out to be necessary for efficient 
binding to DXR. Nevertheless, numerous attempts have been made to omit the use of such an 
extremely polar group. Woo et al.107 synthesized the phosphate analogues of fosmidomycin and of 
FR900098, resp. 5 and 6 (Figure I.5). Both showed a significantly stronger DXR inhibition than 
fosmidomycin (Ki of 19nM (5) and 2nM (6) on Synechocystis DXR vs. 57nM for fosmidomycin). 
Fosmidomycin phosphate analogue 5 was known before as fosfoxacin108 and has antibiotic 
properties. 
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Figure I.5: Phosphate analogues of fosmidomycin and FR900098 
 
 While the phosphonate group provides a chemically and enzymatically stable alternative for the 
labile phosphate109, it is still a diprotic acidic group that makes the molecule extremely polar. Several 
research groups have therefore tried to exchange the phosphonate for less polar groups. Woo et 
al.107 switched the phosphonate in fosmidomycin for a carboxylic acid group (7), and the Rohmer 
group110 published the hydroxamate-carboxylic acid analogues 8 and 9. 
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Figure I.6: Carboxylic acid analogues of fosmidomycin 
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 All three analogues showed at least a 3000-fold decrease in DXR inhibition. This loss of effect 
was ascribed to the planar nature of the carboxylic acid group, which contrasts with the tetrahedral 
shape of the phosphonic acid group. In order to mimic this tetrahedral head group, three sulfonate 
analogues110, 111 (10-12), a series of (aryl)alkylsulfones111 (13a-f) and a series of 
(aryl)alkylsulfonamides111 (15a-e) were synthesized by the groups of Schlitzer, Rohmer and Proteau. 
Again, none of these analogues showed inhibitory potential when tested on EcDXR.  
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Figure I.7: Sulfonate-, sulfone-, sulfonamide- and mono-(aryl)alkylphosphonate 
analogues of fosmidomycin/FR900098 
 
In the same paper of the Schlitzer group111, a series of FR900098 analogues featuring a 
phosphonate mono(aryl)alkyl-ester is described (16a-h). Although these also showed a decrease in 
potency, it was less pronounced than in the former series and especially the phenethyl and 
naphthylethyl derivatives 16f-h showed in vitro growth inhibition of P. falciparum with an IC50 only 
about ten times higher than that of fosmidomycin. Uh et al.98 tested a number of FR900098 
dialkylphosphonate analogues, albeit only for their antibacterial and antimycobacterial potency, and 
found out that these showed hardly any activity at all. From these data we can conclude that the 
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diprotic phosphate or phosphonate functionality is essential for fosmidomycin analogues in order to 
bind to DXR. The introduction of phosphonate mono-esters yields a decrease in the otherwise high 
polarity of these analogues, but it comes at a price of losing potency111, that may be partly 
compensated by improved cellular uptake. 
I.D.1.a. Phosphonate Prodrugs 
An obvious way to overcome the high polarity of phosphonates, and the consequent low cell 
permeability, is to convert them into prodrugs112. This is done by attaching lipophilic, chemically 
and/or enzymatically labile groups to the phosphonate. The lipophilic prodrug can then more easily 
cross membrane barriers before these groups are cleaved, preferably inside the target organism, by 
spontaneous or enzymatic hydrolysis. 
A first implementation of this strategy to FR900098 was published by Reichenberg et al.113, who 
synthesized the three different phenolic phosphonate esters depicted in Figure I.8. 
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Figure I.8: Diaryl phosphonate prodrugs 
 
 Their activity was tested in P.vinckei infected mice. Diphenylphosphonate 17 proved to be more 
active than FR900098, whereas the bis(o-tolyl)-ester 18 was less active. These prodrugs are expected 
to be hydrolyzed by non-specific esterases and probably the o-methyl substituents caused too much 
sterical hindrance for this to occur. Bis-(p-methoxyphenyl)-ester 19 showed the highest activity of the 
three analogues, equaling the potency of i.p. FR900098. Because of the high doses needed in 
fosmidomycin therapies and the toxicity of phenol, this strategy was not pursued. 
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A different kind of prodrugs was proposed by Ortmann et al.114, 115, who published a series of 
acyloxyalkyl and alkyloxycarbonyloxyalkyl-esters of FR900098, including the two ‘mono-prodrugs’ 
20k and 20l (Figure I.9).  
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Figure I.9: Acyloxyalkyl- and alkyloxycarbonyloxyalkyl-ester prodrugs of FR900098 
 
Except for these ‘mono-prodrugs’, all compounds showed good antimalarial activity when tested 
in P.berghei infected mice, surpassing FR900098’s activity. Since this discovery the group of Kurz has 
often reported bis(pivaloyloxymethyl)-ester (“bis-POM”) prodrugs of fosmidomycin analogues116-119 
(in later papers, the free phosphonates are also evaluated120, 121). While this strategy usually results in 
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an enhanced potency, it also precludes the in vitro testing of such analogues for their DXR inhibitory 
potency. Other groups prefer to first assess the enzyme kinetics of fosmidomycin analogues in their 
free acid form and only synthesize prodrugs of the most promising inhibitors afterwards. Anyhow, 
both lines of thought have their pro’s and con’s, but the presence of both strategies in literature 
often complicates the deduction of trends in fosmidomycin SAR. 
I.D.2. Modifications of the retrohydroxamate functionality 
Being an extremely efficient metal chelator, the retrohydroxamate coordinates the divalent 
metal cation (Mg2+, Mn2+ or Co2+) in the active site of the enzyme similarly as the β-hydroxyketone 
moiety in DOXP. This ion is bound in the Plasmodium isozyme by residues Asp231, Glu233 and 
Glu315 and has a distorted trigonal bipyramidal geometry72 (for the E. coli isozyme, Behrendt et al.121 
report an octahedral coordination). The equatorial ligands are: the side chains of Asp231 and Glu233 
together with the N-hydroxyl oxygen of the retrohydroxamate, while the axial ligands are the side 
chain of Glu315 and the carbonyl oxygen of the retrohydroxamate72. It is thus necessary that the 
carbonyl oxygen and the N-OH of the retrohydroxamate adopt a cis-conformation, as is discussed in 
detail in Chapter III. 
I.D.2.a. Necessity of the N-OH group 
From the above, one could infer that an intact retrohydroxamate is necessary for a strong 
interaction of fosmidomycin analogues with DXR. This statement has been corroborated by a vast 
amount of experimental data. Mercklé et al.97 tested the inhibition of EcDXR by propylphosphonate 
21, aminopropylphosphonate 22  and 3-acetamidopropylphosphonate 23 (Figure I.10), which can be 
seen as three fosmidomycin analogues in which the retrohydroxamate has been deconstructed to a 
decreasing extent.  
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Figure I.10: Fosmidomycin analogues with absent or partial retrohydroxamate 
 
Although all three molecules inhibited EcDXR by at least a factor 106 weaker than fosmidomycin, 
surprisingly the primary amine analogue showed the strongest potency of the three. A series of 3-
amidopropylphosphonates (24, Figure I.11) bearing different N-acylsubstituents was synthesized by 
Giessmann et al.105, but none of those showed a detectable DXR inhibition when tested up to 30µM, 
indicating the importance of the N-OH group for DXR inhibition.  
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Figure I.11: Amide analogues of fosmidomycin 
 
This assumption was further proven by Woo et al.107 who synthesized molecules 25 and 26, the 
analogues of fosmidomycin resp. FR900098 in which the N-OH is replaced by an N-Me group, again at 
the cost of all potency.  
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Figure I.12: Dialkylamide fosmidomycin analogues and α-phenyl-substituted amide 
analogue 
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One exception to this “N-OH necessity” was seen in α-phenyl-amidopropylphosphonate 27, 
which was formed as a by-product in the synthesis of α-phenylfosmidomycin by Timothy Haemers122. 
This byproduct was tested for EcDXR-inhibition together with the succeeded products and showed an 
IC50 of 2.39µM, compared to 0.030µM for fosmidomycin and 0.31µM for the corresponding N-acetyl 
retrohydroxamate (51a). More importantly though, when tested for growth inhibition of  the 
chloroquine-sensitive P. falciparum 3D7-strain, it showed an IC50 of only 2.0µM compared to 1.1µM 
for fosmidomycin. Possibly the potency displayed by 27 is an indication that amides may replace the 
retrohydroxamate functionality. Possibly, the lower polarity of the amide compared to the 
retrohydroxamate counterpart leads to a better uptake into the parasite. 
I.D.2.b. Influence of the acyl residue 
Besides the N-OH function, also the N-acyl residue of the retrohydroxamate has been extensively 
varied. The most evident example in this series is FR900098, the acetyl congener of fosmidomycin. 
Reported (relative) activities vary strongly between different publications, research groups and used 
test condition97, 105, 110, 111, 120, 123, 124. Generally, FR900098 has been reported as equipotent to or up to 
twice as potent as fosmidomycin concerning EcDXR inhibition. In the in vitro P. falciparum growth 
inhibition assay FR900098 usually performs twice as well as fosmidomycin105, 120. Therefore, and also 
because of its higher stability, the N-acetyl moiety is usually preferred over the N-formyl residue. 
Giessmann et al.105 and Ortmann et al.123 investigated the further elongation of the N-acyl residue for 
the exploration of additional, undefined binding sites and in search of more lipophilic molecules (28, 
Figure I.13).  
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Figure I.13: Fosmidomycin analogues with varied acyl chain 
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Only an N-benzoyl analogue showed a submicromolar inhibition and was about half as potent as 
fosmidomycin both on EcDXR and against P. falciparum in vitro. All other acyl residues caused a 
significant loss of DXR inhibitory potency. Via flexible docking it was observed that these larger acyl 
residues prevent the retrohydroxamate from adopting the necessary conformation for efficient 
chelation of the divalent metal cation. A comparable series of molecules bearing sterically even more 
demanding analogues is found in the aforementioned paper by Giessmann et al.105 (29, Figure I.14) 
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Figure I.14: Varied acyl moieties connected via a glycine linker to the retrohydroxamate 
 
Here, a glycine linker is used to connect various acyl groups to the nitrogen of a fosmidomycin 
backbone. Again, introduction of such large acyl groups causes a drop in activity for up to three 
orders of magnitude compared to parent fosmidomycin and FR900098, except for a phenylether 
analogue. The authors suggest that the phenylether chain occupies an additional binding site at 
relatively large distance from the actual fosmidomycin binding site, causing a slightly different 
orientation for the retrohydroxamate group and the three-carbon spacer of this molecule relative to 
fosmidomycins bound conformation. 
I.D.2.c. Reversal of the retrohydroxamate 
The essence of the retrohydroxamate in fosmidomycin is a carbonyl function vicinal to an N-OH 
group, forming a bidentate chelator when both groups are in a cis-conformation, thereby mimicking 
the chelating β-hydroxyketone functionality of DOXP. Kuntz et al.125 were the first to infer that the 
vicinal carbonyl and N-OH groups could switch places, thus changing the retrohydroxamate into a 
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hydroxamate, while essentially retaining their chelating properties as depicted in Figure I.15. They 
subsequently synthesized hydroxamates 30 and 31, the reversed analogues of resp. fosmidomycin 
and FR900098. 
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Figure I.15: Reversal of the retrohydroxamate function in fosmidomycin and FR900098 
 
Both analogues were tested for their inhibitory activity on EcDXR and were shown to be slow 
tight-binding inhibitors like fosmidomycin. The N-methylated analogue 31 was a stronger EcDXR 
inhibitor than the N-H analogue 30, which performed equally well as fosmidomycin. Analogue 30 was 
later resynthesized by Woo et al.107 and tested on Synechocystis DXR, indicating that it is a slower 
binder than fosmidomycin, needing more time to form the tightly bound DXR-inhibitor complex. The 
better performance of the N-methylated hydroxamate was ascribed to a hydrophobic interaction 
between the methyl group and the indole ring of Trp212 by Zingle et al.110, analogous to the methyl 
of the acetyl residue of FR900098 or the terminal methyl group of DOXP. They also tested the N-
ethylated analogue 32, but found out that this substituent is too bulky to fit in the apparently narrow 
active site around the metal ion. Phaosiri and Proteau126 had come to the same conclusion earlier 
after testing the substrate analogue 1-methyl-DOXP (33). 
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Figure I.16: N-Ethylated reversed hydroxamate and analogous 1-Me-DOXP 
 
Recently, Behrendt et al.121 combined the reversed hydroxamate with the favourable α-aryl 
substitution (see below), yielding a series of analogues as those depicted in Figure I.17. 
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Figure I.17: α-Aryl reverse hydroxamate analogues of fosmidomycin 
 
These analogues were the first hydroxamate analogues to be tested on both EcDXR and PfDXR 
and for P. falciparum growth inhibition in vitro. As before, N-unsubstituted analogue 34 caused less 
inhibition of EcDXR than N-methylated 35. When tested on PfDXR, 35 was about twice as potent as 
FR900098 and 34. Concerning in vitro P. falciparum growth, N-methylated 35 outperformed 
FR900098, whereas 34 showed comparable activity as fosmidomycin. Once more, N-ethylation as in 
36 caused a severe loss of potency while N-isopropyl analogue 37 had no activity at all. The α-
difluorophenyl analogues 38 and 39 showed the highest potency of this series and were therefore 
also tested in vivo. Both showed an equal activity on PfDXR, and N-methylated 39 was slightly better 
than N-unsubstituted 38 in inhibiting PfK1 growth. When tested in mice infected with P.berghei 
though, an inverse trend was seen as 38 performed better than 39 (89% vs. 78% mean suppression of 
infected RBC; 60% survival rate on day 13 for 38 vs. 25% for 39). 
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Table 1.3: Biological activities of α-substituted reversed hydroxamate analogues 
 Enzyme inhibition 
In vitro growth 
inhibition 
 EcDXR PfDXR P. falciparum K1 
Analogue IC50 (µM) IC50 (µM) IC50 (µM) 
Fosmidomycin (1) 221.3±14.4 143.7±15.5 3.71±2.47 
FR 900098 (2) 131.3±2.9 15.3±1.2 1.48±0.84 
34 592±25 11.6±3.1 3.87±1.81 
35 243±29.6 3.1±0.3 0.59±0.2 
36 15±0.4 0.015±0.002 1.3±1.5 
37 Inactive Inactive inactive 
38 0.21±0.02 0.003±0.001 0.38±0.17 
39 0.12±0.07 0.003±0.001 0.29±0.20 
 
I.D.2.d. Substitution with other metal chelators 
As the (retro)hydroxamate moiety of fosmidomycin (and its analogues discussed so far) “only” 
serves to chelate the divalent metal cation in the active center of DXR, it should theoretically be 
possible to substitute this group with other metal chelators while retaining or improving DXR affinity 
(and perhaps reduce polarity of resultant molecules). Typically, hard metal ions like Mg2+ with a small 
ionic radius, high electronegativity and low polarizability are found in the DXR active site. Stable 
complexation with such ions is achieved by dioxygen based hard ligands such as the 
retrohydroxamate found in fosmidomycin but also catechols127. Catechols 40a and 40b (Figure I.18) 
were synthesized by Deng et al.127 and tested for their inhibitory potency of EcDXR, showing IC50 
values of 24.8µM (40a) and 4.5µM (40b) indicating a strong preference for the 1,3,4-orientation on 
the catechol over the 1,2,3-orientation. In search of lipophilic fosmidomycin analogues against 
M. tuberculosis, Andaloussi et al.101 resynthesized 40b, together with N-hydroxypyridinone 40c, 
oxazolopyridinones 40d-f96, 5-hydantoin 40g and cyclic carbamate 40h. Only catechol 40b and N-
hydroxypyridinone 40c showed more than 50% inhibition of MtDXR at 100µM. Although these data 
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are based on the Mycobacterium isozyme, they confirm that the DXR active site is very narrow 
around the metal cation. 
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Figure I.18: Fosmidomycin analogues based on non-hydroxamate metal chelators 
 
Oxazolidinone 40h had been tested before97 as its phosphate analogue (41c) together with its 
enantiomer (41b), its regioisomers (41d-e) and N-hydroxy-oxazolidinone 41a depicted in Figure I.19. 
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Figure I.19: Fosmidomycin analogues with rigidified chelating moiety 
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These molecules resulted from an attempt to rigidify the fosmidomycin structure by 
incorporation of the retrohydroxamate into a cyclic carbamate. Rigidification of the enzyme inhibitor 
should increase its potency by ameliorating the entropy loss of binding128, 129. All five molecules 
turned out to be weak EcDXR inhibitors in the high-µM to low-mM range. 
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Figure I.20: Phosphonated N-heteroarylcarboxamides as fosmidomycin mimics 
 
In search of alternative metal chelating groups, Bodill et al.130 synthesized phosphonate esters 
42a-e and the corresponding phosphonic acids 43a-e depicted in Figure I.20. Although evidence for 
the binding of these molecules to DXR was found, they probably do so in a different orientation from 
fosmidomycin. When tested in vitro for their EcDXR inhibitory activity, all analogues showed IC50s of 
at least 5 orders of magnitude higher than that of fosmidomycin, with the most bulky analogue 43e 
showing no inhibition at all at 500µM. Overall, substitution of the (retro)hydroxamate function in 
fosmidomycin analogues with more ‘exotic’ metal chelators has up till now not been very successful. 
Apparently the active site of DXR is very tight especially around the bound metal cation and 
introduction of sterically demanding metal-chelating groups is detrimental for inhibitory activity. 
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I.D.3. Modifications of the three-carbon spacer 
In contrast to the phosphonate and hydroxamate groups that turned out to be essential for 
fosmidomycin’s activity and tolerate only little modification, the three-carbon spacer is more 
amenable to synthetic modification, as outlined below. 
I.D.3.a. Spacer length 
An obvious modification is to change the length or the nature of the carbon spacer in 
fosmidomycin. Already at the time of fosmidomycin’s discovery the influence of shortening this 
spacer on the (antibiotic) activity was tested. Ethylene analogues 44 and 45 (Figure I.21) were 
synthesized and tested on a panel of bacteria by Hemmi et al.83 but showed no antibiotic activity at 
all. The influence of both shortening and lengthening with one methylene unit was also tested in the 
reversed hydroxamate series with analogues 46-49110 (Figure I.21). The ‘normal-length’ counterparts 
of these molecules (30 and 31) were described under I.D.2.c. Especially shortening of the molecule 
led to a dramatic decrease in EcDXR affinity (Table I.4). The authors inferred that, by shortening the 
spacer, these molecules probably cannot simultaneously occupy both the phosphonate and metal 
binding sites of DXR anymore leading to the decreased affinity. Lengthening of the spacer by one 
methylene unit in 48 and 49 also led to a decreased activity, although to a lesser extent. Although 
these molecules are theoretically long enough to occupy both binding sites, the longer spacer 
probably prevents adopting the optimal conformation for enzyme binding, or is maybe forced to 
adopt a conformation leading to energetically unfavorable intramolecular interactions. 
Recently, Behrendt et al. synthesized the analogue of 46 bearing a phenyl substituent in 
α-position, because addition of an aromatic group in α-position has led to successful DXR inhibitors 
before (see below). Unfortunately, this substituent did not compensate for the detrimental effect of 
the shortened spacer as 50 showed no EcDXR nor PfDXR inhibitory activity at all120. 
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Figure I.21: Fosmidomycin analogues with shortened and lengthened spacer 
 
Table 1.4: Influence of spacer length on the biological activity of fosmidomycin 
analogues 
 EcDXR inhibition 
 IC50 (µM) IC50 (µM) 
Analogue Without preincubation With preincubation 
Fosmidomycin (1) 0.25 0.032 
FR 900098 (2) - 0.032 
46 1000 1000 
48 77 19 
47 2.8 0.27 
49 0.9 0.11 
50 - inactive 
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From the above, one can conclude that a spacer of exactly three (carbon) atoms length between 
the phosphonate and chelator (hydroxamate or retrohydroxamate) is mandatory for good DXR 
inhibitory activity. 
I.D.3.b. α-Aryl modifications 
Together with the invention of phosphonate prodrugs (see above), the introduction of aromatic 
substituents in α-position of the phosphonate of fosmidomycin/FR900098 has afforded the most 
promising fosmidomycin analogues to date. So far, all α-substituted analogues in this overview have 
been synthesized and tested as racemates. Separation of their enantiomers and testing of those has 
been suggested as a way of finding the preferred binding mode of these analogues. On the other 
hand, in vivo racemization of such molecules is not unthinkable as the benzylic α-proton is quite 
acidic. Crystallographic work on MtDXR with α-aryl FR900098 analogues by Andaloussi et al. 
indicated preferential binding of the S-enantiomers to the enzyme. 
A series of α-aryl analogues of FR900098, substituted according to Topliss’ scheme (up to level 3), 
was synthesized in our group by Haemers et al.122, 124 (Figure I.22, 51a-e) and expanded by Devreux et 
al.131, 132 with some electron-withdrawing substituents (51f, g, j, k),  as well as two aniline analogues 
(51i, j) and two α-thienyl analogues (51l, m). Of the most promising FR900098-analogues, also the 
formylated versions (fosmidomycin analogues) were synthesized. When tested for their EcDXR 
inhibitory activity, all α-aryl analogues showed a weaker activity than fosmidomycin and FR900098, 
except for N-formyl analogue 52a which was equipotent to fosmidomycin. Generally, activity of these 
analogues seems to be Hammett σ+-controlled (4-Cl ≈ 3,4-diCl >H > 4-Me > 4-MeO). When tested for 
their in vitro P. falciparum growth inhibition, analogues 51a-e as well as 4-CN analogues 51g and 52a 
all surpassed fosmidomycin’s activity. Both 4-CN analogues (51g, 52a) were about four times as 
active as fosmidomycin, and about twice as active as FR900098. Contrary to the activity trend 
observed with unsubstituted fosmidomycin and FR900098, the N-formyl analogues (52a-c) were 
consistently more potent than their N-acetyl counterparts (51c, 51e, 51g). 
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Figure I.22: Alpha-aryl substituted analogues of FR900098 and fosmidomycin 
 
Kurz et al. combined the α-aryl modification with the use of phosphonate prodrugs (53a-b and 
54a-d in Figure I.23)116. Again, the N-formyl analogues showed a stronger in vitro P. falciparum 
growth inhibition than their acetyl counterparts, with α-phenyl analogue 53a being about as active as 
the analogous (bis-POM) prodrug of FR900098. Addition of electron-withdrawing substituents to the 
phenyl ring as in 53b and 54b-c slightly improved the antimalarial activity while the electron-
donating ortho-methyl groups in 54d were detrimental.  
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Figure I.23: Prodrugs of α-aryl fosmidomycin/FR900098 analogues 
 
Remarkably, these prodrugs gave comparable IC50 values in the in vitro P. falciparum 3D7 growth 
inhibition assay as the free acids (51 – 52) described above. This may indicate that cellular uptake of 
the phosphonic acids is not a limiting factor for activity. 
The combination of α-aryl substituents with a reversed hydroxamate group was explored by 
Behrendt et al.120, 121, resulting in a series of α-aryl,N-H analogues (55a,55c and 55e) and their 
N-methylated counterparts (55b, 55d, 55f and 55g) depicted in Figure I.24. 
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Figure I.24: α-Aryl fosmidomycin analogues bearing a reversed hydroxamate 
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Table 1.5: Biological activities of α-substituted reversed hydroxamate analogues 
 Enzyme inhibition 
In vitro growth 
inhibition 
 EcDXR PfDXR P. falciparum K1 
Analogue IC50 (µM) IC50 (µM) IC50 (µM) 
Fosmidomycin (1) 0.2213 0.1437 3.71 
FR 900098 (2) 0.1313 0.0153 1.48 
55a 0.592 0.0116 3.87 
55b 0.243 0.0031 0.59 
55c 7.4 0.0037 2.40 
55d 3.8 0.0090 0.97 
55e 0.21 0.0030 0.38 
55f 0.12 0.0030 0.29 
55g 0.18 0.0040 0.41 
 
Here again, these molecules were not very promising compared to fosmidomycin when tested 
for EcDXR inhibition but (see Table 1.5), interestingly, surpassed fosmidomycin’s activity when tested 
on PfDXR, up to two orders of magnitude. Contrary to the retrohydroxamates described above, in 
this series the N-methylated analogues were strongly favored over their N-H counterparts. When 
tested for in vitro P. falciparum (K1 strain) growth inhibition, these molecules appeared to be very 
potent with an IC50 as low as 0.29µM for 55f. To assess the binding mode of these molecules, an X-
ray crystallographic study of the EcDXR-complex of the most potent analogue (55f) was undertaken. 
The overall structure of the EcDXR-55f complex was identical with other published EcDXR structures, 
except for the flexible loop, which was distorted. This could be caused by the absence of NADPH in 
the complex, or by the protruding difluorophenyl substituent. From an overlay of the EcDXR-
fosmidomycin complex with the EcDXR-55f complex a consistent binding mode for the metal 
chelating moiety is seen: both give an octahedral coordination of the divalent metal cation, as can 
also be seen in Diagram I.3. 
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Diagram I.3: (a) Structural superposition of 55f and 1 at the active site of EcDXR (labeled 
IspC) in the open conformation (PDB codes 3R0I (20b) and 1ONP16).(b) Superposition of 55f 
and 1/EcDXR (IspC)/NADPH (closed conformation) complex (PDB codes 3R0I and 1Q0L17). 
The steric clash between the α-difluorophenylsubstituent (green) and three aminoacid 
residues (Asn 211, Trp 212 and Met 214) of the flexible loop can be seen. Figure from: 
Journal of Medicinal Chemistry 2011, 54 (19), 6796-6802. 
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This overlay also suggests a steric clash between the α-aryl substituent with amino acid side 
chains from the flexible loop (especially Asn211, Trp212, Met214), preventing the loop from closing, 
which could explain the relatively low affinity of 55f for EcDXR compared to PfDXR. In PfDXR, Deng et 
al. (see below) describe the possibility of Trp212 to undergo a rotation, leading to a favorable π-π-
stacking interaction with the α-arylsubstituent133. Furthermore, the X-ray structure shows 
intramolecular Van der Waals interactions between the aryl ring, the carbon backbone and the 
N-methyl. The latter has apparently no interactions with the enzyme. A further reason for the 
difference in affinity of 55f for EcDXR versus PfDXR could be that, although the residues forming the 
active sites are conserved, the overall sequence homology between these two enzymes is very low. 
Another variation on the ‘α-aryl theme’ consists of the combination with an α,β-unsaturation, 
resulting in two series of resp. cis-analogues 56a-e and trans-analogues 57a-d as depicted in Figure 
I.25131, 134.  
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Figure I.25: α,β-Unsaturated,α-aryl analogues of fosmidomycin 
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Of these molecules, only the trans-analogues 57a-d showed some inhibition of EcDXR, albeit 
much weaker than fosmidomycin and FR900098. cis-Analogues 56a-e showed IC50 values (EcDXR) 
that are at least three orders of magnitude higher than those for fosmidomycin and FR900098. One 
exception is the unsaturated α-bromo analogue 57a which showed an acceptable EcDXR inhibition 
(IC50 = 0.45µM, compared to 0.034µM for fosmidomycin). Apparently, the unsaturation combined 
with the α-aryl substituents constrains the molecule too much for optimal binding to the enzyme. 
I.D.3.c. α-Alkyl based modifications 
Two kinds of α-alkylated fosmidomycin analogues have been published so far: analogues bearing 
only (hydroxy)alkyl substituents in α-position116 and a series of α-arylmethyl analogues118. Both were 
synthesized and tested as bis-POM prodrugs. The latter series, as depicted in FigureI.26, can be seen 
as analogues of the α-aryl-fosmidomycines described in I.D.3.b. with a methyl tether inserted 
between the aryl group and the fosmidomycin backbone. 
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Figure I.26: α-Arylmethyl substituted fosmidomycin analogues 
 
All of these analogues were synthesized and tested both as formyl (fosmidomycin derived) and 
as acetyl (FR900098 derived) hydroxamates. In line with previous results, formyl derivatives were 
consistently more active than their acetyl counterparts, and electron-withdrawing substituents on 
the phenyl ring improved the antiplasmodial activity in a P. falciparum3D7 growth inhibition assay. 
Electron-donating substituents led to a decreased activity, while also tetrahydronaphthyl-analogues 
showed a decreased activity probably due to steric factors. The most potent molecule of this series 
showed an intermediate activity between bis-POM fosmidomycin and bis-POM FR900098. 
  Chapter I: Introduction 
I.44 
 
A series of analogues with alkyl groups in α-position was also synthesized both as formyl- and 
acetylretrohydroxamates and evaluated as bis-POM prodrugs for their P. falciparum3D7 growth 
inhibition potency116 (59-64 in Figure I.27). 
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Figure I.27: α-Alkyl and α-hydroxymethyl analogues of fosmidomycin and FR900098 
 
Except for α-monomethyl analogues 59a and 59b, which showed a potency equal to that of the 
α-phenylfosmidomycin and FR900098 prodrugs, all other α-alkyl-, α,α-dimethyl- and α-
hydroxymethyl analogues showed a strongly diminished antiplasmodial activity. Generally, formyl 
analogues 59-64a showed better activities than their acetyl counterparts 59-64b. 
I.D.3.d. Conformationally restricted analogues 
Vincent Devreux from our group incorporated the α,β-bond of fosmidomycin into a cyclopropane 
structure131, 135, resulting in molecules 65 – 67 depicted in Figure I.28. First, the racemic trans 
analogue 65 bearing an N-acetyl moiety was synthesized, and due to its promising activity, 
enantiopure 1R,2S-analogues bearing three different acyl moieties were subsequently synthesized. 
Furthermore, α-phenyl analogue 67, which is reminiscent of the α-aryl-α,β-unsaturated 
fosmidomycin analogues described above (that were synthesized later!) was also included. 
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Figure I.28: Cyclopropyl analogues of fosmidomycin 
 
An EcDXR inhibition assay showed that racemic 65 was about three times less potent than 
fosmidomycin and FR900098. Its enantiopure 1R,2S counterpart 66b, on the other hand, showed a 
comparable activity to FR900098, indicating that the 1R,2S-configuration is the favored one for DXR 
binding. Replacing the acetyl group for a formyl resulted in an 8-fold drop in potency, while a 
propionyl group caused an even more drastic loss of activity. Conformationally restricted α-phenyl 
analogue 67 did not inhibit EcDXR to an appreciable extent. When tested for  P. falciparum growth 
inhibition, enantiopure 66b was equipotent with fosmidomycin on the Dd2 strain and surpassed its 
activity against the 3D7 strain. Again, the formyl analogue 66a was less potent (about 5-fold) than 
the acetyl analogue. 
The entire three-carbon spacer of fosmidomycin has been conformationally locked as well, by 
incorporation into a cyclopentane structure122, 136. Timothy Haemers from our group synthesized 
both the racemic cis(68) and trans(69) analogues (Figure I.29). 
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Figure I.29: Cyclopentyl analogues of fosmidomycin 
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From EcDXR inhibition experiments the following was concluded:  1) trans isomers showed a 
higher potency than cis isomers (in accordance with the results of the cyclopropyl analogues); 2) 
formyl analogues performed better than acetyl analogues (cfr. α-aryl analogues). Consequently, 
formylated trans-analogue 69a showed the highest EcDXR inhibition of this series (albeit 1 order of 
magnitude weaker than fosmidomycin), acetylated cis-analogue 68b performed worst (3 orders of 
magnitude weaker than fosmidomycin). 
The modifications described above both retain the sp3-character of the three-carbon spacer. In 
contrast to this is the modification tested by Kurz et al.117 depicted in Figure I.30, which results in 
partially planar fosmidomycin analogues. 
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Figure I.30: Conformationally restrained aromatic fosmidomycin analogues 
 
These molecules were tested as their bis-POM prodrugs and with three different acyl moieties: 
formyl, acetyl and benzoyl. Unfortunately, all of them showed only moderate P. falciparum3D7 
growth inhibition, with IC50 values one to two orders of magnitude higher than those of bis-POM 
fosmidomycin and bis-POM FR900098. Concerning acyl residues, benzoyl was favoured over acetyl, 
which itself performed better than formyl. 
I.D.3.e. β-Position modifications 
There are only two groups of fosmidomycin analogues featuring a modification of the three-
carbon spacer in β-position reported to date. The first is (R)-β-hydroxyfosmidomycin or FR33289 (3), 
which was characterized by Hemmi et al. at the discovery of fosmidomycin and its analogues83. 
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Although this compound was never tested for its DXR inhibitory potency or Plasmodium growth 
inhibition, a low antibacterial effect was reported. The second modification consists of the 
replacement of the β-methylene unit by an oxygen atom122, 137, resulting in ethers 71a-b and 72a-b 
depicted in Figure I.31. 
OP
O
HO
HO
N
OH
O OP
O
HO
HO
N
O
OH
R R
71a R = H
71b R = Me
72a R = H
72b R = Me  
Figure I.31: β-oxa analogues of fosmidomycin 
 
In the EcDXR inhibition assay, the N-acetyl analogue 71b and N-methyl analogue 72b performed 
better than their N-formyl and N-H counterparts. Both 71b and 72b were almost as potent as 
fosmidomycin and FR900098, with reversed hydroxamate 72b being slightly more potent than 
retrohydroxamate 71b. Due to stability issues, 72b was converted to its bis-POM prodrug for in vitro 
P. falciparum growth inhibition testing, where it outperformed the bis-POM prodrug of FR900098. 
I.D.3.f. γ-Position modifications 
Fosmidomycin analogues modified in γ-position are scarcely found in literature, just like the 
β-analogues described above. Compounds 73a and 73b122, 137 depicted in Figure I.32 can be seen as 
γ-oxa-derivatives analogous to the β-oxa-analogues described above. Chemically though, these are 
N-hydroxycarbamates and apparently this change to a different functional group has had a major 
influence on the DXR inhibitory activity of these molecules as none of both was found to inhibit 
EcDXR. 
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Figure I.32: γ-modified fosmidomycin analogues 
 
Kurz et al. reported the synthesis of racemic γ-methyl and γ-phenyl analogues 74a-b and 75a-b, 
as bis-POM prodrugs. Only incomplete inhibition of in vitro P. falciparum growth by these analogues 
at 100µM was seen. This is once more an indication that increasing the steric bulk near the metal 
chelator part of fosmidomycin analogues is detrimental to their activity. 
I.D.4. Modifications with omission of phosphonate or (retro)hydroxamate moiety 
Recently, Deng et al. tried a new strategy in their search for more lipophilic DXR inhibitors, by 
creating fosmidomycin analogues that lack either the phosphonate or the (retro)hydroxamate part. 
First, they tested new metal chelating groups based on the catechol structure127, leading to the 
aforementioned analogues 40a and 40b. In order to enhance the lipophilicity of these molecules, and 
thus increase their antibacterial activity, the ethylphosphonate moiety was replaced for a phenyl or a 
benzyl group. Variations of the catechol metal chelator such as N-hydroxypyridinone were also 
tested, resulting in a series of lipophilic DXR inhibitors of which 76 (Figure I.33) showed the strongest 
EcDXR inhibition as well as a broad antibacterial activity. 
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Figure I.33: Development of lipophilic DXR inhibitors lacking the phosphonate group 
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Having proven that lipophilic molecules lacking the phosphonate group are valuable leads for 
DXR inhibitor design, the group then adopted a rational approach starting from 
α-(3,4-dichlorophenyl)fosmidomycin 52c133. Two ‘halves’ of this molecule were synthesized and 
tested on EcDXR: the benzylphosphonate 77 and phenylalkyl-retrohydroxamate 78 (Figure I.34). Of 
these, only the phosphonate showed DXR inhibition. Because electron-withdrawing substituents on 
the aryl ring caused an increase in activity in the α-aryl series, it was decided to synthesize pyridyl 
analogues 79 and 80. Again, the retrohydroxamate showed no considerable DXR inhibition while the 
phosphonate showed an increased inhibition of EcDXR.  
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Figure I.34: Fragment-based approach toward lipophilic DXR inhibitors starting from 
α-(3,4-dichlorophenyl)fosmidomycin 
 
In order to gain insight in the binding mode of these new structures, X-ray crystallographic 
studies were conducted on the complex of EcDXR with these new benzylphosphonates. Crystal 
structure data illuminate that the pyridyl ring in 81 undergoes a π-π-stacking interaction with the 
indole ring of the highly flexible Trp211 of the flexible loop part of DXR. Possible charge transfer 
makes this interaction particularly strong, which declares the better affinity of 81 for DXR than that 
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of 77. When fosmidomycin itself is bound to DXR, the flexible loop shuts off the active site with 
Trp211 covering the apolar carbon spacer of fosmidomycin in an apolar interaction. Binding of the α-
aryl derivatives like 77 leads to an intermediate case with also a π-π-interaction between the aryl 
group and Trp211 which is then flipped 180°, leading to a weaker interaction than with the above 
pyridyls. This study confirms the very important role of the flexible loop of DXR and especially 
Trp211, which is conserved across the species using the non-mevalonate pathway. In the same 
crystallographic study, two hydrophobic pockets in the DXR active site are also revealed. By means of 
docking experiments, one of these pockets is assigned as the binding pocket for the aryl groups of 
the α-aryl fosmidomycins as well as for the pyridyl group of 79. In order to further explore the 
pyridylmethylphosphonate scaffold of 79 as a lead for DXR inhibitor design, Deng et al. synthesized a 
vast amount of analogues of 79 featuring several substituted aryl groups, different acidic groups and 
various linker lengths99. From the DXR inhibition data of these series, it was concluded that the 
phosphonate group is essential as well as one methylene unit as a linker. Furthermore, a 5-pyridyn-2-
yl-substituent proved optimal, resulting in 82 as the most potent DXR inhibitor of this series. With 
their work, Deng et al. are the first to prove that it is possible to develop potent DXR inhibitors 
starting from the fosmidomycin scaffold by removing one of the major structural motifs: the 
retrohydroxamate. The gain in lipophilicity (leading to more favorable pharmacokinetics) and/or the 
extra interaction of the added lipophilic part with the newly defined hydrophobic pocket of DXR 
clearly makes up for the loss of the strong interaction of the metal chelator with the enzyme’s 
catalytic metal cation. 
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I.D.5. Conclusions regarding fosmidomycin SAR 
The vast amount of experimental data described in the previous sections allows us to postulate a 
few conclusions on the SAR of fosmidomycin analogues as antimalarial DXR inhibitors. 
The importance of the retrohydroxamate in DXR inhibitors has recently become very questionable 
due to the work of Deng et al.99, 133: they show that a (retro)hydroxamate group is not necessary for a 
strong DXR ligand if other functional groups (in this case the phenylpyridyl moiety) cause new 
favorable interactions with the enzyme. In all other, ‘classic’ fosmidomycin analogues, the 
retrohydroxamate moiety proved to be necessary. Furthermore, apart from reversing it into a 
hydroxamate or substituting it for a catechol, all other changes to this group have led to a strong 
decrease in DXR inhibition. 
So far, the diprotic phosphonate group with its tetrahedral configuration has proven essential for 
DXR inhibitory activity. Neither its exchange for other acids (e.g., carboxylic and sulfonic) nor the 
introduction of heterocycle-based groups have led to strong DXR inhibitors so far. Nevertheless, 
finding a more lipophilic substituent for this extremely polar functionality is expected to ameliorate 
the pharmacokinetic properties of such analogues. In order to decrease the polarity of fosmidomycin 
analogues, and thus increase their gastrointestinal uptake, several prodrugs of the phosphonate 
group have been developed. Remarkably, while the use of acyloxyalkyl ester prodrug strategies does 
increase the efficacy of FR900098 after oral administration (see I.D.1.a.), the use of the same strategy 
(in the α-aryl series) did not lead to a significantly higher antimalarial effect in the blood-based in 
vitro assay (see I.D.3.b.). Apparently, the use of phosphonate prodrugs does increase the uptake of 
such analogues after oral administration, but has little influence on the cellular and/or parasitic 
uptake. Probably there is a specific active uptake mechanism involved in the transport of 
fosmidomycin analogues into the Plasmodium parasite. The uptake of highly charged compounds 
such as fosmidomycin analogues into Plasmodium-infected erythrocytes is believed to be facilitated 
by so-called parasite-induced new permeability pathways (NPPs)104. 
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Fosmidomycin’s three-carbon spacer has so far been the most successfully modified part of the 
molecule. A few modifications, such as rigidification of the spacer, led to only a modest increase in 
DXR inhibition but also provided important information on the conformational preferences of DXR 
inhibitors. Except for the β-oxa-modification, which showed a strong DXR inhibition but suffered 
from a low stability, no derivatizations of the β-position have been published so far but studies are 
undubitably underway to explore these. The γ-position of the spacer is apparently too close to the 
(retro)hydroxamate group to allow succesfull modification: any steric bulk that is added in this 
position invariably leads to a loss of activity. α-Substitution, particularly with aryl groups is the most 
promising strategy so far, both for ‘classic’ fosmidomycin analogues as for ‘truncated’ phosphonates 
lacking a metal chelator. Generally, the addition of lipophilic/aromatic groups to an active molecule is 
frowned upon in medicinal chemistry for it does not enhance the ligand efficiency of the molecule, 
but only leads to nonspecific Van der Waals interactions with the apolar surface of the target protein. 
Then again, fosmidomycin with its two acidic functional groups for only a propylene chain is probably 
one of the most polar drugs. Therefore, one can question whether adding lipophilic groups to this 
molecule is also disfavored. Furthermore, besides increasing the molecules lipophilicity and thereby 
improving its pharmacokinetics, the added aryl substituents lead to an extra interaction with the 
enzyme under the form of a π-π-stacking with a Trp from the loop. We could thus conclude that 
these α-aryl substituents do increase the ligand efficiency in an active manner and do not categorize 
under the ‘adding grease-strategy’. 
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II.Objectives 
As described in the general introduction, one way to reduce the high daily dose of fosmidomycin 
required in clinical studies is to structurallyoptimize  it in order to improve its potency as an 
antimalarial. Many efforts towards this goal have already been made, and from these we learned 
that: 
-The phosphonate group is essential for good binding to DXR. A phosphate functionality may 
yield a better interaction with the enzyme, but is too unstable to be used in potential drugs. 
-According to the most recent findings, the retrohydroxamate group can be omitted, provided 
that well-chosen aromatic groups in α-position to the phosphonate enhance the binding efficiency by 
forming π-π-stacking interactions with a Trp residue in DXR. If DXR inhibitors are to be designed with 
a metal chelating group, a retrohydroxamate (acetyl or formyl) or a hydroxamate (preferably N-
methylated) are preferred. 
-Derivatization of the three-carbon spacer of fosmidomycin may lead to analogues that show 
enhanced DXR inhibition. Among these, α-aryl analogues are the most promising, especially if the 
aryl moiety bears electron-withdrawing substituents. 
The objective of this work is the synthesis of new and potent DXR inhibitors as antimalarials. We 
chose FR900098 as the lead structure, because of the higher stability of the acetylhydroxamic acid 
compared to the formylhydroxamic acid in fosmidomycin, and its higher potency (except in the α-aryl 
series). Formylhydroxamic acid analogues of selected promising derivatives can be synthesized in a 
second phase. 
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Figure II.1: Overview of planned modifications of FR900098 
Four main strategies toward new FR900098 analogues are proposed (Figure II.1): 
(I) The introduction of (a) halogen atom(s) in α-position of the phosphonate. In the α-aryl 
series of fosmidomycin analogues, the strongest DXR inhibition was detected with 
electron withdrawing substituents. We inferred that these might increase the acidity of 
the phosphonic acid and thereby lead to a stronger interaction with the phosphate 
binding site of the enzyme (apart from possible interactions between the aryl moiety and 
the enzyme which became clear only later during this work). A similar effect could 
possibly be achieved by introducing halogen atoms on the α-carbon of FR900098, 
hopefully also resulting in an increased affinity for DXR. Since α-halogenated 
phosphonates are known as excellent phosphate mimics, the envisaged molecules 
represent stable analogues of fosfoxacin, a potent but unstable DXR inhibitor. 
(II) Restriction of the preferred binding conformation of the (retro)hydroxamate by 
cyclization. The retrohydroxamate in fosmidomycin or FR900098 can adopt two 
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conformations: E and Z, forming an equilibrium mixture. Of these, only the Z 
conformation is favorable for binding the divalent metal cation in the enzyme. By 
incorporating the (retro)hydroxamate into a cyclic structure, we aim at restricting it in a 
conformation that is favorable for binding to the enzyme, which should result in an 
increased affinity. 
(III) α-Heteroatom analogues. Introduction of a heteroatom (N or O) in α-position of 
FR900098 will lead to new analogues that can serve as starting points for extensive 
derivatisation via N- or O-based functional groups. This strategy may lead to new DXR 
inhibitors and allows for exploration of a broad range of substituents. 
(IV) Addressing the polarity issue by means of phosphonate prodrugs. As described in the 
general introduction, the high polarity of the phosphonic acid in fosmidomycin analogues 
significantly limits their gastrointestinal uptake. To address this issue, synthesized 
analogues exhibiting good in vitro activity will be converted to their corresponding 
phosphonate prodrugs for in vivo evaluation.  
 
  
Chapter II : Objectives 
II.4 
 
 
  
 
Chapter III 
Alpha-halogenated 
analogues of 
FR900098 
  
 
 Chapter III: Alpha-halogenated analogues of FR900098 
III.1 
III.Alpha-halogenated analogues of FR900098 
III.A Introduction 
III.A.1. Fluorinated phosphonates 
The organic phosphate group (R-OPO3
2-) is omnipresent in a wide range of biologically active 
natural products1, but is considered impractical in drug design due to its low stability towards 
hydrolysis, either spontaneous or enzymatic by digestive phosphatases. Therefore, stable isosteric 
analogues of this group have been heavily sought-after. A popular surrogate for the phosphate group 
is the phosphonate functionality (R-CH2PO3
2-), in which the bridging oxygen is replaced by a carbon 
directly linked to the phosphorus atom resulting in a chemically very stable phosphate isostere. The 
chemistry of phosphonates has been thoroughly studied and well reviewed2. The phosphonate group 
is also present in many natural products3, of which fosmidomycin and FR900098 are the most 
relevant in the context of this work. In these compounds the phosphonate acts as an isostere for the 
phosphate group of DOXP.  
In the 1980’s the groups of Blackburn4, 5 and McKenna and Shen6 suggested that introduction of one 
or two halogen atoms, and in particular fluorine, in α-position of the phosphonate should lead to 
superior bioisosteres more accurately mimicking the steric and polar character of the phosphate 
moiety. It is a well known principle in medicinal chemistry that the CHF and CF2 groups can sterically 
and electronically mimic an oxygen7, and in this case decrease the second pKa of the phosphonic acid 
(Figure III.1).  
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Figure III.1: Comparison of the phosphate group to its different isosteres8 
In fact, the α-monofluorophosphonate is the best phosphate mimic in terms of pKa2
9, whereas 
the α,α-difluorophosphonate more closely resembles the polarity profile of the phosphate group10, 11. 
Other parameters that potentially favor α-fluorinated phosphonates over their nonhalogenated 
congeners are: (a) an increased P-CF2-C or P-CHF-C dihedral angle, (b) the possibility for C-F•••H-R 
hydrogen (halogen) bonding, (c) an increased hydrolytic and oxidative stability8. 
The chemistry of α-fluorinated phosphonates forms a much younger field of research than that of 
the ordinary phosphonates, but good reviews on this topic have already been published8, 12. Six major 
synthetic methodologies for the construction of α-fluorinated (and sometimes α-chlorinated) 
phosphonates can be distinguished:  
1. Arbuzov or Michaelis-Becker reaction. This reaction between a trivalent phosphorus 
derivative (di- or trialkyl phosphite) and a fluorohaloalkane13-16 suffers from 
incompatibility with functional groups and has only been successful with relatively short, 
unfunctionalized and polyhalogenated alkanes or alkenes. 
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2. Electrophilic halogenation of a phosphonate carbanion17. This reaction involves the 
abstraction of a phosphonate α-proton with a strong base, followed by attack of the 
formed carbanion at low temperature on a suitable source of electrophilic halogen18-21, 
for instance N-fluorobenzenesulfonimide (NFBS), hexachloroethane, 
1,2-dibromotetrachloroethane or I2. The α,α-difluoromethylenephosphonate moiety can 
be constructed in this fashion in two consecutive fluorination steps. 
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Electrophilic monohalogenation
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X+ = electrophilic halogen donor, e.g. (PhSO2)2NF, Cl3C-CCl3, BrCl2C-CCl2Br, I2
F+ = electrophilic fluorine donor, e.g. NFBS, NFOBS, NFPMS, SelectfluorTM  
3. Nucleophilic fluorination of a functionalized phosphonate substrate. Due to the 
generally poor nucleophilic character of fluoride-containing reagents, only phosphonate 
substrates containing leaving groups with high nucleofugicity meet the requirements for 
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useful transformations. In practice, the most successful procedures for mono- and 
difluorination of alkylphosphonate derivatives are the C-OH → C-F resp. C=O → CF2 
transformations of resp. α-hydroxy- and α-ketophosphonates with DAST22-24. This 
strategy implies that functional groups that could also react with DAST should be 
appropriately protected or avoided. 
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4. Syntheses via (alkylation of) fluorinated phosphonate carbanions. This is a quite 
broadly applicable and hence popular strategy that may give access to both 
α-monofluorophosphonate and α,α-difluorophosphonate derivatives25, 26. The carbanions 
can be formed either by metalation of a dialkyl difluoromethylphosphonate with 
common alkali metal bases15, 27-30 or by insertion of a metal (Mg, Zn, Cd,…) into the C-Br 
bond of a dialkyl bromodifluoromethylphosphonate31-33, followed by attack of the 
carbanion on a whole range of electrophiles32-36 (alkyl halides, alkyl triflates, aldehydes, 
acyl halides, activated olefins, epoxides…). 
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5. Transition metal catalysis. This approach is mostly restricted to the palladium-catalyzed 
addition of dialkyl iodo(di- or mono)fluoromethylphosphonate to terminal alkenes 
resulting in α-fluoro,γ-iodoalkylphosphonates37. The latter can be selectively reduced to 
remove the γ-iodine38. 
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6. Radical reactions. These form a totally different field of chemistry and suffer from low 
tolerability towards functional groups. Perhaps of greatest importance is the radical 
addition of dialkyl (thio)phosphites to gem-difluoroenol ethers39, 40 or 2,2-alkyl,1,1-
difluoroalkenes41 to form the corresponding α,α-difluorophosphonates, although also 
the addition of dialkyl difluoromethyl(thio)phosphonate radicals to alkenes and alkynes 
has been reported42. 
P
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F
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R1
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R1Radical
Initiator
R = alkyl; X = O, S; R1 = O-alkyl, alkyl; R2 = alkyl  
III.A.2. Halogenated fosmidomycin analogues 
Fosmidomycin and FR900098 are potent DXR inhibitors showing structural analogy to DOXP, the 
phosphate-bearing substrate of the enzyme. As stated above, the phosphonate structure in 
fosmidomycin is a useful mimic of the DOXP phosphate moiety in terms of stability, though it does 
not perfectly mimic its polarity and pKa2. Woo et al. synthesized analogues 2 and 3 (Figure III.2) of 
fosmidomycin and FR900098 in which the phosphonate functionality was switched back to a 
phosphate, and found out that both analogues surpassed fosmidomycin in inhibition of Synechocystis 
DXR activity43. The N-formyl-analogue 2 was actually described before and known as fosfoxacin44, but 
its activity against DXR had not been tested. Following the above reasoning, α-fluorinated analogues 
 Chapter III: Alpha-halogenated analogues of FR900098 
III.6 
of fosmidomycin were expected to be good DXR inhibitors. Therefore we undertook the synthesis of 
α-fluoro- and α,α-difluoro-FR900098 analogues 4a and 6 as well as α-chloro-analogue 4b (which 
could be synthesized in an analogues manner, see below), as well as the hydroxamate congener 5. 
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Figure III.2: Inhibitory effect of fosmidomycin, fosfoxacin and its acetyl congener on Synechocystis 
DXR43 as a rationale for the synthesis of halogenated phosphonate analogues. 
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III.B Mono-halogenated analogues 
III.B.1. α-Halogenated retrohydroxamates 
For the introduction of the desired halogens into FR900098, we adopted the strategy of Iorga et 
al., who described a straightforward one-pot method for the electrophilic halogenation of diethyl 
alkylphosphonates45 (Scheme III.1). 
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EtO
O
EtO
TMS Li
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EtO
O
EtO
TMS X
RP
EtO
O
X
EtOa b c
X = F, Cl
Reagents and Conditions: (a) LDA (2eq.), TMSCl, THF, -78 °C; (b) (PhSO2)2NF or 
C2Cl6, -78 to 0 °C; (c) EtOLi/EtOH, 0 °C  
Scheme III.1: Method for the α-monohalogenation of alkylphosphonates45 
First, the alkylphosphonate is deprotonated with LDA followed by a monosilylation in order to 
prevent overhalogenation. A second equivalent of LDA then again forms an α-carbanion, which may 
attack an electrophilic halogen source, in this case N-fluorobenzenesulfonimide46 or 
hexachloroethane, resulting in an α-TMS,α-halogenated alkylphosphonate. Finally, the silyl group is 
removed in situ by lithium ethoxide – ethanol. This strategy has several advantages such as high 
yield, high speed, ready availability of electrophilic halogenating reagents and easy elimination of 
byproducts. Hence it seemed obvious to apply it for the α-halogenation of a suitably protected 
FR900098 derivative. Apart from the obvious necessity to protect the retrohydroxamate N-OH, we 
anticipated enolization of the N-acetyl might cause additional problems. Iorgas halogenation 
conditions were tried on both an N-Boc,O-benzyl- and an N-Boc,O-Boc-protected FR900098 
precursor (7a and 7b, SchemeIII.2), unfortunately without success: reaction mixtures immediately 
turned black and no product nor any desired intermediate could be isolated. Knowing the 
susceptibility of some benzyl ethers towards LDA and nucleophiles, we also tested the reaction on N-
Boc,O-silyl-protected precursor 7c, alas without success. 
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Scheme III.2: Substrates failed in the α-monohalogenation  reaction 
Apparently, the retrohydroxamate functionality –and even its protected precursors- are too 
sensitive to the reaction conditions used. It has to be mentioned here that Iorga only describes the 
halogenation of unfunctionalized alkylphosphonates and also elsewhere in literature this procedure 
is only applied to structurally robust/simple molecules47. Therefore, we retreated a step from the 
protected FR900098 toward a more robust / structurally simpler precursor from which the 
retrohydroxamate could be synthesized in a later stage. Protected amines or alcohols were a logical 
choice, but unfortunately, neither azide 7e, nor phthalimide 7d or silylated alcohol 7f could be 
halogenated using this protocol. Trying to cut down even more on functionality in our precursor, or 
move more towards the alkanes described in the original paper, we ended up with diethyl but-3-
enylphosphonate 8 which could cleanly be fluorinated. However, upon applying the described 
conditions for α-chlorination, we noticed the formation of a side product that could be identified as 
diene 10 (Scheme III.3). This originated most probably from elimination of HCl from the desired 
product with the formation of a conjugated diene as the driving force. Later we also noticed this 
reaction to take place during fluorination, although to a lesser extent. We circumvented this side 
reaction by switching from the basic lithium ethoxide – ethanol conditions to TBAF in acetic acid for 
the removal of the α-TMS group. 
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Scheme III.3: Desilylation conditions 
With the α-halogenated precursors 11a-b in hand, we then assembled the hydroxamate head 
group as depicted in Scheme III. 4. First the double bond was oxidized with NMO and osmium 
tetroxide as a catalyst.  
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Scheme III.4: General synthesis of α-monohalogenated FR900098 analogues 
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The resulting vicinal diol was then cleaved oxidatively with sodium periodate and the resulting 
aldehyde reduced with sodium borohydride to give alcohols 13a-b. Subsequently, the alcohols were 
converted into tosylates 14a-b, which were substituted with N-Boc,O-benzylhydroxylamine. 
Treatment of 15a-b with trifluoroacetic acid in dichloromethane gave oxyamines 16a-b, which were 
acetylated with acetic anhydride. For the upscaling of the fluorinated analogue, the procedure was 
shortened both in reaction time and number of steps (Scheme III.5). The olefin was cleaved in a one-
pot dihydroxylation – oxidative cleavage using catalytic potassium osmate and potassium periodate 
both as a cooxidant in the dihydroxylation and as main oxidant in the vicinal diol oxidative cleavage. 
Not only did we win a step this way, the dihydroxylation also proceeded much smoother with 
periodate as the oxidant instead of NMO. Furthermore, instead of reducing the aldehyde, it was 
reacted with O-benzylhydroxylamine in acetic acid to form oxime 20. A comparable oxime 
formation48 was successfully accomplished before in pyridine, but according to literature, it can also 
be realized in acidic media49 with an optimal reaction rate around pH = 4. We deliberately chose for 
an acidic reaction medium in order to prevent elimination of HF from aldehyde 12b and formation of 
phosphonoacrylate 19. The resulting oxime was then reduced with sodium cyanoborohydride in 
hydrochloric acid - methanol affording oxyamine 16b in a shorter, more convenient and more atom-
economic way. Other, more benign reductants  (NaBH4, sodium triacetoxyborohydride, borane) for 
the reduction of this kind of oximes, as well as one-pot reductive oxyaminations have been explored 
before in our lab and proved unsuccessful. Clearly, a two-step strategy, involving oximation, isolation 
of the oxime and then reduction with cyanoborohydride in acidic methanol is preferred. 
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Scheme III.5: Shorter synthesis of α-fluoro-oxyamine precursor 16b 
Finally, debenzylation of the retrohydroxamate by hydrogenation over palladium on carbon, 
followed by TMSBr-deprotection of the phosphonate esters and basic workup gave 4a and 4b as 
bisammonium salts. 
III.B.2. α-Fluoro hydroxamate analogue 
One advantage of executing the electrophilic halogenation on the butenylphosphonate is that we 
ended up with a more versatile synthon. Having α-fluorophosphonate 11b in hands, we decided to 
also explore its conversion to hydroxamate 5 (Scheme III.6). As was described in the introduction, 
replacing the native retrohydroxamate in fosmidomycin or FR900098 for a N-methylated 
hydroxamate (N-methyl,N-hydroxyamide) has often resulted in potent DXR ligands. Hydroboration of 
11b gave rise to alcohol 21 which was oxidized with TEMPO-BAIB to carboxylic acid 22. This acid was 
activated with 1,1’-carbonyldiimidazole (CDI) and coupled with N-methyl,O-benzylhydroxylamine to 
give 23, which was then deprotected in the same way as 17a-b to give 5 as the bisammonium salt. 
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Reagents and conditions: (a) (i) BH3.THF (ii) NaOH, H2O2; (b) TEMPO, BAIB, MeCN/H2O; 
(c) 1,1'-carbonyldiimidazole, Me-NH-OBn;  (d) H2, Pd/C, EtOAc; (e) (i) TMSBr, CH2Cl2, 
(ii) NH4OH, THF
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Scheme III.6: Synthesis of α-fluoro hydroxamate analogue 5 
III.B.3. Influence of α-halogen substitution on pKa 
In order to assess the influence of the introduced halogens on the ionization of these 
phosphonates, the pKa’s of compounds 4a and 4b, as well as the FR900098 reference were estimated 
from the pH dependence of their 31P chemical shift. Towards this end, the 31P chemical shift of each 
compound was measured at different pH and plotted as a function of these pH values. The pKa of 
each compound is estimated to be at the pH of the inflection point of its titration curve.  
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Figure III.3: Overall titration curves for α-chloro- and α-fluoro-FR900098 and FR900098 itself 
Of special interest here is the second pKa of each molecule, as the value of this pKa determines 
whether the phosphonate will be in its single- or double-ionized form at physiological pH. Therefore 
a cutout of the titration curves is displayed from which the pKa2 can be estimated. 
 Figure III.4: Detail of titration curves around their second inflection point 
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 From these figures, a pKa2 of 7.35 can be estimated for FR900098, whereas both the 
α-chlorinated analogue 4a and the α-fluorinated analogue 4b show a pKa2 of around 6. It can thus be 
concluded that introduction of a halogen in α-position of the phosphonate moiety indeed lowered 
the pKa2 of those compounds thereby more closely resembling that of a phosphate moiety
9. 
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III.C α,α-Difluoro-FR900098 
III.C.1. Electrophilic fluorination of an α-fluorophosphonate 
Having successfully performed the electrophilic monohalogenation as described above, we 
decided to explore a similar strategy for the synthesis of α,α-difluoro-FR900098 by performing a 
second fluorination of α-monofluoro-phosphonate 11b under the same conditions (Scheme III.7). A 
first attempt, using the same conditions as for the first fluorination without the silylation step (LDA, 
NFBS, THF, -78 °C) resulted in a deep brown coloration of the reaction mixture indicating breakdown, 
and indeed no product nor any starting material could be recovered. In their paper on the discovery 
and use of NFBS, Differding et al.47 documented the sensitivity of this type of reaction to temperature 
and the base involved, and recommended the use of KDA (from nBuLi and KOtBu) and to work below 
-90 °C. Unfortunately, in our hands these conditions (KDA, NFBS, THF, -95 °C) also resulted in total 
decomposition of the α-fluoro butenylphosphonate 11b.  
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Scheme III.7: Attempted electrophilic second fluorination 
Therefore, we switched to method 4 outlined in the introduction: alkylation of a fluorinated 
phosphonate carbanion. 
III.C.2. Alkylation of diethyl bromodifluoromethylphosphonate 
First we tried to reproduce an experiment by the Burton group32 comprising the insertion of 
cadmium into the bromine-carbon bond of diethyl bromodifluoromethylphosphonate followed by 
the attack of this organometal reagent onto allyl bromide, resulting in the difluoro-analogue of 11b 
(Scheme III.8). 
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Scheme III.8: Metal insertion into bromodifluoromethylphosphonate and subsequent alkylation 
The metal insertion proved to be quite hard and not reproducible, resulting in low yields for the 
coupling with allyl bromide. It has to be noted here that the monitoring of this reaction is not trivial 
as diethyl bromodifluoromethylphosphonate 26 is slightly volatile, does not quench UV light on TLC 
and also does not stain with common reagents such as permanganate, phosphomolibdic acid or 
cerium-ammonium-molybdate. The bad results obtained when using cadmium, together with its 
toxicity, urged us to try out other metals such as magnesium and zinc. The reaction of 26 with 
magnesium turnings resulted in a red-black solution, pointing to breakdown probably via carbene 
formation (Scheme III.9). 
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Reagents and Conditions: (EtO)2P(O)CH2Br, Mg powder, THF, 
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Scheme III.9: Postulated carbene formation upon magnesium insertion 
According to literature data50, 51, Mg insertion into 26 can only be accomplished through the use 
of Grignard reagents such as iPrMgBr. Finally, we achieved nearly quantitative metal insertion using 
activated zinc dust in DME32 though only upon prolonged sonication. The formation of the metalated 
species, which is described as quite stable at room temperature, can be followed by 31P-NMR: the 
starting bromide shows up as a triplet at δ=5.29ppm which upon Zn insertion shifts downfield to 
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δ=13.85ppm. On 19F-NMR a shift is seen from δ=-136.5 to δ=-128ppm. The use of Rieke-zinc52-55 
(preformed from lithium naphthalenide and anhydrous zinc chloride), in order to speed up the metal 
insertion and improve the yield, only resulted in debromination of the starting phosphonate resulting 
in diethyl difluoromethylphosphonate. The copper(I)-catalyzed addition of the phosphonate-zinc 
reagent proceeded rather slowly (which is in accordance to literature findings32), typically giving 
yields between 50% and 70% after two days of reaction at room temperature. Here again, difficulties 
in monitoring the volatile and hard-to-stain reagents complicated the procedure. In the end, the use 
of ordinary zinc dust (activated by simply washing with dilute hydrochloric acid) and the copper(I)-
catalyzed allyl bromide coupling allowed us to synthesize a sufficient amount of precursor 25. 
With the α,α-difluorobutenylphosphonate 25 in hand, we envisaged the construction of the 
retrohydroxamate as accomplished for the monohalogenated analogues (Scheme II.10). 
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Scheme III.10: Anticipated general synthetic route toward α,α-difluoro-FR900098 
Osmium tetroxide-catalyzed NMO oxidation of the double bond in 25 followed by cleavage with 
sodium periodate gave aldehyde 28 together with undefined polar products. These ‘polar products’ 
were visible as a significant baseline spot on TLC and their formation, with concomitant reduction of 
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the yield, was a problem with most reactions involving the difluorophosphonate. Only much later in 
this work their origin became clear, as will be described further in this thesis. Attempted reduction of 
aldehyde 28 with sodium borohydride also suffered heavily from this breakdown to polar products 
and on top of that, the only product that could be effectively isolated was allylic alcohol 35 (Scheme 
III.11), probably formed by E2 elimination. 
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Scheme III.11: Elimination upon attempted borohydride reduction 
To circumvent the use of basic reaction conditions, we explored the reductive amination of 
aldehyde 28 with O-benzylhydroxylamine and triacetoxyborohydride in acidic conditions, but 
unfortunately this reaction got stuck at the oxime stage and also suffered from fluoride elimination 
(Scheme III.12).  
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Scheme III.12: Attempted reductive (oxy)amination of aldehyde 28 
Attempted reduction of oxime 36 with sodium cyanoborohydride in hydrochloric acid – methanol 
led to total decomposition of the oxime. These findings indicated that an α,α-difluorophosphonate 
bearing molecule is not amenable to many synthetic manipulations. Therefore, we considered a 
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more convergent synthesis based on the coupling of the difluoromethylphosphonate with a ‘tail part’ 
that already features a (protected) retrohydroxamate (Scheme III.13). 
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Scheme III.13: Attempted convergent route toward protected α,α-difluoro-precursor 31 
 N-Boc,O-benzylhydroxylamine (40) was coupled with 1,2-dibromoethane (39) resulting in the 
alkyl bromide 41. Attempts to couple this ‘tail’ with zinc halide 38, analogous to the coupling with 
allyl bromide in the presence of copper(I)bromide, were unsuccessful. Either the protected 
retrohydroxamate degrades under the reaction conditions used, or the coupling reaction is very 
limited in terms of substrates. This assumption, together with the difficulties associated with the zinc 
insertion into the bromodifluorophosphonate building block, led us to invstigate another strategy: 
the attack of a lithiated difluoromethylphosphonate onto a primary alkyl triflate29, 30. 
III.C.3. Alkylation of diethyl difluoromethylphosphonate 
Retaining the idea of convergence, a hydroxyethylated hydroxamate tail 47 was constructed first, 
using two different strategies as depicted in Scheme III.14. Method A is based on the alkylation of N-
Boc,O-benzylhydroxylamine with silylated 2-bromoethanol 42, followed by sequential deprotection, 
bis-acetylation and ester hydrolysis. Method B is more straightforwardand involves a two-step 
reductive oxyamination of silylated glycolaldehyde followed by acetylation and final desilylation. 
 Chapter III: Alpha-halogenated analogues of FR900098 
III.20 
Alcohol 47 was then quantitatively converted to its triflate using triflic anhydride and DIPEA in 
dichloromethane, followed by extraction at 0 °C and removal of the volatiles in vacuo. 
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Scheme III.14: Synthesis of 'tail' alcohol 47 via two different routes 
In their original paper29, Berkowitz et al. propose two basic strategies for the displacement of 
triflates by difluoromethylphosphonates. The first encompasses the in situ formation of the anion, by 
mixing diethyl difluoromethyl phosphonate with the triflate and a lithium complexant (HMPA or 
TMEDA) in THF followed by addition of LDA. The second method consists of the lithiation of diethyl 
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difluoromethyl phosphonate with LDA in the presence of HMPA or TMEDA in THF followed by the 
addition of a solution of the triflate. Because of the risk of elimination reactions we chose the latter 
method (Scheme III.15). A solution of LDA in THF was prepared, HMPA or DMPU (as a non-
carcinogenic alternative) was added followed by diethyl difluoromethylphosphonate (53). After a few 
minutes, this mixture was added to a solution of triflate 48 in THF at -78 °C and stirred for five 
minutes. The reaction mixture was quenched by the addition of saturated aqueous ammonium 
chloride. Analysis of the reaction mixture revealed degradation of the starting material to very polar 
products.  
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Scheme III.15: Attempted convergent synthesis via triflate displacement with 
difluoromethylenephosphonate anion 
Apparently the protected retrohydroxamate moiety of 48, which resembles a Weinreb amide, 
did not withstand the harsh reaction conditions. According to the literature28-30 though, the triflate-
displacing strategy has given satisfying yields with a whole range of differently protected (benzyl, 
allyl, TES, TBDMS, BOM, PMB, isopropylidene) sugar primary triflates as well as an (1H-pyrrol-1-
yl)alkyl triflate and silyloxyalkyl-  or naphthylalkyltriflates. Therefore, we wanted to give this strategy 
another try, this time with a less elaborated ‘tail’. Having already ruled out the use of an alkene, we 
set our hopes on a simple alcohol as a handle for the construction of the retrohydroxamate, 
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protected with the robust benzyl group (Scheme III.16). Thus, 2-benzyloxyethanol (55) was triflated 
under the same conditions as 47 in good yield, followed by lithium diethyl 
difluoromethylphosphonate attack in THF and DMPU at -78 °C resulting in α,α-difluoro 
benzyloxypropylphosphonate 57 in acceptable yield. According to NMR, however, this product was 
contaminated with a considerable amount of the starting phosphonate (53) that coeluted upon 
purification and which, as stated before, is not visible on TLC.  
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Scheme III.16: Triflate displacement by diethyl difluoromethylphosphonate anion 
To get rid of this contaminant, we figured that the reductive debenzylation of 57 might shift the 
product to a lower Rf, thus enabling its chromatographic purification. To our amazement, the 
debenzylation of 57 under ‘standard’ conditions (atmospheric pressure hydrogen, 10% palladium on 
charcoal or Pd black in methanol or THF) gave no result at all. Probably, the diethyl 
difluoromethylphosphonate in the starting material inhibited the reduction by poisoning of the 
palladium catalyst. This problem was overcome by switching to catalytic hydrogen transfer 
debenzylation56, 57 using formic acid as a hydrogen donor on the one hand, and recycling the 
difluoromethyl phosphonate contaminant by means of distillation upon resynthesis of 57 on big scale 
on the other hand. Alcohol 58 was subsequently converted to its tosylate 59, which could then be 
substituted by a suitable oxyamine (Scheme III.17). Because of the ease with which these molecules 
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undergo elimination, we were reluctant to use strong bases and therefore tried to substitute the 
tosylate with simple O-benzylhydroxylamine (60) in the presence of triethylamine.  
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Scheme III.17: Synthesis of tosylate 59 and attempts toward substitution by a suitably protected 
hydroxylamine. 
This proved to be unsuccessful, forcing us to try the more established route using N-Boc,O-
benzylhydroxylamine (40) and sodium hydride. This wasn’t a big success either as the desired 
product 31 was only formed in a very low yield, due to formation of two major products: 
propylenephosphonate 60, resulting from E2-elimination of the tosylate, and ethylated oxyamine 61, 
possibly resulting from the attack of deprotonated N-Boc,O-benzylhydroxylamine onto one of the 
ethyl esters of the phosphonate as depicted in Scheme III.18. The elimination product could not be 
entirely separated from the desired product. 
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Scheme III.18: Attack of deprotonated BocN(Na)OBn onto an ethyl ester of the 
difluorophosphonate 
Indeed, the introduction of two fluorine atoms onto the α-carbon increases the acidity of the 
phosphonate and thus also its leaving group capacity, thereby decreasing the stability of the 
phosphonate ethyl esters as protecting groups (Scheme III.19). This also explains the generally low 
yields and the presence of polar (breakdown) products in most reactions involving the 
difluoromethylene moiety: whenever basic/nucleophilic conditions are present, a (partial) 
breakdown ensues resulting in ethylated nucleophile (probably volatile and/or non-chromophoric 
hence unnoticed on TLC in the case of small nucleophiles) and a monoethyl 
α,α-difluoroalkylphosphonic mono-acid. It also explains that reactions involving acidic conditions 
usually gave better yields and cleaner reaction mixtures. 
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Scheme III.19: Formation of a stabilized anion by loss of an ester from a 
α,α-difluoroalkylphosphonate 
In line with these assumptions, the subsequent Boc removal from 31 with TFA proceeded in good 
yield without any problems (Scheme III.20). Also the acetylation of oxyamine 32 with acetic 
anhydride in the presence of triethylamine proceeded smoothly to yield protected α,α-difluoro-
FR900098, albeit in a minute quantity. 
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Scheme III.20: Boc removal and acetylation 
 Because of the poor yield of the tosylate displacement, we set out for another synthesis of the 
retrohydroxamate functionality using gentler reaction conditions (Scheme III.21). Our first choice was 
the Mitsunobu reaction for it provides both the required mild conditions and allows direct 
conversion of the free alcohol to a protected retrohydroxamate. Trying to introduce N-Boc,O-
benzylhydroxylamine under these conditions proved unsuccessful, due to the insufficient acidity of 
this carbamate on the one hand and the inactivated alcohol 58 on the other hand. Previously, 
Vincent Devreux from our group tackled a similar problem by replacing the Boc-group for a nosyl 
(2-nitrobenzenesulfonyl) group, thereby lowering the pKa of the N-H and increasing its reactiveity58-
60. When we applied this strategy, N-nosyl,O-benzylhydroxylamine 64 was formed in 54% yield, 
without any elimination occurring.  
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Scheme III.21: Mitsunobu approach toward 33 
For the subsequent nosyl deprotection and acetylation, we borrowed the practical one-pot 
strategy also developed by Vincent Devreux: first the nosyl group is removed by nucleophilic attack 
with thiophenol under basic conditions (K2CO3), followed by the addition of acetic anhydride to 
acetylate the formed oxyamine and any remaining thiophenol, thus avoiding problems of thiophenol 
smell and toxicity. Applied to nosylate 64, this strategy yielded once again protected α,α-difluoro-
FR900098 33 in 53% yield. Phosphonate ethyl ester cleavage by thiophenol was also noticed by 
negative mode MS of the reaction mixture (signal of phosphonate mono-ethyl ester). 
Finally, having synthesized a sufficient amount of protected product 33, attempts toward final 
deprotection were made (Scheme III.22). First the benzyl group was removed using catalytic transfer 
hydrogenation with formic acid as the hydrogen donor. It is known that the solvent can have a 
dramatic effect on the hydrogenation rate, and therefore it was carried out in ethyl acetate resulting 
in a total deprotection in only one hour with a yield of 80% after column chromatography. 
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Scheme III.22: Final deprotection of protected α,α-difluoro-FR900098 (33) 
Deprotection of phosphonate esters with TMSBr, despite being a frequently used technique, still 
remains a bit of a black box for several reasons. To better understand these, we should first take a 
closer look on the (postulated) mechanism of TMSBr mediated phosphonate ester deprotection61 
depicted in Scheme III.23. The reaction follows a mechanism similar to that of the Arbuzov reaction 
for phosphonate synthesis, going via a σ4λ4 intermediate: it begins with the attack of an electron pair 
of the phosphoryl functionality onto TMSBr with expulsion of bromide, forming the σ4λ4 
phosphonium intermediate. The bromide then attacks one of the esters of the phosphonium 
intermediate, resulting in an alkyl bromide and restoration of the σ4λ5 configuration of the mixed 
alkyl-silyl phosphonate ester. 
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Scheme III.23: Postulated mechanism for the TMSBr-mediated phosphonate de-esterification 
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This mechanism is repeated for the second alkyl ester, finally resulting in a bis-silylated 
phosphonate and two equivalents of alkyl bromide. Generally, all volatiles (excess TMSBr, solvent 
and alkyl bromide) are then removed in vacuo before water is added to hydrolyze the silyl 
phosphonate. In this manner, a clean and uncontaminated product can be obtained. In practice, 
however, the monitoring of this reaction poses a few problems. As the introduction of moisture leads 
to formation of harmful HBr and may prematurely hydrolyze the (mono)silylated phosphonate 
leading to precipitation from the reaction mixture thus rendering it unavailable for further reaction, 
reaction sampling should be restricted to a minimum. Moreover, as long as the reaction is not 
finished, only unstable silyl(hemi)esters are present, which should be hydrolyzed to their 
corresponding mono-esters or free phosphonates before TLC or MS analysis, thus calling for tedious 
sample preparation. Good monitoring of the reaction mixture by (LC)MS is further complicated by 
the fact that the starting material (= protected phosphonate) is best ionized in positive mode, 
whereas intermediate and final products exclusively ionize in negative mode. Followup by TLC is 
impractical as the silylether intermediates are not stable enough whereas the free phosphonic acid 
and the monoester are far too polar for straight-phase chromatography. Again, the absence of any 
chromophore at all in these molecules as well as their problematic staining hamper their detection 
via chromatography, both TLC and HPLC. Fortunately, 31P-NMR can be successfully applied to monitor 
phosphonate deprotections. Because the deprotection of a phosphonate goes via intermediates with 
a pretty large difference in chemical environment around the phosphorus atom, all these 
intermediates have a different chemical shift and can usually be easily differentiated in a 31P-NMR 
spectrum of the reaction mixture. Generally the fully alkylated phosphonate will be most downfield 
(δ = 5 to 30 ppm) and the deprotected phosphonate most upfield (δ = -10 to 5 ppm) with the 
intermediates in between these values. Since follow-up of a bigger-scale phosphonate deprotection 
via sample prelevation poses the same problems of moisture sensitivity, the reaction rate of a 
particular deprotection can elegantly be estimated by performing a test deprotection in a flame-
sealed NMR tube as used for the deprotection of the difluoro-molecule.  A small amount of 33 was 
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dissolved in deuterochloroform in a standard NMR tube, 10 equivalents of TMSBr was added and the 
tube was flame-sealed. The tube was vortexed regularly to ensure proper mixing of the reaction 
mixture and the reaction was followed by 31P-NMR (δstarting material = 7 ppm). As we noticed by MS that 
the first ethyl ester was quickly removed, the peak appearing at δ = -1.5 ppm was attributed to the 
formation of the mixed ethyl-silylester 67 (Scheme III.24). Knowing the reactivity of the 
difluorophosphonate and the loss of ethyl groups we encountered during almost all reactions this is 
not surprising. Opposed to the ease with which the first ester was removed, removal of the second 
ethyl ester proved problematic62. This reaction proceeded so slowly that, before it was finished, a by-
product started forming, which was visible as a second triplet on the 31P-NMR spectrum, intertwined 
with the product triplet around δ = -10 ppm. Judging from its chemical shift that was so close to that 
of the free phosphonate, this side-product must originate from breakdown remote from the 
phosphorous atom, probably de-acetylation of the retrohydroxamate (69). In an attempt to speed up 
the (second) ester removal, we decided to use a higher concentration of TMSBr (using a 1:1 mixture 
of CDCl3 and TMSBr): this time the second ester could be removed before noticeable formation of 
any side product.  
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Scheme III.24: Phosphonate deprotection of 34 at low (up) and high (down) TMSBr concentration 
 Unfortunately, upon workup of the reaction mixture containing bis-TMS intermediate 68 
(removal of all volatiles in vacuo at 25 °C, followed by hydrolysis of the silyl esters with water) a quick 
breakdown of the retrohydroxamate (loss of acetyl) was noticed, giving rise to an inseparable 
mixture of desired product 6 and its N-deacetyl analogue 70. Even upon using ammonium hydroxide 
to neutralize the acid in a second attempt, with formation of the phosphonate ammonium salt, loss 
of the N-acetyl was noticed. Acid mediated breakdown is thus apparently already taking place during 
the removal of the reaction volatiles, which indicates the high acid sensitivity of the 
retrohydroxamate moiety. 
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III.C.4. Benzylphosphonate approach 
The problems encountered with the workup of the TMSBr-deprotection forced us to try a 
different protecting group strategy for the phosphonate that would allow for a gentler deprotection, 
preferably not involving the generation of acid (apart from the phosphonic acid itself). In 
(fluoroalkyl)phosphonate chemistry, two such groups are commonly used: the di-allylphosphonate 
and the dibenzylphosphonate30. The former is deprotected using catalytic palladium (Pd(PPh3)4) and 
a suitable allyl acceptor (e.g. potassium 2-methylhexanoate), whereas the latter can be debenzylated 
by reduction on palladium metal (Pd black or Pd/C), followed by filtration to remove the catalyst. The 
latter method is preferred since it allows for an easy deprotection under gentle conditions and an 
easy workup. Unfortunately, benzyl phosphonate esters are less stable and more prone to 
nucleophilic attack than their alkyl counterparts. Together with the experienced increased 
electrophilicity of α,α-difluoromethylphosphonate esters, this could lead to (too) labile protecting 
groups. Nevertheless, this strategy was tried as a last resort in our attempts to synthesize 
α,α-difluoro-FR900098 (6). 
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Scheme III.25: Anticipated synthetic route toward α,α-difluoro-FR900098 using phosphonate 
benzyl esters 
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Essentially, we planned to repeat the triflate displacement strategy onto a suitably protected 
ethylene glycol triflate 72 analogous to the ethylphosphonate route28, followed by introduction of 
the retrohydroxamate by a Mitsunobu reaction with N-nosyl,O-benzylhydroxylamine as depicted in 
Scheme III.25. Evidently, 2-benzyloxyethanol could not be used this time due to its incompatibility 
with the benzyl protection of the phosphonate.Contrary to its ethyl counterpart, dibenzyl 
difluoromethylphosphonate 79 is not commercially available so it had to be synthesized from 
chlorodifluoromethane (78) and sodium dibenzylphosphite at low temperature30, 63, resulting in the 
desired product (79) together with an amount of benzyl alcohol (81) and dibenzyl 
benzylphosphonate (80) (Scheme III.26). 
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Scheme III.26: Synthesis of dibenzyl difluoromethylphosphonate 
 The latter is the result of an attack of deprotonated dibenzylphosphite 82 onto a benzyl ester of 
the already formed dibenzyl difluoromethylphosphonate 83 (Scheme III.27), illustrating the increased 
electrophilicity mentioned above.  
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Scheme III.27: Formation of dibenzyl benzylphosphonate from dibenzylphosphite and a 
benzylphosphonate 
 Next, ethyleneglycol was mono-protected with a tert-butyldiphenylsilyl-group, triflated and 
subjected to triflate displacement with lithium dibenzyl difluoromethylphosphonate 71 in DMPU/THF 
resulting in silylether phosphonate 87 in 66% yield. Unfortunately, all attempts to desilylate ether 87 
resulted in extensive breakdown of the benzylphosphonate (Scheme III.28). 
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Scheme III.28: Attempted synthesis of alcohol precursor 74 
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In a final attempt we tried to circumvent the need for an alcohol deprotection step (step b in 
Scheme III.25) by synthesizing alcohol 74 from dibenzyl lithiodifluoromethylphosphonate 71 and 
ethylene oxide as depicted in Scheme III.29.  
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-78 °C, 3h  
Scheme III.29: Attempted synthesis of alcohol 74 from ethylene oxide 
Also this attempt was unsuccessful, yielding mainly benzyl alcohol and phosphonate breakdown 
products and no desired alcohol 74. 
Apparently, benzyl esters are too weak as protecting groups for this synthesis, and together with the 
knowledge of the acid sensitivity of the retrohydroxamate combined with a quite strong 
α,α-difluorophosphonic acid this made us cease our attempts towards α,α-difluoro-FR900098. 
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III.D. Prodrugs 
As mentioned above, the α-halogenated FR900098-analogues showed the expected decreased 
pKa which should lead to a better affinity for DXR. On the other hand, the increased polarity of these 
analogues might also hamper their pharmacokinetic properties. Therefore, we decided to synthesize 
two phosphonate prodrug forms of α-fluoro-FR900098 (4b): its bis(pivaloyloxymethyl)-ester (93) and 
its bis(isopropyloxycarbonyloxymethyl)-ester (94)(Scheme III.30). 
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Scheme III.30: Synthesis of prodrugs of α-fluoro-FR900098 
Prodrugs of the acyloxymethyl-phosphonate ester type are generally synthesized in three steps 
from fully protected fosmidomycin precursors64-70: first, the phosphonate is deprotected while 
maintaining the (retro)hydroxamate protecting benzyl group. Then the free phosphonic acid is 
treated with an appropriate chloromethyl ester or –carbonate in the presence of a base, often at 
elevated temperatures and with addition of sodium iodide to improve the yield. Finally, the 
(retro)hydroxamate is debenzylated, resulting in the desired phosphonate prodrug. When the free 
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phosphonate of α-fluoro-analogue 17b was reacted with chloromethyl pivalate (POMCl), the desired 
protected bis-POM ester 91 was only obtained in 18% yield. 
To increase this low yield, two adaptations to the above strategy were made. First, commercial 
chloromethyl pivalate was transformed into iodomethyl pivalate under Finkelstein conditions71. 
Secondly, after phosphonate deprotection of 17b the phosphonic acid was neutralized with a 
stoichiometric amount of sodium hydroxide to convert it into its disodium salt 89. This disodium salt 
was then converted into the disilver salt 90 by aqueous metathesis with a silver nitrate solution. 
Reaction of 90 with iodomethyl pivalate in toluene gave the protected bis-POM analogue 91 in 32% 
yield. 
For the synthesis of carbonate 92, chloromethyl isopropyl carbonate was first synthesized according 
to a literature procedure72 and then transformed into iodomethyl isopropyl carbonate under 
Finkelstein conditions71. Reaction of disilver phosphonate 90 with iodomethyl isopropyl carbonate in 
toluene gave bis-carbonate analogue 92 in 17% yield. Both protected hydroxamates were then 
debenzylated in good yields, resulting in α-fluoro prodrugs 93 and 94. 
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III.E. Biological Results 
The three α-halogenated phosphonic acids 4a, 4b and 5 were tested for their capacity to inhibit 
EcDXR using a spectrophotometric assay i.e. by monitoring the decrease in NADPH absorption at 
340 nm. EcDXR inhibition caused by these analogues was compared with fosmidomycin, FR900098 
and α-(3,4-dichlorophenyl)fosmidomycin, all incubated at 100nM (Table III.1). Both α-fluorinated 
analogues 4b and 5 outperformed the three reference compounds, whereas the α-chloro analogue 
4a exhibited stronger EcDXR inhibition than both fosmidomycin and α-(3,4-dichlorophenyl) 
fosmidomycin, but slightly weaker than FR900098. 
The free phosphonic acids and the prodrugs 93 and 94 were also tested in duplicate for their 
inhibitory effect against intraerythrocytic forms of P. falciparum (strains GHA and K1) using a 
microdilution assay73. Phosphonic acids 4a, 4b and 5 showed submicromolar activity on both strains 
and appeared to be 5- to 6-fold more active than fosmidomycin and slightly superior to FR900098 on 
the K1 strain. More spectacular, though, is the submicromolar activity displayed by both prodrugs of 
α-fluoro FR900098. Remarkably, the bis-carbonate based prodrug (94) was twice as active as the 
more ‘classic’ bis-POM prodrug (93) . To the best of our knowledge, these are the lowest IC50 values 
for a fosmidomycin based DXR inhibitor encountered so far (the former being Behrendt’s α-aryl 
reversed hydroxamates74), and further in vivo testing for these compounds is warranted. All 
α-halogenated compounds and their prodrugs were also tested for their cytotoxicity against MRC-5 
SV2 cells, human fetal lung fibroblast, where they showed IC50 values of more than 64 µM. 
Furthermore, the title compounds were screened for their activity against T. cruzei, L. infantum, T. 
brucei, T. rhodesiense, E. coli, S. aureus, C. albicans, T. rubrum and A. fumigatus. No activity (IC50 >64 
µM) was seen for all analogues against any of these organisms, confirming their selectivity for 
Plasmodium species. 
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Chart III.1: EcDXR inhibition of α-halogenated FR900098 analogues incubated at 100 nM 
(α-(Cl2Ph)-Fos = α-(3,4-dichlorophenyl) fosmidomycin) 
 
Table III.1: In vitro EcDXR inhibition and P. falciparum growth inhibition by α-halogenated 
FR900098 analogues and their prodrugs. 
 
EcDXR Enzyme Inhibition 
In vitro 
P. falciparum 
growth inhibition 
(IC50 in µM) 
Compound % inhibition 
at 100 nM 
Ki 
(nM) 
IC50 
(nM) 
Pf  GHA Pf K1 
Fosmidomycin 75.57 - - - 1.73 
FR900098 67.60 15.11 30.23 - 0.42 
α-(3,4-dichlorophenyl) 
fosmidomycin 
56.92 - - 0.60 0.16 
      
4a 72.94 14.2 28.3 0.82 0.30 
4b 89.75 11.3 22.7 0.70 0.29 
5 78.73 - - 0.73 0.31 
93 - - - - 0.07 
94 - - - - 0.03 
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The reference α-(3,4-dichlorophenyl)fosmidomycin and the fluorinated analogues 4b and 5 were 
also evaluated in vivo in the P. berghei (GFP ANKAstrain) acute mouse model after intraperitoneal 
dosing at 50 mg/kg for 5 consecutive days. Chloroquine (10 mg/kg for 5 days) was included as 
reference treatment. The animals were observed for the occurrence/presence of clinical or adverse 
effects during the course of the experiment. In case of very severe clinical signs, either due to toxicity 
or malaria, animals were euthanized for welfare reasons. Parasitemia was determined on days 4, 7, 
and 14 on surviving animals using flow cytometry (10 μL of blood in 2000 μL of PBS). Percentage 
reduction of parasitemia compared to vehicle-treated infected controls is used as a measure for drug 
activity, and the mean survival time (MST) was calculated (Table III.2). Strangely enough, 
α-(3,4-dichlorophenyl)fosmidomycin did not show any relevant activity. On the other hand, 5 
resulted in 85% suppression of parasitemia at 4 dpi, which dropped to 42% at 7 dpi and 41% at 14 
dpi. The mean survival time was 11.7 days. Compound 4b resulted in 88% suppression of parasitemia 
at 4 dpi, which after ending the treatment also dropped to 62% at 7 dpi and 32% at 14 dpi. The 
overall MST was 15.8 days.  
Table III.2: In vivo testing of α-fluoro FR900098 analogues: Survivors and Mean Survival Time 
(MST in Days) in the P. berghei (GFP ANKA Strain) Acute Mouse Model 
  Survivors  
Treatment  
(ip for 5 consecutive days) 
Parasitemia suppression 
(day 4) 
day 
7 
day 
11 
day 
14 
day 
25 
MST 
Vehicle 0 1/6 1/6 1/6 0/6 8.5 
Chloroquine (10 mg/kg) 100 6/6 6/6 6/6 3/6 20.7 
Fosmidomycin (50 mg/kg) 82 6/6 4/6 3/6 nd 11.5 
FR900098 (50 mg/kg) 93 6/6 3/6 2/6 nd 10.8 
α-(3,4-dichlorophenyl) 
fosmidomycin (50 mg/kg) 
46 4/5 0/5 0/5 0/5 7.0 
4b (50 mg/kg) 88 4/4 2/4 2/4 0/4 15.8 
5 (50 mg/kg) 85 2/3 2/3 1/3 0/3 11.7 
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These data clearly demonstrate that the three synthesized phosphonic acids have promising in 
vitro activity and that 4b and 5 surpass the antimalarial activity of FR900098 in vivo. Both prodrugs 93 
and 94 evoke high expectations and in vivo testing of these compounds is awaited. 
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III.F. Experimental Details 
 
General Methods and Materials. 1H, 13C, 19F and 31PNMR spectra were recorded in CDCl3, 
acetone-d6, DMSO-d6 or D2O on a Varian Mercury 300 spectrometer. Chemical shifts are given in 
parts per million (ppm) ( relative to residual solvent peak for 1H and 13C and to external D3PO4 for 
31P). All solvents and chemicals were used as purchased unless otherwise stated. Purity of the final 
compounds was deduced from clean 1H, 13C and 31P NMR spectra, high resolution mass spectra and 
assessed by LC-DAD-MS. Reversed phase chromatograms were recorded on a Phenomenex Luna C-
18 2.5 µm particle (100 x 2.00 mm) column in a Waters Alliance 2695 XE HPLC system spectrometer 
with quaternary pump, DAD detector and coupled to a Waters LCT Premier XE orthogonal time-of-
flight spectrometer with API-ES source. High resolution mass spectroscopy spectra for all compounds 
were also recorded on a Waters LCT Premier XE orthogonal time-of-flight spectrometer with API-ES 
source. 
Spectrophotometric DXR inhibition assay. This assay was performed by the Unit of theoretical 
and structural physico-chemistry, Department of Chemistry, University of Namur (FUNDP). 
In vitro P. falciparum growth inhibition assay and microbial screening. Performed by the 
Laboratory for Microbiology, Parasitology and Hygiene, Faculty of Pharmaceutical, Biomedical and 
Veterinary Sciences, University of Antwerp. Two strains of P.falciparum are used: 1/ GHA strain (P. 
falciparum GHA), derived from a Ghanese patient and chloroquine sensitive and 2/ K1 strain 
(P.falciparum K1) resistant to chloroquine. The strains are maintained in RPMI-1640 medium 
supplemented with 0.37 mM hypoxanthine, 25 mM Hepes, 25 mM NaHC03, and 10% O+ human 
serum together with 2-4% washed human O+ erythrocytes. All cultures and assays are conducted 
under an atmosphere of 4% C02, 3% 02 and 93% N2. Assays are performed in 96-well microtiter 
plates, each well containing 10 µl of the watery compound dilutions together with 190 µl of the 
malaria parasite inoculum (1% parasitaemia, 2% HCT). After 72h incubation, plates are frozen and 
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stored at –20°C. After thawing, 20 µl of each well is transferred into another plate together with 100 
µl Malstat reagent and 20 µl of a 1/1 mixture of PES (phenazine ethosulfate, 0.1 mg/ml) and NBT 
(Nitro Blue Tetrazolium Grade III, 2 mg/ml). Change in colour is measured spectrophotometrically at 
655 nm. Biological screening tests: The integrated panel of microbial screens used in this study and 
the standard screening methodologies were adopted from those described by Cos et al. 
Cytotoxicity. Performed by the Laboratory for Microbiology, Parasitology and Hygiene, Faculty of 
Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp. MRC-5SV2 cells are 
cultured in Earl’s MEM + 5% FCSi. Assays are performed in 96-well microtiter plates, each well 
containing about 104 cells/well. After 3 days incubation, cell viability is assessed fluorimetrically after 
addition of resazurin and fluorescence is measured (lex 550 nm, lem 590 nm). The results are 
expressed as % reduction in cell growth/viability compared to untreated control wells and a CC50 is 
determined. Cytotoxic reference compounds include tamoxifen.  
Diethyl 1-chlorobut-3-enylphosphonate (11a). To a solution of diisopropylamine (4.42 mL, 31 
mmol) in dry THF (90 mL) was added nBuLi (20 mL of a 1.5 M solution in THF) while stirring at -80 °C. 
After 15 min, diethyl but-3-enylphosphonate (2.89 g, 15 mmol) was slowly added to this solution, 
maintaining the temperature at -80 °C. Stirring was continued for 10 min at this temperature and 
then TMSCl (2.11 mL, 16.5 mmol) was added. The mixture was allowed to warm slowly to 0 °C, 
cooled again to -80 °C, and hexacloroethane (3.91 g, 16 mmol) in THF (60 mL) was added. The 
reaction mixture was allowed to warm to room temperature again and quenched by addition of 
aqueous hydrochloric acid. The mixture was poured into 2 M hydrochloric acid and ice and extracted 
with dichloromethane. The combined organic layers were washed with brine, dried over anhydrous 
MgSO4 and the solvents were removed by rotoevaporation. The residue was then dissolved in THF 
(150 mL) and acetic acid (50 mL) was added, followed by TBAF in THF (20 mL of a 1 M solution). After 
7 hours of stirring at room temperature, 31P NMR revealed that the reaction was complete (shift from 
 24.39 to 19.89 ppm) and an aqueous solution of NaHCO3 was added. The mixture was extracted 
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three times with dichloromethane, the combined organic layers were shaken against brine and dried 
over MgSO4 and the solvent was removed in vacuo. Purification by column chromatography 
(hexanes/ethyl acetate: 25/75) gave 3.01g of the title compound as a light yellow oil (89%). 1H-NMR 
(300.01 MHz, CDCl3)  1.36 (6H, t, J = 7.2   Hz), 2.52-2.63 (1H, m), 2.79-2.87 (1H, m), 3.87 (1H, dt, J = 
10.8 and 3.0 Hz), 4.22 (4H, dq, app. sx, J = 7.3 Hz), 5.17 (2H, t, J = 8.6 Hz), 5.81-5.94 (1H, m);
13C NMR 
(75 MHz, CDCl3)  16.6 (CH3, 
3JPC = 2.8 Hz), 16.7 (CH3, 
3JPC = 2.8 Hz), 36.8 (CH2), 51.6 (CHCl, 
1JPC = 159.6 
Hz), 63.7 (OCH2, 
2JPC = 6.9 Hz), 64.0 (OCH2, 
2JPC = 6.8 Hz), 118.9 (=CH2), 133.2 (=CH, 
3JPC= 13.6 Hz); 
31P 
NMR (121.45 MHz, CDCl3)  19.86; HRMS (ESI) m/z 227,0601 [(M+H)
+, calcd for C8H17ClO3P
+ 
227.0598]. 
Diethyl 1-fluorobut-3-enylphosphonate (11b). To a solution of diisopropylamine (5.05 mL, 
36 mmol) in dry THF (60 mL) was added nBuLi (23 mL of a 1.5 M solution in THF) while stirring at 
-80 °C. After 15 min  , diethyl but-3-enylphosphonate (2.88 g, 15 mmol) was slowly added to this 
solution, maintaining the temperature at -80 °C. Stirring was continued for 10 min at this 
temperature and then TMSCl (2.11 mL, 17 mmol) was added. The mixture was allowed to warm 
slowly to 0 °C, cooled again to -80 °C, and N-fluorobenzenesulfonimide (5.20 g, 16 mmol) in THF 
(60mL) was added. The reaction mixture was allowed to warm to room temperature again and 
quenched by addition of aqueous hydrochloric acid. The mixture was poured into 2 M hydrochloric 
acid and ice and extracted with dichloromethane. The combined organic layers were washed with 
saturated aqueous sodium bicarbonate, brine, dried over anhydrous MgSO4 and the solvents were 
removed by rotoevaporation. The residue was then dissolved in dichloromethane (20 mL), hexane 
(200 mL) was added and the white precipitate was filtered off over a celite filter. The filtrate was 
evaporated in vacuo and the residue redissolved in THF (50 mL), followed by the addition of a 1 M 
solution of lithium ethoxide in ethanol (20 mL). After stirring at 0 °C for 30 min the reaction mixture 
was diluted with dichloromethane and washed with 2 M hydrochloric acid. The organic layer was 
shaken with brine, dried over anhydrous MgSO4 and the solvents were removed in vacuo. Flash 
 Chapter III: Alpha-halogenated analogues of FR900098 
III.44 
column chromatography (hexanes/ethyl acetate: 25/75) gave 2.62 g (83%) of 11b as a colorless 
liquid. 1H NMR (300.01 MHz, CDCl3) δ 1.35 (6H, t, J = 7.2 Hz), 2.56-2.74 (2H, m), 4.14-4.26, (4H, m), 
4.63-4.84, (1H, m), 5.15-5.23, (2H, m), 5.80-5.93, (1H, m); 13C NMR (75.44MHz, CDCl3): δ 16.5 (CH3, 
3JPC = 2.5 Hz), 16.6 (CH3, 
3JPC = 2.5 Hz), 34.7 (CH2, 
2JPC =1.7 Hz, 
2JFC = 20.5 Hz), 63.0 (OCH2, 
2JPC = 6.6 Hz), 
63.4 (OCH2, 
2JPC = 6.9 Hz), 88.2 (CHF, 
1JPC = 170.0 Hz, 
1JCF = 182.2 Hz); 118.8 (=CH2), 132.2 (=CH, 
3JCF = 
13.8 Hz, 3JCP= 3.9 Hz); 
31P NMR (121.45 MHz, CDCl3)  17.41 (
2JPF = 74.8 Hz); HRMS (ESI) m/z 211.0900 
[(M+H)+, calcd for C8H17FO3P
+ 211.0899]. 
Diethyl 1-chloro-3-hydroxypropylphosphonate (13a). To a solution of 11a (2.27 g, 10 mmol) and 
4-methylmorpholine-N-oxide (1.41 g, 12 mmol) in dioxane (80 mL) was added 3.8 mL of a 4% 
aqueous solution of OsO4. After 4 hours of stirring at room temperature and protected from light, the 
reaction was complete according to TLC. The reaction mixture was quenched by addition of an 
aqueous solution of Na2S2O3 and extracted thrice with EtOAc. The combined organic fractions were 
washed with brine and dried over Na2SO4 after which the solvent was removed in vacuo. The 
resulting oil was dissolved in THF (25 mL) and sodium periodate (4.28 g, 20 mmol) in water (25 mL) 
was added. After 3 hours the reaction mixture was diluted with EtOAc and filtered over a celite pad. 
The filtrate was washed with brine, dried over Na2SO4 and evaporated to give crude diethyl 1-chloro-
2-formylethylphosphonate 12a. This residue was dissolved in ethanol (80 mL) and sodium 
borohydride (1.21 g, 32 mmol) was added. The mixture was stirred overnight at room temperature, 
diluted with EtOAc and washed with water. The aqueous layer was extracted twice with EtOAc. The 
combined organic phases were washed with brine and dried over Na2SO4. Removal of the solvent 
followed by column chromatography (hexanes/acetone: 25/75) yielded 1.11 g of the title compound 
as a colorless oil (48%). 1H NMR (300.01 MHz, CDCl3) δ 1.37 (6H, t, J = 7.2 Hz), 2.02-2.38, (2H, m), 
2.43-2.46 (1H, m), 3.76-3.97 (2H, m), 4.11-4.3051 (5H, m); 31P NMR (121.45MHz, CDCl3) δ 21.24; 
HRMS (ESI) m/z 231.0540 [(M+H)+, calcd for C7H17ClO4P
+ 231.0547]. 
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Diethyl 1-fluoro-3-hydroxypropylphosphonate (13b). To a solution of diethyl 1-fluorobut-3-
enylphosphonate (11b) (918mg, 4.37 mmol) and 4-methylmorpholine-N-oxide (614 mg, 5.24 mmol) 
in dioxane (40 mL) was added 1.67 mL of a 4% aqueous solution of OsO4. After 4 hours of stirring at 
room temperature and protected from light, the reaction was complete according to TLC. The 
reaction mixture was quenched by addition of an aqueous solution of Na2S2O3 and extracted thrice 
with EtOAc. The combined organic fractions were washed with brine and dried over Na2SO4 after 
which the solvent was removed in vacuo. The resulting oil was dissolved in THF (15 mL) and sodium 
periodate (1.50 g, 6.99 mmol) in water (10 mL) was added. After 3 hours the reaction mixture was 
diluted with EtOAc and filtered over a celite pad. The filtrate was washed with brine, dried over 
Na2SO4 and evaporated to give crude diethyl 1-fluoro-2-formylethylphosphonate (12b). This was 
dissolved in ethanol (45 mL) and sodium borohydride (653 mg, 17 mmol) was added. The mixture 
was stirred overnight at room temperature, diluted with EtOAc and washed with water. The aqueous 
layer was extracted twice with EtOAc. The combined organic phases were washed with brine and 
dried over Na2SO4. Removal of the solvent followed by column chromatography (hexanes/acetone: 
25/75) yielded 421 mg of diethyl 1-fluoro 3-hydroxypropylphosphonate (13b) as a colorless oil (45%). 
1H NMR (300.01 MHz, CDCl3) δ 1.38 (6H, t, J = 7.0 Hz), 2.05-2.24 (2H, m), 2.71 (1H, br.s), 3.77-3.85 
(2H, m), 4.21 (4H, dq, app. sx, J = 7.0 Hz), 4.96 (1H, dddd, J = 3.2, 5.6, 9.1 and 46.3 Hz); 13C NMR 
(75.44 MHz, CDCl3)  16.6 (CH3, 
3JPC = 3.0 Hz), 16.7 (CH3, 
3JPC = 3.0 Hz), 33.5 (CH2, 
2JCF = 19.6 Hz), 57.8 
(CH2, 
3JCF = 5.0 Hz,
 3JPC = 11.1 Hz), 63.4 (CH2, 
3JCF = 6.9 Hz,
 2JPC = 34.0 Hz), 86.4 (CHF,
 1JCF = 179.4 Hz,
 1JPC 
= 171.4 Hz); 31P NMR (121.43 MHz, CDCl3) δ 18.63 (d, 
2JPF = 74.7 Hz); HRMS (ESI) m/z 215.0845 
[(M+H)+, calcd for C7H17FO4P
+ 215,0843]. 
3-(Ethoxyphosphono)-3-chloropropyl 4-methylbenzenesulfonate (14a). To a solution of 13a 
(1.05 g, 4.6 mmol) in dichloromethane (9 mL) was added Et3N (1.91 mL, 1.4 mmol), DMAP (167 mg, 
0.14 mmol) and TsCl (1.3 g, 6.8 mmol). After one hour of stirring at room temperature the reaction 
was quenched with saturated aqueous NH4Cl and extracted thrice with dichloromethane. The 
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combined organic phases were washed with brine and dried over anhydrous MgSO4. Purification by 
flash column chromatography over two consecutive columns (dichloromethane/acetone: 9/1 then 
hexanes/dichloromethane/acetone: 6/2/2) yielded 1.64 g (90%) of a colorless oil. 1H NMR (300.01 
MHz, CDCl3) δ 1.33 (6H, t, J = 7.0 Hz), 1.98-2.54 (2H, m), 2.44 (3H, s), 3.95 (1H, dt, J = 11.4 and 3.2 Hz), 
4.13 – 4.27 (6H, m), 7.35 (2H, d, J = 8.4 Hz), 7.79 (2H, d, J = 8.1 Hz); 13C NMR (75.44 MHz, CDCl3): δ 
16.5 (CH3, 
3JPC = 2.2 Hz), 16.6 (CH3, 
3JPC = 1.9 Hz), 21.8 (CH3), 32.0 (CH2), 47.9 (P-CHCl, 
1JPC = 162.9 Hz), 
63.7 (OCH2, 
2JPC = 6.9 Hz), 64.2 (OCH2, 
2JPC = 6.9 Hz), 66.0 (CH2, 
3JPC = 13.6 Hz); 128.1 (=CH2), 130.1 
(=CH2), 132.7 (=CH2), 145.2 (=CH2);
 31P NMR (121.45 MHz, CDCl3) δ 19.21; HRMS (ESI) m/z 385.0687 
[(M+H)+, calcd for C14H23ClO6PS
+ 385.0636]. 
3-(Ethoxyphosphono)-3-fluoropropyl 4-methylbenzenesulfonate (14b). To a solution of diethyl 
1-fluoro 3-hydroxypropylphosphonate (13b) (420 mg, 2.0 mmol) in dichloromethane (4 mL) was 
added Et3N (0.82 mL, 5.9 mmol), DMAP (72mg, 0.59 mmol) and TsCl (561 mg, 2.9 mmol). After one 
hour of stirring at room temperature the reaction was quenched with saturated aqueous NH4Cl and 
extracted thrice with dichloromethane. The combined organic phases were washed with brine and 
dried over MgSO4. Purification by flash column chromatography (hexanes/dichloromethane/acetone: 
6/2/2) yielded 720 mg (99%) of a colorless oil. 1H NMR (300.01 MHz, CDCl3) δ 1.33 (6H, 2t, J = 7.0 Hz), 
2.14-2.33 (2H, m), 2.44 (3H, s), 4.11-4.24 (2 + 4H, m), 4.79 (1H, dddd, J = 3.9, 8.1, 14.1 and 47.1 Hz), 
7.28-7.36 (2H, m), 7.77-7.81 (2H, m);13C NMR (75.44 MHz, CDCl3): δ 16.5 (CH3), 16.6 (CH3), 21.8 (CH3), 
30.2 (CH2, 
2JCF = 20.2 Hz,
 2JPC = 0.6 Hz), 63.4 (OCH2, 
4JCF = 6.9 Hz,
 2JPC = 27.9 Hz), 65.3 (SCH2, 
3JCF = 4.4 
Hz, 3JPC = 14.1 Hz), 84.6 (CHF,
 1JCF = 173.6 Hz,
 1JPC = 180.8 Hz), 128.1 (=CH), 130.1 (=CH), 132.8 (=Cq), 
145.2 (=Cq);
 31P NMR (121.45MHz, CDCl3) δ 16.75 (d, 
2JPF = 49.9 Hz); HRMS (ESI) m/z 369.0946 
[(M+H)+, calcd for C14H23FO6PS
+ 369,0932]. 
tert-Butyl N-benzyloxy(3-(ethoxyphosphono)-3-chloropropyl)carbamate (15a). To a solution of 
t-butyl N-benzyloxycarbamate (1.04 g, 4.7 mmol) in dry DMF (20 mL) cooled to 0 °C was added 
sodium hydride (186 mg of a 60% dispersion in mineral oil; 4.7 mmol) while stirring. After a few 
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minutes the ice bath was removed and the solution stirred for another half hour. Then, 14a (1.63 g, 
4.2 mmol) dissolved in 20 mL dry DMF was added and the mixture was heated to 50 °C. After 3 hours 
the mixture was allowed to cool down, quenched by addition of aqueous NH4Cl and extracted three 
times with dichloromethane. The combined organic fractions were washed with brine and dried over 
MgSO4. Purification of the crude product by flash column chromatography (hexanes/ethyl acetate: 
50/50) yielded 1.22 g of 15a as a colorless oil (66%). 1H NMR (300.01 MHz, CDCl3) δ 1.33 (6H, 2t, J = 
7.3 Hz), 1.51 (9H, s), 1.96-2.50 (2H, m), 3.65-3.70 (2H, m), 3.97 (1H, dt, J = 11.1 and 2.9 Hz), 4.84 (2H, 
ABq, J = 9.7 Hz), 7.33-7.42 (5H, m); 13C NMR (75.44 MHz, CDCl3): δ 16.5 (CH3, 
3JPC = 2.5 Hz), 16.6 (CH3, 
3JPC = 2.5 Hz), 28.4 (3 x CH3), 30.3 (CH2), 46.8 (CH2, 
3JPC = 14.4 Hz), 50.0 (CClH, 
1JPC = 161.7 Hz), 63.6 
(OCH2, 
2JPC = 6.9 Hz), 63.9 (OCH2, 
2JPC = 7.2 Hz), 77.2 (CH2), 81.9 (C(CH3)3), 128.6 (=CH2), 128.8 (=CH2), 
129.6 (=CH2), 135.5 (CH2C(CH)2), 156.5 (C=O);
 31P NMR (121.45 MHz, CDCl3) δ 19.89; HRMS (ESI) m/z 
436.1645 [(M+H)+, calcd for C19H32ClNO6P
+ 436.1650].  
tert-Butyl N-benzyloxy(3-(ethoxyphosphono)-3-fluoropropyl)carbamate (15b). To a solution of 
t-butyl N-benzyloxycarbamate (473 mg, 2.1 mmol) in dry DMF (10mL) cooled to 0 °C was added 
sodium hydride (85 mg of a 60% dispersion in mineral oil, 2.1 mmol) while stirring. After a few 
minutes the icebath was removed and the solution stirred for another half hour. Then, 
3-(ethoxyphosphono) 3-fluoropropyl 4-methylbenzenesulfonate (14b) (710 mg, 1.9 mmol) dissolved 
in 10 mL dry DMF was added and the mixture was heated to 50 °C. After 2.5 hours the mixture was 
allowed to cool down, quenched by addition of aqueous NH4Cl and extracted three times with 
dichloromethane. The combined organic fractions were washed with brine and dried over MgSO4. 
Purification of the crude product by flash column chromatography (hexanes/ethyl acetate: 50/50) 
yielded 711 mg of a colorless oil (88%).1H NMR (300.01 MHz, CDCl3) δ 1.34 (6H, 2t, J = 7.2 Hz), 1.50 
(9H, s), 2.08-2.32 (2H, m), 3.63 (2H, t, J = 6.9 Hz), 4.18 (4H, dq, app. sx, J = 7.2 and 6.9 Hz), 4.80 (1H, 
ddt, J = 46.8, 13.5 and 3.9 Hz), 4.86 (2H, ABq, J = 10.2 Hz), 7.29-7.42 (5H, m);13C NMR (75.44 MHz, 
CDCl3): δ 16.6 (CH3, 
3JPC = 2.8 Hz), 16.7 (CH3, 
3JPC = 2.8 Hz), 28.5 (3 x CH3), 45.9 (CH2, 
3JCF = 15.2 Hz,
 3JPC 
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= 3.6 Hz), 63.3 (OCH2, 
4JCF = 6.9 Hz,
 2JPC = 23.8 Hz), 77.4 (OCH2), 82.0 (Cq), 86.8 (CHF,
 1JCF = 180.0 Hz,
 1JPC 
= 171.9 Hz), 128.7 (=CH), 128.8 (=CH), 129.6 (=CH), 135.6 (Cq), 156.6 (C=O);
 31P NMR (121.45 MHz, 
CDCl3) δ 17.45 (d, 
2JPF = 74.8 Hz); HRMS (ESI) m/z 420.1904 [(M+H)
+, calcd for C19H32FNO6P
+ 
420.1946]. 
Diethyl 3-(N-(benzyloxy)acetamido)-1-chloropropylphosphonate (17a). 15a (1.2 g; 2.8 mmol) 
was dissolved in dichloromethane (27 mL), cooled to 0 °C and TFA (15 mL) was added. After stirring 
for 30 minutes, the ice bath was removed and 15 minutes later the reaction was complete according 
to TLC. Toluene (15 mL) was added to the mixture and the solvents were removed in vacuo. When 
the product approached dryness, another 7 mL of toluene was added and the solution 
rotoevaporated again. The residue was then redissolved in dry dichloromethane (20 mL) and acetic 
anhydride (1.75 mL; 18 mmol), Et3N (0.8 mL; 5.5 mmol) and DMAP (67 mg; 0.55 mmol) were added. 
After 4 hours of stirring at room temperature, the reaction was quenched with 0.1 M HCl and 
extracted with dichloromethane. The combined organic fractions were washed with saturated 
aqueous sodium bicarbonate and dried over anhydrous Na2SO4. Flash column chromatography 
(dichloromethane/acetone: 8/2) yielded 669 mg of 17a as a colorless oil (98%). 1H NMR (300.01 MHz, 
CDCl3) δ 1.31-1.36 (6H, 2t, J = 7.3 Hz), 2.02-2.54 (2H, m), 2.10 (3H, s), 3.89 (2H, t, J = 6.5 Hz), 3.96 (1H, 
dt, J = 11.1 and 3.2 Hz), 4.14-4.26 (m, 4H), 4.83 (2H, ABq, J = 10.3 Hz), 7.39 (5H, s); 13C NMR (75.44 
MHz, CDCl3): δ 16.6 (CH3, 
3JPC = 2.2 Hz), 16.6 (CH3, 
3JPC = 2.2 Hz), 20.7 (CH3), 30.1 (CH2), 42.5 (CH2), 50.1 
(CClH, 1JPC = 162.0 Hz), 63.7 (OCH2, 
2JPC = 6.9 Hz), 64.0 (OCH2, 
2JPC = 6.9 Hz), 77.4 (CH2), 128.9 (=CH2), 
129.3 (=CH2), 129.5 (=CH2), 134.3 (C=O);
 31P NMR (121.45 MHz, CDCl3) δ 19.58; HRMS (ESI) m/z 
378.1207 [(M+H)+, calcd for C16H26ClNO5P
+ 378.1232]. 
Diethyl 3-(N-(benzyloxy)acetamido)-1-fluoropropylphosphonate (17b). 15b (700 mg, 1.7 mmol) 
was dissolved in dichloromethane (20 mL), cooled to 0 °C and TFA (10 mL) was added. After stirring 
for 30 minutes, the icebath was removed and 20 minutes later the reaction was done, according to 
TLC. Toluene (15mL) was added to the mixture and the solvents were removed in vacuo. When the 
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product approached dryness, another 5 mL of toluene was added and the solution rotoevaporated 
again. The residue was then redissolved in dry dichloromethane (14 mL) and acetic anhydride (1.3 
mL, 14 mmol), Et3N (0.58 mL, 4.2 mmol) and DMAP (51 mg, 0.42 mmol) were added. After 2 hours of 
stirring at room temperature, the reaction was quenched with 0,1 M HCl and extracted with 
dichloromethane. The combined organic fractions were washed with saturated aqueous NaHCO3 and 
dried over anhydrous Na2SO4. Flash column chromatography (dichloromethane/acetone: 8/2) yielded 
384 mg of a colorless oil (63%).1H NMR (300.01 MHz, (CD3)2CO) δ 1.39 (6H, td, J = 1.5 and 7.0 Hz), 
2.15 (3H, s), 2.17-2.43 (2H, m), 3.97 (2H, t, J = 6.7 Hz), 4.24 (4H, app. sx t, J = 7.0 and 1.5 Hz), 4.97 (1H, 
ddt, J = 46.6, 9.4 and 4.1 Hz), 5.05 (2H, s), 7.48-7.60 (5H, m); 13C NMR (75.44MHz, (CD3)2CO)): δ 16.8 
(CH3, 
3JPC = 3.0 Hz), 16.8 (CH3, 
3JPC = 3.0 Hz), 20.7 (CH3), 28.6 (CH2, 
2JCF = 21.6 Hz), 42.4 (CH2), 63.4 
(OCH2, 
4JCF = 6.6 Hz,
 2JPC = 23.8 Hz), 76.8 (OCH2), 87.6 (CHF,
 1JCF = 178.9 Hz,
 1JPC = 170.6 Hz), 
129.4 (=CH2), 129.6 (=CH2), 130.4 (=CH2), 136.1 (Cq), 172.0 (C=O);
 31P NMR (121.45MHz, (CD3)2CO) δ 
17.97 (d, 2JPF = 72.6 Hz); 
19F NMR (282.29 MHz, (CD3)2CO)  -211.14 (dddd, J = 91.4, 54.3, 36.2 and 
19.0 Hz); HRMS (ESI) m/z 362.1561 [(M+H)+, calcd for C16H26FNO5P
+ 362.1527]. 
Diethyl 3-(N-hydroxyacetamido)-1-chloropropylphosphonate (18a). A mixture of 17a (465 mg; 
1.2 mmol) and Pd/C (10%; 90 mg) in THF (12 mL) was stirred under an H2-atmosphere for 6 hours. 
The reaction mixture was then filtered over a celite pad and the filtrate was evaporated in vacuo. 
Purification of the residue over two consecutive flash columns (hexanes/acetone: 50/50, then 
dichloromethane/methanol: 98/2) yielded 207 mg (60%) of the title compound as a colorless oil. 
1H NMR (300.01 MHz, DMSO-d6) δ 1.26 (6H, t, J = 7.0 Hz), 1.83-2.31 (2H, m), 1.98 (3H, s), 3.67-3.72 
(2H, m), 4.06-4.17 (4H, m), 4.34 (1H, dt, J = 2.9 and 10.5 Hz); 13C NMR (75.44 MHz, DMSO-d6): δ 16.2 
(CH3, 
3JPC = 1.7 Hz), 16.3 (CH3, 
3JPC = 1.7 Hz), 20.3 (CH3), 29.3 (CH2), 44.5 (CH2,
 3JPC = 14.4 Hz), 49.4 
(CClH, 1JPC = 158.4 Hz), 62.8 (OCH2, 
2JPC = 6.6 Hz), 63.1 (OCH2, 
2JPC = 6.9 Hz), 170.7 (C=O);
 31P NMR 
(121.45 MHz, DMSO-d6) δ 20.57; HRMS (ESI) m/z 288.0762 [(M+H)+, calcd for C9H20ClNO5P
+ 
288.0762]. 
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Diethyl 3-(N-hydroxyacetamido)-1-fluoropropylphosphonate (18b). A mixture of 17b (364 mg, 
1.0 mmol) and Pd/C (10%, 73 mg) in THF (10 mL) was stirred under an H2-atmosphere for 5 hours. 
The reaction mixture was then filtered over a celite pad and the filtrate was evaporated in vacuo. 
Purification of the residue by flash column chromatography (dichloromethane/methanol: 98/2 to 
95/5) yielded 248 mg (91%) of a colorless oil. 1H NMR (300.01 MHz, DMSO-d6) δ 1.26 (6H, t, J = 7.03 
Hz), 1.92-2.20 (2H, m), 1.99 (s, 3H), 3.56-3.76 (2H, m), 4.05-4.16 (4H, m), 4.98 (1H, ddt, J = 46.3, 10.3 
and 3.2 Hz), 9.84 (1H, s); 13C NMR (75.44 MHz, DMSO-d6): δ 16.3 (CH3, 
3JPC = 2.8 Hz), 16.3 (CH3, 
3JPC = 
3.0 Hz), 20.3 (CH3), 27.4 (CH2, 
2JCF = 20.5 Hz), 43.4 (CH2,
 3JPC = 16.0 Hz), 62.6 (OCH2, 
4JCF = 6.6 Hz,
 2JPC = 
19.1 Hz), 86.1 (CHF, 1JCF = 177.5 Hz,
 1JPC = 168.9 Hz), 170.7 (C=O);
 31P NMR (121.45 MHz, DMSO-d6) δ 
18.15 (d, 2JPF = 72.1 Hz);
 19F NMR (282.29 MHz, DMSO-d6)  -210.42 (dddd, J = 91.4, 56.0, 37.1 and 
19.8 Hz) HRMS (ESI) m/z 272.1037 [(M+H)+, calcd for C9H20FNO5P
+ 272.1058]. 
3-(N-hydroxyacetamido)-1-chloropropylphosphonic acid, bisammonium salt (4a). To a solution 
of 18a (150 mg; 0.52 mmol) in dry dichloromethane (5 mL) was added TMSBr (0.7 mL, 5.20 mmol) 
while stirring at 0 °C. After 45 minutes the ice bath was removed and stirring was continued at room 
temperature. After three days, 31P-NMR revealed the presence of uncompletely deprotected 
material, so another 0.2 mL of TMSBr was added. After another three days of stirring at room 
temperature, the volatiles were removed in vacuo, the residue was redissolved in 5% aqueous 
ammonia and washed with diethyl ether. The aqueous phase was then lyophilized to give 138 mg of 
a very hygroscopic, off-white powder. 1H NMR (300.01 MHz, D2O) δ 1.92-2.57 (2H, m), 2.16 (3H, s), 
3.71-3.92 (2H, m), 3.92-4.06 (1H, m); 13C NMR (75.44 MHz, D2O): δ 19.5 (CH3), 30.7 (CH2), 45.9 (CH2,
 
3JPC = 13.0 Hz), 54.8 (CClH, 
1JPC = 139.0 Hz), 174.0 (C=O);
 31P NMR (121.45 MHz, DMSO-d6) δ 11.85; 
HRMS (ESI) m/z 232.0135 [(M+H)+, calcd for C5H12ClNO5P
+ 232.0136]. 
3-(N-hydroxyacetamido)-1-fluoropropylphosphonic acid, bisammonium salt (4b). To a solution 
of 18b (223 mg, 0.82 mmol) in dry dichloromethane (8 mL) was added TMSBr (1.1 mL, 8.2 mmol) 
while stirring at 0 °C. After 45 minutes the icebath was removed and stirring was continued at room 
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temperature. After 3 days, 31P NMR revealed the presence of uncompletely deprotected material, so 
another 0.2mL of TMSBr was added. After another 4 days of stirring at room temperature, the 
volatiles were removed in vacuo, the residue was redissolved in 5% aqueous ammonia and washed 
with diethyl ether. The aqueous phase was then lyophilized to give 207 mg of 4b as a very 
hygroscopic, off-white powder. 1H NMR (300.01 MHz, D2O) δ 1.96-2.22 (2H, m), 2.11 (3H, s), 3.77 (2H, 
app. d sx, J = 70.8 and 7.5 Hz), 4.33 (1H, ddt, J = 48.6, 10.3 and 4.1 Hz); 13C NMR (75.44 MHz, D2O): δ 
19.5 (CH3), 28.4 (CH2, 
2JCF = 20.2 Hz), 45.0 (CH2, 
3JCF = 13.6 Hz,
 3JPC = 3.6 Hz), 90.7 (CHF,
 1JCF = 171.0 Hz,
 
1JPC = 154.0 Hz), 174.0 (C=O);
 31P NMR (121.45 MHz, D2O) δ 11.80 (d, 
2JPF = 62.3 Hz); HRMS (ESI) m/z 
216.0455 [(M+H)+, calcd for C5H12FNO5P
+ 216.0432]. 
Diethyl 3-(benzyloxy)imino-1-fluoropropylphosphonate (20). Diethyl 1-fluoro-2-
formylethylphosphonate 12b (4.24g, 20 mmol) was dissolved in THF (15 mL) and acetic acid (20 mL) 
and cooled to 0 °C with an icebath. Benzylhydroxylamine (free base, 1.82g, 14.74 mmol) was 
dissolved in 5 mL THF in a separate flask and this was transferred to the above mixture. The icebath 
was removed and the mixture was stirred for two hours at room temperature. Ethyl acetate was 
then added and the mixture was extracted two times with water. The combined water layers were 
back-extracted twice with ethyl acetate. The combined organic fractions were washed with brine, 
dried over anhydrous Na2SO4 and the solvents were removed in vacuo. Column chromatography 
(hexanes/ethyl acetate: 50/50) afforded 3.34g (53%) of the product as a colorless liquid. The product 
is formed as a 1:2.4 mixture of E and Z isomers of the oxime. 1H NMR (300 MHz, acetone) δ ppm 1.27 
- 1.35 (m, 6 H) 2.78 - 3.08 (m, 2 H) 4.09 - 4.25 (m, 4 H) 4.92 - 5.09 (m, 1 H) 5.09 - 5.25 (m, 2 H) 6.93 (t, 
J=5.13 Hz,1 H) 7.25 - 7.43 (m, 5 H); HRMS (ESI) m/z 318.1243 [(M+H)+, calcd for C14H22FNO4P+ 
318,1265]. 
Diethyl 3-(benzyloxyamino)-1-fluoropropylphosphonate (16b). A solution of 20 (3.34g, 10.53 
mmol) in methanol (50 mL) was cooled to 0 °C, 5 drops of methyl orange solution were added 
followed by one drop of 6 M aqueous HCl, resulting in a red-pink coloring of the reaction mixture. 
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Sodium cyanoborohydride powder (2.65g, 42.11 mmol) was added over the course of a few minutes 
and more HCl was added in order to keep a milky pink solution. After  4.5 hours of stirring at room 
temperature, another 630 mg of sodium cyanoborohydride were added and the reaction mixture 
was stirred for 1 more hour. The reaction was then quenched by the addition of aqueous 2.5 M 
NaOH and extracted three times with ethyl acetate (Caution! HCN is volatile and very toxic! The 
aqueous phase should be kept at pH > 12). The combined organic fractions were washed with brine, 
dried over anhydrous Na2SO4 and the solvents were removed in vacuo, resulting in the crude 
oxyamine 16b that was used as such in the next reaction.  
pKa determination of phosphonates by 31P NMR titration. A small amount (3 mg) of compound 
4a, 4b or FR900098 was dissolved in acetate buffer (pH3, 0.025M) and D2O (100 µL) was added. The 
mixture was further acidified by dropwise addition of aqueous HCl (2M), the pH was measured and 
the 31P NMR was acquired. The pH was then increased stepwise by addition of aqueous NaOH 
(dropwise, 0.1 and 0.05M), followed by measurement of the 31P chemical shift (D3PO4 in D2O as an 
external standard). The measured 31P shifts were plotted in function of their corresponding pH and 
the pKa’s could be estimated to be at the pH of the inflection points of each titration curve. 
Diethyl 1-fluoro-4-hydroxybutylphosphonate (21). To a solution of 11b (1.05 g, 5 mmol) in dry 
THF (50 mL) was added BH3.THF (1 M in THF, 5.5 mL) while stirring at 0 °C. After 10 minutes the 
icebath was removed and the reaction mixture was stirred at room temperature for 2 hours. Water 
(0.1 mL) was added, then aqueous sodium hydroxide (0.5 mL of a 3 M solution) and aqueous 
hydrogen peroxide (0.5 mL of a 30% solution) and the mixture was stirred at 50 °C for 1 hour. The 
reaction was quenched by addition of aqueous Na2S2O3 and extracted with ethyl acetate. The 
combined organic fractions were washed with brine, dried over anhydrous Na2SO4 and the solvents 
were removed in vacuo. Purification of the crude material by flash column chromatography 
(hexanes/acetone: 75/25 to 25/75) gave 506 mg of a colorless oil (44%).1H NMR (300.01 MHz, CDCl3) 
δ 1.34 (6H, s, J = 7.0 Hz), 1.69-2.12 (5H, m), 3.68 (2H, t, J = 5.9 Hz), 4.19 (4H, app sx, J = 7.03 Hz), 4.75 
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(1H, dddd, J = 47.2, 9.4, 4.4 and 3.2 Hz); 31P NMR (121.45 MHz, CDCl3) δ 18.00 (d, 
2JPF = 75.3 Hz); 
HRMS (ESI) m/z 229.0994 [(M+H)+, calcd forC8H19FO4P
+ 229.1000]. 
Diethyl 1-fluoro-4-carboxybutylphosphonate (22). To 21 (465 mg, 2.04 mmol), TEMPO (65 mg, 
0.41 mmol) and BAIB (1.446 g, 4.49 mmol) in a flask was added MeCN (5 mL) and the contents were 
sonicated in order to dissolve all solids. Subsequently, water (5 mL) was added and the reaction was 
stirred for 6 hours at room temperature and protected from light. The volatiles were then removed 
in vacuo, the resulting crude material was co-evaporated twice with THF and purified on a silica gel 
column (CH2Cl2/MeOH/HCOOH: 95/5/0.1) to yield 498 mg of a golden oil (quantitative).
 1H NMR 
(300.01 MHz, CDCl3) δ 1.35 (6H, td, J = 2.6 and 7.3 Hz), 2.10-2.31 (2H, m), 2.51-2.65 (2H, m), 4.21 (4H, 
app sx d, J = 1.8 and 6.9 Hz), 4.73-4.95 (2H, m), 10.39 (1H, br s); 31P NMR (121.43 MHz, CDCl3) δ 17.38 
(d, 2JPF = 75.18 Hz); HRMS (ESI) m/z 243.0793 [(M+H)
+, calcd for C8H17FO5P
+ 243.0792]. 
Diethyl 3-(N-(benzyloxy)-N-methylcarbamoyl)-1-fluoropropylphosphonate (23). To a solution of 
22 (372 mg, 1.54 mmol) in dry dichloromethane (5 mL) was added CDI (290 mg, 1.79 mmol) while 
stirring vigorously. In a separate flask, BnO-NH(Me).TFA (553 mg, 2.20 mmol) was dissolved in 3 mL 
dry dichloromethane and Et3N (0.31 mL, 2.23 mmol) was added, resulting in the precipitation of 
Et3N.TFA. After 90 minutes of stirring at room temperature, the BnO-NH(Me) solution was added to 
the phosphonate solution and the reaction was stirred overnight at room temperature. The reaction 
was then quenched with aqueous NH4Cl and extracted thrice with dichloromethane. The combined 
organic fractions were washed with brine, dried over anhydrous Na2SO4 and evaporated in vacuo. 
Purification of the crude material by silica gel column chromatography (hexanes/ethyl acetate: 25/75 
to 0/100) resulted in 498 mg of a colorless oil (89%).1H NMR (300.01 MHz, (CD3)2CO) δ 1.31 (6H, t, J = 
7.0 Hz), 2.03-2.21 (2H, m), 2.65-2.78 (2H, m), 3.18 (3H, s), 4.10-4.21 (4H, m), 4.76-4.97 (1H, m), 4.95 
(2H, s), 7.39-7.51 (5H, m); 31P NMR (121.45 MHz, (CD3)2CO) δ 18.24 (d, 
2JPF = 37.72 Hz); HRMS (ESI) 
m/z 362.1367 [(M+H)+, calcd for C16H26FNO5P
+ 362.1527]. 
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Diethyl 3-(N-hydroxy-N-methylcarbamoyl)-1-fluoropropylphosphonate (24). A solution of 23 
(297 mg, 0.82 mmol) in THF (8 mL) was hydrogenated at atmospheric pressure in the presence of Pd 
(10% wt. on activated carbon, 60 mg). After stirring for 2 hours, the reaction mixture was filtered 
through a celite pad. The solvent was removed under vacuum, and the crude mixture was purified by 
flash column chromatography on two consecutive columns (hexanes/acetone: 50/50 then 
dichloromethane/methanol: 95/5) to yield 138 mg (62%) of a golden brown oil. 1H NMR (300.01 MHz, 
(CD3)2CO) δ 1.33 (6H, t, J = 7.3 Hz), 2.08-2.22 (4H, m), 2.57-2.79 (2H, m), 3.18 (3H, s), 4.18 (4H, qdd, J 
= 11.1, 7.0 and 4.1 Hz), 4.91 (1H, dddd, J = 46.6, 9.7, 4.1 and 2.9 Hz), 8.95 (1H, br s); 13C NMR (75.44 
MHz, (CD3)2CO) δ 16.7 (CH3, 
3JPC = 2.5 Hz), 16.8 (CH3, 
3JPC = 2.8 Hz), 26.3 (CH2, 
2JCF = 19.6 Hz), 27.8 (CH2,
 
3JPC = 10.8 Hz), 36.2 (CH3), 63.4 (OCH2, 
4JCF = 6.6 Hz,
 2JPC = 22.1 Hz), 89.0 (CHF,
 1JCF = 177.7 Hz,
 1JPC = 
169.5 Hz), 173.3 (C=O); 31P NMR (121.45 MHz, (CD3)2CO) δ 18.40 (d, 
2JPF = 74.2Hz); HRMS (ESI) m/z 
272.1047 [(M+H)+, calcd for C9H20FNO5P
+ 272.1058]. 
3-(N-hydroxy-N-methylcarbamoyl)-1-fluoropropylphosphonic acid, bisammonium salt (5). 24 
(119 mg, 0.44 mmol) was dissolved in dry dichloromethane under inert atmosphere and cooled to 
0 °C. TMSBr (0.6 mL, 4.4 mmol) was added dropwise while stirring. The icebath was removed and the 
reaction was stirred at room temperature. After 24 hours another 0.3 mL of TMSBr were added and 
the reaction was stirred for another 4 days. The volatiles were removed in vacuo, the crude material 
was dissolved in 5% aqueous ammonia and washed with diethyl ether. Lyophilisation of the ammonia 
solution yielded the product as a brown solid in quantitative yield. 1H NMR (300.01 MHz, D2O) δ 1.82-
2.00 (2H, m), 2.11-2.62 (2H, m), 3.07 (3H, s), 4.18-4.45 (1H, m); 13C NMR (75.44 MHz, D2O) 
(CH2, 
2JCF = 19.6 Hz), 34.5 (CH2, 
3JCF = 12.2 Hz,
 3JPC = 1.0 Hz),36.1 (CH3), 92.9 (CHF,
 1JCF = 171.1 Hz,
 
1JPC = 153.7 Hz), 175.5 (C=O);
 31P NMR (121.45 MHz, D2O) δ 11.74 (d, 
2JPF = 63.27 Hz); HRMS (ESI) m/z 
216.0437 [(M+H)+, calcd for C5H12FNO5P
+ 216.0432]. 
Diethyl 1,1-difluorobut-3-enylphosphonate (25). Zinc dust (10 µm particle size) was activated by 
washing with the following sequence: 2% aq. HCl (2x) – H2O (2x) – acetone – ether, and dried in 
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vacuo at 120 °C overnight. 1.1g (16.85 mmol) of this zinc dust was suspended in dry 
dimethoxyethane and diethyl bromodifluoromethylphosphonate (3.0 g, 11.24 mmol) was injected 
slowly in this suspension. After 24 hours of stirring at room temperature, no progress was seen in the 
formation of the metal insertion product so the reaction mixture was sonicated for four hours, 
resulting in the consumption of the zinc dust. The solution of phosphonodifluoromethyl zinc reagent 
was then transferred to a separate flamedried flask containing anhydrous CuBr (6.5 mg, 0.044 mmol). 
Allyl bromide (0.98 mL, 11.24 mmol) was added and the reaction mixture was stirred overnight at 
room temperature after which 31P-NMR confirmed the formation of 25 (triplet at δ = 5.92 ppm). The 
reaction was quenched by addition of aqueous NH4Cl and extracted three times with 
dichloromethane. The combined organic fractions were washed with brine and dried over anhydrous 
Na2SO4. Purification of the crude product by flash column chromatography (hexanes/ethyl acetate: 
75/25) yielded 1.73 g of a colorless liquid (68%). 1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.36 (t, 
J=7.18 Hz, 6 H) 2.82 (tt, J=19.48, 6.59 Hz, 2 H) 4.25 (quin, J=7.25 Hz, 4 H) 5.21 - 5.26 (m, 1 H) 5.28 (s, 1 
H) 5.72 - 5.95 (m, 1 H) 31P NMR (121.45 MHz, CHLOROFORM-d) δ 6.889 (t, 2JPF = 107.48 Hz); HRMS 
(ESI) m/z 229.0788 [(M+H)+, calcd for C8H16F2O3P+ 229.0800]. 
Diethyl 1,1-difluoro-2-formylethylphosphonate (28). The title compound was synthesized from 
diethyl 1,1-difluorobut-3-enylphosphonate (25) (955 mg, 4.19 mmol) using the same method as for 
12b, giving 560mg (58%) of crude 28 that was used as such in the next reactions. HRMS (ESI) m/z 
231.0614 [(M+H)+, calcd for C7H14F2O4P+ 231,0592]. 
tert-Butyl N-(benzyloxy)-N-(2-bromoethyl)carbamate (41). To a solution of t-butyl N-
benzyloxycarbamate (447 mg, 2 mmol) in dry DMF (4 mL) was added sodium hydride (88 mg of a 60% 
dispersion in mineral oil, 2.2 mmol) under vigorous stirring at room temperature. After 30 minutes, 
neat 1,2-dibromoethane (1.7 mL, 3758 mg, 20 mmol) was added quickly via syringe to the clear 
solution. The reaction mixture was stirred overnight at room temperature, quenched by the addition 
of saturated aqueous NH4Cl and partitioned between aqueous 0.1N HCl and diethyl ether. The 
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extraction with diethyl ether was repeated two times, the combined organic phases were washed 
with brine, dried over anhydrous Na2SO4 and evaporated in vacuo. The resulting crude mixture was 
purified by flash column chromatography (hexanes/ethyl acetate: 90/10)to yield 433.6 mg (66 %) of 
41 as a colourless oil. 1H NMR (300 MHz, acetone) δ ppm 1.34 - 1.62 (m, 9 H) 3.44 - 3.64 (m, 2 H) 
3.70 - 3.92 (m, 2 H) 4.91 (s, 2 H) 7.23 - 7.61 (m, 5 H); HRMS (ESI) m/z 330.0705 [(M+H)+, calcd for 
C14H21BrNO3+ 330,0699] 
tert-Butyl benzyloxy(2-((tert-butyldimethylsilyl)oxy)ethyl)carbamate (43). The title compound 
was synthesized from (2-bromoethoxy)(tert-butyl)dimethylsilane (42) (613.25 mg, 2.56 mmol) and 
t-butyl N-benzyloxycarbamate (520 mg, 2.33 mmol)using the same method as for 41, giving 688 mg 
(77%) of pure 43 after column chromatography. 1H NMR (300 MHz, CHLOROFORM-d) d ppm 0.07 (s, 
6 H) 0.90 (s, 9 H) 1.51 (s, 9 H) 3.55 (t, J=6.44 Hz, 2 H) 3.76 (t, J=6.44 Hz, 2 H) 4.87 (s, 2 H) 7.27 - 7.52 
(m, 5 H) ; HRMS (ESI) m/z 382.2446 [(M+H)+, calcd for C20H36NO4Si+ 382,2408] 
tert-Butyl N-(benzyloxy)-N-(2-hydroxyethyl)carbamate (44). To a solution of 43 (686 mg, 1.80 
mmol) in methanol was added ammonium fluoride (133 mg, 3.60 mmol) and the reaction mixture 
was stirred at 50 °C for 3.5 hours. All volatiles were removed and the resulting crude material was 
purified by flash column chromatography (hexanes/ethyl acetate: 75/25)to yield 437 mg (90 %) of 44 
as a colourless oil. 1H NMR (300 MHz, acetone) δ ppm 1.41 - 1.57 (m, 9 H) 3.50 - 3.62 (m, 2 H) 3.63 - 
3.78 (m, 3 H) 4.89 (s, 2 H) 7.18 - 7.50 (m, 5 H); HRMS (ESI) m/z 268.1555 [(M+H)+, calcd for 
C14H22NO4+ 268,1543] 
2-(N-(benzyloxy)acetamido)ethyl acetate (46). 44 (408 mg; 1.53 mmol) was dissolved in 
dichloromethane (10 mL), cooled to 0 °C and TFA (6 mL) was added. After stirring for 30 minutes, the 
ice bath was removed and 15 minutes later the reaction was complete according to TLC. Toluene (10 
mL) was added to the mixture and the solvents were removed in vacuo. When the product 
approached dryness, another 25 mL of toluene was added and the solution rotoevaporated again, 
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giving 454 mg of a yellow oil. This oil was dissolved in ethyl acetate and washed with aqueous K2CO3, 
water and aqueous NaOH, dried over anhydrous Na2SO4 and evaporated in vacuo, yielding 264 mg of 
45 as a free base. The residue was then redissolved in dry dichloromethane (15 mL) and acetic 
anhydride (2.93 mL; 31 mmol), Et3N (1.3 mL; 9.24 mmol) and DMAP (56 mg; 0.46 mmol) were added. 
After 6 hours of stirring at room temperature, the reaction mixture was reduced to half its volume in 
vacuo, 10 mL of toluene was added and the mixture was evaporated to dryness. The residue was 
taken up in dichloromethane and washed with saturated aqueous sodium bicarbonate, then brine 
and dried over anhydrous Na2SO4. Evaporation yielded 333 mg of crude 46 as a colorless oil (86 %) 
that was used as such in the next reaction. HRMS (ESI) m/z 252.1285 [(M+H)+, calcd for C13H18NO4+ 
252,1230] 
N-(Benzyloxy)-N-(2-hydroxyethyl)acetamide (47). 46 (341 mg, 1.4 mmol) and sodium methoxide 
(7 mg, 0.14 mmol) were dissolved in methanol (8 mL) and stirred at room temperature for 1.5 hour. 
All volatiles were removed in vacuo, the residue was taken up in ethyl acetate and washed with 
aqueous NH4Cl, brine, dried over anhydrous Na2SO4 and evaporated. Purification by flash column 
chromatography (hexanes/ethyl acetate: 50/50 to 0/100)of the crude material gave 123 mg (42 %) of 
47 as a white solid. 1H NMR (300 MHz, CHLOROFORM-d) δ ppm 2.14 (s, 3 H) 3.82 (s, 4 H) 4.88 (s, 2 H) 
7.40 (s, 5 H); HRMS (ESI) m/z 210.1123 [(M+H)+, calcd for C11H16NO3+ 210,1125] 
tert-Butyldimethyl((N-benzyloxy)iminoethoxy)silane (50). 
2-((tert-butyldimethylsilyl)oxy)acetaldehyde (49) (334 mg, 1.92 mmol) and benzylhydroxylamine 
hydrochloride (336 mg, 1.1 mmol) were suspended in methanol, Et3N (0.29 m L, 212 mg, 2.1 mmol) 
was added and the mixture was stirred at room temperature for two hours. Water was added and 
the mixture was extracted with diethyl ether (2x). The combined organic fractions were washed with 
brine, dried over anhydrous MgSO4 and evaporated, yielding 348 mg of crude imine 50 that was 
immediately reduced in the next reaction. 
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tert-Butyldimethyl(2-(N-benzyloxyamino)ethoxy)silane (51).Crude imine 50 was reduced using 
the same method as for 16b, resulting in 300 mg (56%, two steps) of crude 51 as a colourless oil that 
was used as such in the next step. 
N-(Benzyloxy)-N-(2-((tert-butyldimethylsilyl)oxy)ethyl)acetamide (52). Crude oxyamine 51 was 
dissolved in dry dichloromethane (10 mL) and acetic anhydride (1.13 mL, 12 mmol), Et3N (0.50 mL, 
3.6 mmol) and DMAP (44 mg, 0.36 mmol) were added. The reaction mixture was stirred overnight at 
room temperature, quenched with 0,1 M HCl and extracted with dichloromethane. The combined 
organic fractions were washed with saturated aqueous NaHCO3 and dried over anhydrous Na2SO4. 
Flash column chromatography (hexanes/ethyl acetate: 75/25 to 50/50) afforded 222 mg of 52 as a 
colorless oil (64%).1H NMR (300 MHz, CHLOROFORM-d) δ ppm 0.07 (s, 6 H) 0.89 (s, 9 H) 2.09 (s, 3 H) 
3.80 (d, J=3.51 Hz, 4 H) 4.89 (s, 2 H) 7.39 (s, 5 H); HRMS (ESI) m/z 324.1972 [(M+H)+, calcd for 
C17H30NO3Si+ 324,1989] 
N-(Benzyloxy)-N-(2-hydroxyethyl)acetamide (47). The title compound was synthesized from N-
(benzyloxy)-N-(2-((tert-butyldimethylsilyl)oxy)ethyl)acetamide (52) (220 mg, 0.68 mmol) using the 
same method as for 44, giving 111 mg (78%) of 47 as a white solid. Spectral data: see above. 
2-(N-(Benzyloxy)acetamido)ethyl trifluoromethanesulfonate (48). Triflic anhydride (162 mg, 
0.57 mmol) was  dissolved in dry dichloromethane cooled to -78 °C. To this, a cooled solution of 
alcohol 47 (100 mg, 0.48 mmol) and DIPEA (74 mg, 0.574 mmol) in dichloromethane was added and 
the mixture was allowed to warm to 0° C. The reaction mixture was then partitioned between ice-
cold diethyl ether and saturated aqueous NaHCO3, the aqueous phase was extracted two times with 
diethyl ether and once with dichloromethane. The combined organic fractions were washed with ice-
cold brine and dried over anhydrous Na2SO4, followed by removal of the solvent in vacuo at 12°C, 
giving crude 48 as a slight yellow oil that was used as such in the next reaction. 
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2-(Benzyloxy)ethyl trifluoromethanesulfonate (56). The title compound was synthesized from 
2-benzyloxyethanol (55) (761 mg, 0.71 mmol) and triflic anhydride (1552 mg, 5.5 mmol) using the 
same method as for 48, giving crude 56 as a dark purple liquid that was used as such in the next 
reaction. 
Diethyl 3-(benzyloxy)-1,1-difluoropropylphosphonate (57). Preparation of LDA – DMPU 
solution: Diisopropylamine (1.8 mL, 12.8 mmol) and DMPU (1.35 mL, 11.2 mmol) were mixed with 
THF (6 mL) and cooled to -78 °C. nBuLi (7.5 mL of a 1.6 M solution in hexanes) was added, the 
mixture was warmed up to room temperature and cooled again to -78 °C. 
Diethyl difluoromethyl phosphonate (2107 mg, 11.2 mmol) and 2-(benzyloxy)ethyl triflate 56 were 
dissolved in THF (6 mL) and cooled to -78 °C, and the freshly prepared LDA – DMPU solution was 
added, followed by stirring of the reaction mixture at -78°C for 20 minutes. The reaction was 
quenched by the addition of saturated aqueous NH4Cl and extracted three times with ethyl acetate. 
The combined organic phases were washed with brine, dried over anhydrous Na2SO4 and evaporated 
in vacuo to give 3.101g of a brown liquid that contained a considerable amount of unreacted diethyl 
difluoromethyl phosphonate according to 31P-NMR. This was removed by vacuum distillation (55 °C, 
1.2 mbar), followed by purification of the product by flash column chromatography (hexanes/ethyl 
acetate: 75/25 to 25/75), yielding 561 mg (54%) of 57 as a colorless liquid. 1H NMR (300 MHz, 
CHLOROFORM-d) δ ppm 1.26 - 1.50 (m, 6 H) 2.26 - 2.62 (m, 2 H) 3.77 (t, J=7.18 Hz, 2 H) 4.27 (quin, 
J=7.32 Hz, 4 H) 4.54 (s, 2 H) 7.19 - 7.47 (m, 5 H); HRMS (ESI) m/z 323.1200 [(M+H)+, calcd for 
C14H22F2O4P+ 323,1218] 
Diethyl 1,1-difluoro-3-hydroxypropylphosphonate (58). To a solution of 57 (1280 mg, 3.97 
mmol) in methanol was added formic acid (2 mL) and Pd (10% wt. on carbon). The reaction mixture 
was stirred overnight at room temperature, filtered over a celite pad and evaporated to dryness. The 
resulting turbid yellow liquid was purified by flash column chromatography (hexanes/ethyl acetate: 
50/50 to 0/100), yielding 746 mg (81%) of 58 as a colorless liquid. 1H NMR (300 MHz, acetone) δ ppm 
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1.25 - 1.45 (m, 6 H) 2.17 - 2.45 (m, 2 H) 3.80 (t, J=6.74 Hz, 2 H) 4.15 - 4.35 (m, 4 H) 4.46 (br. s., 1 H); 
HRMS (ESI) m/z 233.0756 [(M+H)+, calcd for C7H16F2O4P+ 233,0749] 
3-(Ethoxyphosphono)-3,3-difluoropropyl 4-methylbenzenesulfonate (59). The title compound 
was synthesized from diethyl 1,1-difluoro-3-hydroxypropylphosphonate (58) (516 mg, 2.22 mmol), 
TsCl (636 mg, 3.33 mmol), Et3N(0.93 mL, 6.66 mmol) and DMAP (82 mg, 0.67 mmol) using the same 
method as for 14b, giving crude 59 as a brown oil that was used as such in the next reaction. 1H NMR 
(300 MHz, acetone) δ ppm 1.32 (t, J=6.88 Hz, 6 H) 2.31 - 2.65 (m, 6 H) 4.11 - 4.40 (m, 6 H) 7.37 - 7.60 
(m, 2 H) 7.72 - 7.93 (m, 2 H); HRMS (ESI) m/z 233.0756 [(M+H)+, calcd for C14H22F2O6PS+ 387,0837] 
tert-Butyl N-benzyloxy(3-(ethoxyphosphono)-3,3-difluoropropyl)carbamate (31). To a solution 
of t-butyl N-benzyloxycarbamate (639 mg, 2.86 mmol) in dry DMF (7 mL) cooled to 0 °C was added 
sodium hydride (120 mg of a 60% dispersion in mineral oil, 2.9 mmol) while stirring. After a few 
minutes the icebath was removed and the solution stirred for another half hour. Then, 
3-(ethoxyphosphono) 3,3-difluoropropyl 4-methylbenzenesulfonate (59) (866 mg, 2.2 mmol) 
dissolved in 4 mL dry DMF was added and the mixture was stirred overnight at room temperature. 
Then, another equivalent of t-butyl N-benzyloxycarbamate (491 mg, 2.2 mmol) in dry DMF (2 mL) 
was added and the reaction mixture was stirred for another 3 hours. The reaction was quenched by 
addition of aqueous NH4Cl and extracted three times with ethyl acetate. The combined organic 
fractions were washed with brine and dried over MgSO4 giving 1.58g of a yellow oil. Purification of 
the crude product by flash column chromatography (hexanes/ethyl acetate: 75/25 to 60/40) yielded 
95 mg of 31 as a colorless oil (10%).1H NMR (300 MHz, acetone) δ ppm 1.25 - 1.39 (m, 6 H) 1.50 (s, 9 
H) 2.19 - 2.49 (m, 2 H) 3.59 - 3.81 (m, 2 H) 4.13 - 4.37 (m, 4 H) 4.89 (s, 2 H) 7.25 - 7.56 (m, 5 H); HRMS 
(ESI) m/z 438.1859 [(M+H)+, calcd for C19H31F2NO6P+ 438,1852] 
Diethyl 3-(N-(benzyloxy)acetamido)-1,1-difluoropropylphosphonate (33). 31 (270 mg, 0.62 
mmol) was dissolved in dichloromethane (6 mL), cooled to 0 °C and TFA (2.5 mL) was added. After 
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stirring for 10 minutes, the icebath was removed and 1hour later the reaction was done, according to 
TLC. Toluene (15mL) was added to the mixture and the solvents were removed in vacuo. When the 
product approached dryness, another 5 mL of toluene was added and the solution rotoevaporated 
again. The residue was then redissolved in dry dichloromethane (4 mL) and acetic anhydride (0.6 mL, 
6.4 mmol), Et3N (0.25 mL, 1.8 mmol) and DMAP (5 mg, 0.04 mmol) were added. After 2 hours of 
stirring at room temperature, the reaction was quenched with 0,1 M HCl and extracted with 
dichloromethane. The combined organic fractions were washed with saturated aqueous NaHCO3, 
then with brine and dried over anhydrous Na2SO4. Flash column chromatography (hexanes/ethyl 
acetate: 50/50) yielded 136 mg of a colorless oil (91%).1H NMR (300 MHz, acetone) δ ppm 1.22 - 1.45 
(m, 6 H) 2.05 (s, 3 H) 2.20 - 2.55 (m, 2 H) 3.78 - 4.00 (m, 2 H) 4.13 - 4.37 (m, 4 H) 4.97 (s, 2 H) 7.24 - 
7.63 (m, 5 H); HRMS (ESI) m/z 380.1426 [(M+H)+, calcd for C16H25F2NO5P+ 380,1433] 
Diethyl (3-(N-(benzyloxy)-2-nitrophenylsulfonamido)-1,1-difluoropropyl)phosphonate (64). To 
a stirred solution of alcohol 58 (81 mg, 0.35 mmol), N-(benzyloxy)-2-nitrobenzenesulfonamide 63 
(117 mg, 0.38 mmol) and triphenylphosphine (100 mg, 0.38 mmol) was added DIAD (0.08 mL, 0.38 
mmol) at room temperature. After stirring overnight at room temperature, another 0.3 equivalents 
of each N-(benzyloxy)-2-nitrobenzenesulfonamide 63 (34 mg, 0.11 mmol), triphenylphosphine (29 
mg, 0.11 mmol) and DIAD (0.02 mL, 0.11 mmol) were added and the mixture was stirred for another 
3 hours. All volatiles were subsequently removed in vacuo and the resulting crude was purified by 
flash column chromatography (hexanes/ethyl acetate: 50/50) to yield 99 mg of 64 as a gold oil 
(54 %). 1H NMR (300 MHz, acetone) δ ppm 1.23 - 1.44 (m, 6 H) 2.12 - 2.45 (m, 2 H) 3.40 (br. s., 2 H) 
4.22 (dqd, J=8.57, 7.01, 7.01, 7.01, 1.76 Hz, 4 H) 5.12 (s, 2 H) 7.29 - 7.63 (m, 5 H) 7.74 - 7.99 (m, 2 H) 
7.99 - 8.12 (m, 1 H) 8.12 - 8.29 (m, 1 H); HRMS (ESI) m/z 523.1118 [(M+H)+, calcd for 
C20H26F2N2O8PS+ 523,1110] 
Diethyl 3-(N-(benzyloxy)acetamido)-1,1-difluoropropylphosphonate (33). To a solution of 64 (22 
mg, 0.042 mmol) and anhydrous K2CO3 (23 mg, 0.168 mmol) in acetonitrile (0.98 mL) and DMSO 
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(20µL) was added thiophenol (15µL, 0.126 mmol). After stirring at room temperature for 2.5 hours, 
acetic anhydride (45µL, 0.480 mmol) was added and stirring was continued overnight. Water and 
ethyl acetate were then added, resulting in the formation of a homogeneous emulsion which was 
broken up by the addition of aqueous HCl. The acidified aqueous phase was extracted two times with 
ethyl acetate and the combined organic fractions were dried over anhydrous Na2SO4. All volatiles 
were subsequently removed in vacuo and the resulting crude was purified by flash column 
chromatography (hexanes/ethyl acetate: 50/50) to yield 8.44 mg of 33 as a gold oil (53 %). Analytical 
data: see above. 
Diethyl 3-(N-hydroxyacetamido)-1,1-difluoropropylphosphonate (34). To a solution of 33 (120 
mg, 0.316 mmol) in ethyl acetate was added formic acid (0.15 mL) and Pd (10% wt. on carbon). The 
reaction mixture was stirred for 1 hour at room temperature, filtered over a celite pad and 
evaporated to dryness. The resulting brown liquid was purified by flash column chromatography 
(hexanes/ethyl acetate: 25/75), yielding 73 mg (80%) of 34 as a colorless oil. 1H NMR (300 MHz, 
acetone) d ppm 1.30 - 1.44 (m, 6 H) 1.98 - 2.10 (m, 3 H) 2.22 - 2.57 (m, 2 H) 3.74 - 3.94 (m, 2 H) 4.17 - 
4.38 (m, 4 H); HRMS (ESI) m/z 290.0977 [(M+H)+, calcd for C9H19F2NO5P+ 290,0963] 
Dibenzyl difluoromethyl phosphonate (79). To a solution of dibenzyl phosphite (14.61 g, 44.6 
mmol) in THF (65 mL)cooled to 0 °C was added NaHMDS (25 mL of a 2M solution in THF, 50 mmol). 
The reaction mixture was then cooled to -55 °C and a dry-ice condenser was installed on the reaction 
flask. Chlorodifluoromethane (10 g, 116 mmol) from a pressure tin was pumped into the reaction 
mixture via a submerged needle (no bubbling was noticed!) and the mixture was stirred at -55 °C. 
After 4 hours, the cooling bath was removed, another 16g (185 mmol) of chlorodifluoromethane was 
added and the reaction mixture was stirred overnight at room temperature. The reaction was 
quenched by addition of saturated aqueous NH4Cl and extracted three times with dichloromethane. 
The combined organic fractions were washed with saturated aqueous NaHCO3, brine and dried over 
anhydrous Na2SO4giving 11 g of a brown oily liquid. Purification of the crude product by flash column 
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chromatography (toluene/ethyl acetate: 80/20) yielded 9.470 g of 79 as a colorless oil (68%).1H 1H 
NMR (300 MHz, acetone) δ ppm 5.22 (d, J=8.49 Hz, 4 H) 6.29 (app dt, J=27.30 Hz, J = 48.30 Hz, 1H) 
7.24 - 7.56 (m, 9 H); HRMS (ESI) m/z 313.0795 [(M+H)+, calcd for C15H16F2O3P+ 313,0800] 
2-((tert-butyldiphenylsilyl)oxy)ethyl trifluoromethanesulfonate (86). The title compound was 
synthesized from 2-((tert-butyldiphenylsilyl)oxy)ethanol (85) (300 mg, 1 mmol) and triflic anhydride 
(339 mg, 1.2 mmol) using the same method as for 48, giving crude 86 as a brown oil that was used as 
such in the next reaction. 
Dibenzyl (3-((tert-butyldiphenylsilyl)oxy)-1,1-difluoropropyl)phosphonate (87). The title 
compound was synthesized from dibenzyl difluoromethyl phosphonate (79) and 2-((tert-
butyldiphenylsilyl)oxy)ethyl trifluoromethanesulfonate (86) using the same method as for compound 
57, giving 196 mg (66%) of 87 as a colourless oil. 1H NMR (300 MHz, acetone) δ ppm 0.93 - 1.15 (m, 9 
H) 2.24 - 2.60 (m, 2 H) 3.98 (t, J=6.88 Hz, 2 H) 5.16 (dd, J=8.49, 1.17 Hz, 4 H) 7.24 - 7.56 (m, 15 H) 7.56 
- 7.85 (m, 5 H); HRMS (ESI) m/z 595.2235 [(M+H)+, calcd for C33H38F2O4PSi+ 595,2240] 
(3-(N-(benzyloxy)acetamido)-1-fluoropropyl)phosphonic acid, disilver salt (90). Diethyl 3-(N-
(benzyloxy)acetamido)-1-fluoropropylphosphonate (17b) (317 mg, 0.87 mmol) was coevaporated 
twice with dry toluene, dissolved in dry acetonitrile (1 mL) and the solution was cooled to 0 °C. BSTFA 
(0.7 mL, 1.74 mmol) was added, followed by TMSBr. The cooling bath was removed and the reaction 
mixture was stirred at room temperature for 3 hours after which 31P-NMR of a reaction sample 
confirmed that the reaction was finished. Dry toluene (10 mL) was added to the reaction mixture and 
all volatiles were removed by rotoevaporation. The resulting oil was taken up in THF and water (1 
mL) was added. After stirring for 10 minutes, volatiles were removed again and a little methanol was 
added which caused the product to form a white foam upon rotoevaporation. 
The resulting white foam was dissolved in water and NaOH (1.75 mL of a 1 M aqueous solution) was 
added under vigorous stirring, followed by aqueous AgNO3 (298 mg, dissolved in 1 mL H2O), resulting 
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in a very fine white opaque suspension of 90. The suspension was filtered over a glassfibre pad, 
washed consecutively with water, ethanol and diethyl ether and dried, shielded from light, under 
vacuum over P2O5 to give 448 mg of 90 as an off-white powder. 
(((3-(N-(benzyloxy)acetamido)-1-fluoropropyl)phosphoryl)bis(oxy))bis(methylene) bis(2,2-
dimethylpropanoate) (91). Disilver salt 90 (430.74 mg, 0.83 mmol) was dissolved in toluene (2 mL) 
and iodomethyl pivalate (703 mg, 2.91 mmol), dissolved in 1 mL toluene, was added. The reaction 
mixture was shielded from light and stirred at room temperature for 5 hours, after which TLC showed 
that all starting material was consumed. Water and ethyl acetate were added and the aqueous layer 
was extracted three times with ethyl acetate. The combined organic fractions were washed with 
brine and dried over anhydrous MgSO4. Purification of the crude product by flash column 
chromatography (hexanes/ethyl acetate: 75/25 to 50/50) yielded 143 mg of 91 as a colorless oil 
(32%).1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.09 - 1.35 (m, 18 H) 2.09 (s, 3 H) 2.11 - 2.24 (m, 1 
H) 2.24 - 2.37 (m, 1 H) 3.68 - 3.98 (m, 2 H) 4.70 - 4.87 (m, 2 H) 4.95 (dt, J=9.81, 3.73 Hz, 1 H) 5.54 - 
5.86 (m, 4 H) 7.28 - 7.51 (m, 5 H); 13C NMR (75 MHz, CHLOROFORM-d) δ ppm 20.49, 26.78, 26.79, 
27.52 (d, J= 18.80 Hz), 38.71, 38.72, 41.38, 76.54, 81.81 (dd, app. t, J=6.91 Hz), 86.16 (dd, J= 
183.27Hz, J=171.40 Hz), 128.76, 129.08, 129.34, 134.16, 172.59, 176.69, 176.73; HRMS (ESI) m/z 
534.2274 [(M+H)+, calcd for C24H38FNO9P+ 534,2263] 
(((3-(N-(benzyloxy)acetamido)-1-fluoropropyl)phosphoryl)bis(oxy))bis(methylene) diisopropyl 
dicarbonate (92). The title compound was synthesized from disilver salt 90 (450 mg, 0.87 mmol) and 
iodomethyl isopropyl carbonate (743 mg, 3.05 mmol) using the same method as described for 91, 
giving 80 mg (17%) of 92 as a colourless oil. 1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.30 (d, 
J=6.15 Hz, 12 H) 2.08 (s, 3 H) 2.12 - 2.41 (m, 2 H) 3.70 - 3.91 (m, 2 H) 4.74 - 4.86 (m, 2 H) 4.86 - 5.04 
(m, 2 H) 5.70 (dd, J=12.45, 3.37 Hz, 4 H) 7.29 - 7.51 (m, 5 H); 13C NMR (75 MHz, CHLOROFORM-d) δ 
ppm 20.43, 21.52, 27.35 (dd, J= 19.90 Hz, J= 1.38 Hz), 41.39, 73.44 (dd, J= 3.32Hz, J=0.55 Hz), 76.48, 
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84.38 (dt, app. t, J= 6.08 Hz), 86.17 (dd, J= 183.00 Hz, J=172.49 Hz), 128.68, 128.98, 129.26, 134.13, 
152.90, 152.93, 172.52;HRMS (ESI) m/z 538.1822 [(M+H)+, calcd for C22H34FNO11P+ 538,1848] 
(((1-fluoro-3-(N-hydroxyacetamido)propyl)phosphoryl)bis(oxy))bis(methylene) bis(2,2-
dimethylpropanoate) (93). 91 (145 mg, 0.27 mmol) was dissolved in freshly distilled THF (2.7 mL), Pd 
(10% wt. on activated carbon) was added and the mixture was stirred under a hydrogen atmosphere 
at room temperature. After 6 hours, the reaction mixture was filtered over a glassfibre pad and the 
filter was rinsed with ethyl acetate. The combined organic fractions were evaporated and the 
resulting oil was purified by flash column chromatography (hexanes/ethyl acetate: 50/50 to 25/75) to 
give 104 mg (87 %) of 93 as a colourless oil. 1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.09 - 1.44 
(m, 18 H) 2.15 (s, 3 H) 2.13 - 2.27 (m, 1 H) 2.30 - 2.39 (m, 1 H) 3.59 - 3.80 (m, 2 H) 4.95 – 5.18 (m, 1 H) 
5.55 - 5.90 (m, 4 H); 13C NMR (75 MHz, CHLOROFORM-d) δ ppm 20.50, 26.79, 26.80, 27.58 (d, J= 
18.75 Hz), 38.66, 38.67, 41.55, 81.10 (dd, app. t, J=6.80 Hz), 86.70 (dd, J= 185.23Hz, J=171.92 Hz), 
173.44, 177.00, 177.75; HRMS (ESI) m/z 444.1809 [(M+H)+, calcd for C17H32FNO9P+ 444,1793] 
(((1-fluoro-3-(N-hydroxyacetamido)propyl)phosphoryl)bis(oxy))bis(methylene) diisopropyl 
dicarbonate (94). The title compound was synthesized from 92 (80 mg, 0.149 mmol) using the same 
method as described for 93, giving 58 mg (89%) of 94 as a colourless oil. 1H NMR (300 MHz, 
CHLOROFORM-d) d ppm 1.15 - 1.42 (m, 12 H) 1.95 - 2.33 (m, 3 H) 2.36 (br. s., 2 H) 3.53 - 4.21 (m, 2 H) 
4.70 - 5.09 (m, 3 H) 5.52 - 5.89 (m, 4 H); 13C NMR (75 MHz, CHLOROFORM-d) δ ppm 14.07, 21.54, 
27.33, 27.55, 29.65, 44.03, 73.10, 73.63, 73.75, 84.57, 152.92, 152.95; 13C NMR (75 MHz, 
CHLOROFORM-d) δ ppm 14.07, 21.54, 27.42 (dd, J= 19.50 Hz, J= 1.20 Hz), 41.39, 73.44 (dd, J= 3.32Hz, 
J=0.55 Hz), 84.57 (dt, app. t, J= 6.10 Hz), 86.17 (dd, J= 184.12 Hz, J=172.55 Hz), 152.90, 152.93, 
172.52  31P NMR (121.45MHz, CDCl3) δ 18.01 (d, 
2JPF = 68.2 Hz);HRMS (ESI) m/z 448.1390 [(M+H)
+, 
calcd for C15H28FNO11P+ 448,1379]  
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IV.Conformationally restricted (retro)hydroxamates 
IV.A Rationale: Conformational Analysis of Hydroxamates 
Judging from the bond lengths in hydroxamic acids and the planarity of their structure, a partial 
double-bond character is expected for the carbonyl-nitrogen bond1. This implies the existence of 
stable conformations with restricted rotation about this bond2, with an average bond rotation energy 
barrier of 67 kJ/mol (compared to 50 kJ/mol for an ester and 75-95 kJ/mol for an amide). Kolasa3 
studied the influence of N-substituents, acyl groups and solvent polarity on the conformation of 
structurally small (mainly N-formyl and N-acetyl) hydroxamic acids and came to the following 
conclusions (summarized in Figure IV.1): 
1. N-formyl and N-acetyl hydroxamates show Z-E-equilibrium in solution with a Z/E ratio 
dependent on solvent polarity: the higher the polarity of the solvent, the more E-
conformer in the mixture. 
2. Bulky N-substituents in formyl- and acetylhydroxamic acids favor the presence of the 
Z-conformer. 
3. Substitution of the N-formyl group for an N-acetyl group favours the formation of the E-
conformer. 
4. The presence of electron-donating groups in α-position of the N-substituent favours the 
formation of E-conformer. 
5. Protonation of the hydroxamic acid group leads to a decreased amount of the E-
conformer. 
6. For N-unsubstituted hydroxamates, the Z-conformation is preferred (mainly in the solid 
state). 
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FigureIV.1: Cis-trans (E-Z) equilibrium of N-alkylhydroxamic acids and the factors influencing it3 
As stated in the general introduction, the retrohydroxamate moiety is one of the main features 
of fosmidomycin, FR900098 and their (bioactive) analogues. Apart from a few exceptions in the form 
of larger/more lipophilic acyl residues, only inverting the retrohydroxamate into a (preferentially N-
methylated) hydroxamate is allowed in order not to lose all DXR inhibitory activity. Both the 
retrohydroxamate and the hydroxamate groups act as strong bidentate chelators for the bivalent 
metal cation (usually Mn2+) in the active site of the enzyme4, a function for which it is necessary to 
adopt the Z-conformation5. Under standard conditions, however, we can assume that the 
(retro)hydroxamate in fosmidomycin and its analogues will be present as a mixture of E and Z 
conformer and that, according to the above, in vivo the unwanted E-conformer will be favoured. 
Hence, better DXR ligands could be designed by stabilizing the Z conformer in fosmidomycin 
analogues. Towards this end, the (retro)hydroxamate may be locked in its metal-chelating (cis) 
conformation by incorporating it into a ring structure, which means (see also Figure 2): 
-For the retrohydroxamate: interconnection of the acetyl-CH3 with the γ-carbon of the propyl spacer. 
-For the hydroxamate: interconnection of the N-methyl with the γ-carbon of the propyl spacer. 
This principle has been applied before in the development of hydroxamic acid-containing molecules, 
usually by incorporation of the hydroxamate into a six-membered ring6, a functionality that is also 
present in several natural products7. In the case of fosmidomycin analogues, literature data (see 
Chapter I: Introduction) indicate that the active site of DXR is very tight especially around the 
aforementioned divalent metal cation and any sterical bulk around the (retro)hydroxamate is 
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disfavoured. In the case of hydroxamate analogues, the only ‘bulk’ that is tolerated is the methyl 
group: N-methylation has resulted in a higher potency8, 9. For retrohydroxamate analogues 
exchanging the N-formyl hydrogen of fosmidomycin for a methyl group as in FR900098 tends to 
slightly improve the inhibitory activity. Larger N-alkyl (for hydroxamates) or N-acyl (for 
retrohydroxamates) substituents generally lead to a significant drop in inhibitory activity. With 
respect to the interconnection strategy outlined above, this means a direct connection of the 
mentioned methyl groups with the spacer γ-carbon, implying the synthesis of N-hydroxybetalactams 
or 3/4-phosphonoethyl N-hydroxyazetidin-2-ones (“NHAs”) 3 and 4.  
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FigureIV.2: (Retro)Hydroxamate E/Z-equilibrium in FR900098 (1) and its hydroxamate analogue 
(2), metal binding by the Z-conformers and restriction of the preferred conformation by cyclization 
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IV.B Previous Attempts 
A first attempt toward the synthesis of the 4-(ω-phosphonoethyl)-NHA (3) and the 4-(ω-
phosphonomethyl)-NHA (9) analogues (“retrohydroxamate N-hydroxybetalactam” analogues with 1- 
resp. 2-carbon spacer) was made by Timothy Haemers from our group10, based on a procedure by 
Rajendra and Miller11.  
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SchemeIV.1: Attempted synthesis of N-hydroxyazetidinone analogues by Haemers10 
The key step in this procedure was the construction of benzyl (2-(bromomethyl)-4-oxoazetidin-1-
yl) carbonate (or “CBz-protected bromomethyl N-hydroxybetalactam”) 6 from but-3-enoic acid 5 
(vinylacetic acid). The so formed alkyl bromide 6 would then be phosphonylated by either an Arbuzov 
reaction, leading to the ‘short-chain’ analogue 9 or by a substitution with a protected 
methylphosphonate carbanion, leading to the ‘long-chain’ analogue 3, but unfortunately both 
attempts failed. Most probably this is the result of the inherent susceptibility of N-hydroxyazetidin-2-
ones toward nucleophilic ring opening, which will be further illustrated throughout this chapter. 
IV.C New Strategy 
An elegant strategy for the synthesis of benzyl protected 4-alkyl-NHA 13 was developed by the 
group of Miller, based on the intramolecular ring closure of a β-hydroxy O-benzylated hydroxamate 
12 under Mitsunobu conditions12 as depicted in scheme 2. This β-OH-hydroxamate is derived from a 
β-keto-ester 11 through a ketone reduction, ester hydrolysis and amidation with O-
benzylhydroxylamine. An interesting fact is that β-keto-ester 11 is synthesized by alkylation of the 4-
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position of methyl acetoacetate 10 (via its dianion13), potentially allowing for variation in the alkyl 
chain of the azetidinone. 
O
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BnO NH
OH O
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OBn
BnO
N O
BnO
a b
10 11 12 13
Reagents and Conditions: (a) NaH (1eq.), nBuLi (1eq.), BOMCl, THF; (b) Ph3P, DIAD, THF
 
SchemeIV.2: Synthesis of protected N-hydroxyazetidin-2-ones from betaketo-esters via a 
Mitsunobu reaction according to Miller et al.12 
Applying this strategy to the synthesis of retrohydroxamate analogue 3 is evident: only a formal 
exchange of the benzyl ether in 13 for a phosphonic acid group should give access to the desired 
product. 
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Figure IV.3: Retrosynthetic analysis towards N-hydroxyazetidinone FR900098 analogues 
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 But also hydroxamate analogue 14 could probably be synthesized from the same starting 
compound 10. Alkylation of methyl acetoacetate in 2-position (via its ‘first’ anion) would result in the 
3-methylated ‘inverted’ N-hydroxybetalactam 14. The non-methylated version of this molecule (4) 
should be synthesized starting from a formylacetate 17 instead of an acetoacetate, although 
(polymerization) problems are to be expected with such an aldehyde. Formylation of the γ-carbon of 
a γ-butyrylphosphonate could be a workaround here. 
IV.D Chemistry 
We directed our attention first toward 4-phosphonoethyl NHA 3 because its synthesis was 
expected to be highly analogous to the described procedure by Lee et al.12 
IV.D.1. First Approach: phosphonomethylation of acetoacetate 
As stated above, the formal exchange of the alkyl benzylether in 13 with a phosphonate group 
would result in desired analogue 3. With the difficulties in mind experienced by Haemers when trying 
to introduce a phosphonate onto an NHA, we opted to introduce the phosphonate group as early as 
possible in the synthetic sequence, preferably before ring closure. Therefore, we tried to alkylate the 
methyl acetoacetate dianion with diethyl chloromethylphosphonate (instead of BOMCl used by 
Miller), unfortunately without success. 
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O O
P
EtO
O
EtO
O O
O
Reagents and Conditions: (i) NaH (1 eq.), nBuLi (1.1 eq.), 
THF, -40° C, (ii) (EtO)2P(O)CH2Cl (1eq.)
10 18
 
SchemeIV.3: Attempted phosphonomethylation of methyl acetoacetate 
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IV.D.2. Second Approach: phosphonate substitution of benzyl ether 
As an obvious alternative for the unsuccessful phosphonomethylation we repeated Lee’s 
procedure for the synthesis of benzylether 11. Subsequent debenzylation and turning the resulting 
alcohol into a leaving group should allow to install the phosphonate functionality.  
O
O O
BnO O
O O
HO P
EtO
O
EtO
O O
O
1811 19
Reagents and conditions: see table
Scheme IV.4: Debenzylation and attempted phosphonylation of a β-keto ester 
Table IV.1:Debenzylation conditions tested 
 Entry Method Result 
1 Pd/C, H2 atmospheric pressure, EtOAc No reaction 
2 Pd black, H2 bubbling, EtOAc No reaction 
3 Pd black, H2 bubbling, THF No reaction 
4 Pd/C, formic acid, MeOH Total conversion 
 
To our surprise, 11 turned out to be very reluctant towards debenzylation. Probably this product, 
or a contaminant, poisoned the catalyst because only when we turned toward the more aggressive 
hydrogen transfer debenzylation with formic acid, good conversion into alcohol 19 was seen. Small 
scale test reactions also showed that the phosphonylation of 19 was problematic. Therefore, a new 
and more robust approach was developed: 
IV.D.3. Third Approach: Claisen condensation of phosphonopropionate 
Instead of trying to introduce the phosphonate functionality onto a β-keto-ester, it turned out to 
be much more convenient to synthesize the desired δ-phosphono-β-keto-ester from an alkyl 
phosphonopropionate and an alkyl acetate via a Claisen condensation. Thus, methyl 
(diethylphosphono)propionate 21 was synthesized first through an Arbuzov reaction of methyl 3-
bromopropionate 20 and triethyl phosphite, and subsequently used in a Claisen condensation  with 
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tert-butyl acetate using lithium N-isopropyl-N-cyclohexylamide (LICA) as a base14 with good result. 
We chose for a t-butyl ester because it allows for an acidic hydrolysis (TFA) with simple removal of all 
volatiles in vacuo, obviating the need for the tedious extraction of a carboxylic acid. 
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Reagents and Conditions: (a) (EtO)3P, 100 °C; (b) LICA, tBuOAc, THF, -60 °C; (c) NaBH4, MeOH, 0 °C; (d) TFA, 
Et3SiH, CH2Cl2, 0 °C; (e) EDC.HCl, BnONH2, THF, H2O, rt; (f)DIAD, Ph3P, THF; (g)H2, Pd/C, MeOH, rt, 45 min; 
(h) TMSBr, CH2Cl2 or HCl, H2O
quant. 65% 95%
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SchemeIV.5: Attempted synthesis of the 4-phosphonoalkyl N-hydroxyazetidin-2-one analogue 
 With phosphonate 22 in hands, we envisaged to follow a synthetic route analogous to Lee’s 
protocol, as depicted in Scheme 5: reduction of ketone 22 with sodium borohydride proceeded in 
excellent yield. The t-butyl ester was then hydrolyzed with TFA resulting in the free acid (24) which 
was activated using EDC and subsequently coupled with O-benzylhydroxylamine hydrochloride in the 
presence of triethylamine. The ring closure by intramolecular Mitsunobu reaction gave NHA 26 in a 
modest yield upon first attempt, with as a main side-product a dimeric species resulting from 
intermolecular Mitsunobu reaction. This side-reaction could be suppressed by diluting the reaction 
mixture from the original 0.1M to 0.05M (starting material concentration). The crude reaction 
mixture after Mitsunobu reaction also contained a considerable amount of triphenylphosphine oxide, 
which eluted very close to the desired product and complicated the purification. Three flash 
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chromatographic separations were necessary to obtain 26 in pure form. although we made two 
efforts to reduce the number of synthetic steps.  
Two attempts were made to reduce the number of steps in this synthetic route. First, we tried to 
make the synthesis a little more convergent by trying to use the enolate of protected oxyamide 29 in 
the Claisen condensation with (diethylphosphono)propionate 21, alas without success. To the best of 
our knowledge, the enolization and subsequent use as a nucleophile of protected 
acetohydroxamates has only very rarely been reported in literature. 
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Reagents and Conditions: (a) Boc2O, DMAP, Et3N, CH2Cl2, rt, on.; 
(b) LICA, THF, -70° C to rt, on.  
Scheme IV.6: Attempted oxyamide enolate formation and addition to methyl ester 21 
 Secondly, we attempted the direct displacement of the t-butyl ester in 22 with 
O-benzylhydroxylamine in toluene15, but only the oxime formation (32) from reaction with the 
ketone was noticed here, and no trace of the desired oxyamide 31 could be detected. 
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Scheme IV.7: Attempted direct ester – oxyamide conversion 
In the end, a sufficient amount of penultimate intermediate 26 was synthesized using the 
‘original’ protocol and final deprotection was attempted. The first step of the final deprotection of 
26, i.e. reductive debenzylation of the NHA, proceeded smoothly under standard conditions (Pd/C, 
ethanol, hydrogen at atmospheric pressure for 1 hour) resulting in a very pure and clean product 
(27). 
Unfortunately, attempts to deprotect the phosphonate moiety of 27 with TMSBr led to extensive 
hydrolytic opening of the NHA ring with formation of β-oxyamino acid 33 as demonstrated by MS 
analysis. Also when we tried acidic hydrolysis of the phosphonate esters (aqueous HCl), the same 
ring-opening occurred, even at a faster rate than the ester removal itself. These facts once more 
illustrate the susceptibility of the NHA structure toward hydrolysis and ring-opening. 
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27 3
Reagents and Conditions: HCl, H2O; or: (i) TMSBr, CH2Cl2, (ii) THF, H2O  
SchemeIV.8: Hydrolytic NHA-ring opening upon phosphonate deprotection 
On a positive note, however, the ring-structure perfectly survived the hydrogenative 
debenzylation in the penultimate step. This called for an “all-benzyl” protection strategy for this 
molecule with only a final debenzylation as the last synthesis step. We did not use this strategy in the 
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first place because, on the one hand, most phosphonate building blocks are commercially available 
as ethyl esters. On the other hand, as was also described in Chapter II, benzyl phosphonate esters are 
more susceptible toward basic/nucleophilic conditions such as the Claisen reaction employed here. 
Moreover, the more (types of) benzyl protecting groups present in a molecule, the longer one 
potentially needs to hydrogenate in order to remove them all. In the case of oxyamines there is 
always the risk of overreduction resulting in oxyamine N-deoxygenation. With regard to phosphonate 
protecting groups (particularly in fosmidomycin), in the synthesis of analogues it is often a dilemma 
to choose for (potentially too) reductive conditions using Pd/C, or to use (potentially too) 
nucleophilic/acidic conditions using TMSBr. Anyhow, we decided to try and resynthesize the 4-
phosphonoethyl NHA using benzyl protecting groups for both the phosphonate and the hydroxamide 
moieties. 
IV.D.4. Fourth Approach: Benzyl protected phosphonate 
Methyl (dibenzylphosphono)propionate 34 was synthesized by a Michaelis-Becker reaction from 
methyl 3-bromopropionate 20 and dibenzyl phosphite in excellent yield. Because of the low volatility 
of benzyl halides, Arbuzov reactions involving tribenzyl phophite are seldom successful and for the 
synthesis of dibenzyl phosphonates the Michaelis-Becker reaction is preferred.  
Much to our delight, the phosphonate benzyl esters survived the subsequent Claisen-reduction-
hydrolysis-amidation cascade without any problems, affording 38 in an acceptable overall yield.  
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Scheme IV.9: Synthesis of NHA analogue 3 via benzylphosphonate intermediates 
Also the intramolecular Mitsunobu reaction went flawless, apart from the tedious separation of 
triphenylphosphine oxide from the product afterwards. Finally, both the hydroxamate benzyl ether 
and phosphonate benzyl esters in 39 were removed by hydrogenation over Pd/C in methanol. Use of 
a non-protic/non-nucleophilic solvent would be preferable here, but to our knowledge no such 
solvent that is also capable of dissolving both the perbenzylated starting material as well as all 
reaction intermediates and the deprotected phosphonate 3 exists. Fortunately, upon careful 
monitoring of the reaction by MS we were able to restrict the reaction time to a minimum and no 
breakdown of the NHA was noticed, resulting in clean deprotected 3. This product could be stored 
dry at -38 °C for several months without breakdown. However, upon dissolving the product in water 
or aqueous buffer it hydrolizes quite fast to the ring-opened product. Because of this inherent low 
hydrolytic stability and a low DXR inhibitory potential in preliminary enzyme inhibition tests (18.83 % 
EcDXR inhibition at 100nM), we decided to cancel all efforts to synthesize the hydroxamate-based  
isomer 4. 
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IV.E Experimental Details 
General Methods and Materials. See III.F. 
Methyl 5-hydroxy-3-oxopentanoate (19). Methyl 5-(benzyloxy)-3-oxopentanoate (398 mg, 1.7 
mmol) was dissolved in methanol (16 mL) and formic acid (0.85 mL). Pd (10 % wt. on activated 
carbon) was added and the mixture was stirred overnight at room temperature. The reaction mixture 
was filtered over a Celite pad, the pad was rinsed with ethyl acetate, and all volatiles were 
evaporated. The resulting crude material was purified by flash column chromatography 
(hexanes/ethyl acetate: 50/50), yielding 142 mg (57 %) of 19 as a colorless liquid. Analytical data 
were in accordance with previously reported data16. 
Methyl 3-(diethoxyphosphoryl)propanoate (21). Triethylphosphite (5.2 mL, 30 mmol) and 
methyl 3-bromopropionate (3.27 mL, 30 mmol) were mixed in a three necked flask and a distillation 
setup was installed. The flask was heated at 80 °C for 24 hours under a N2 atmosphere, and then a 
slow stream of N2 was blown into the reaction flask, over the reaction mixture and outward via the 
distillation cooler and receiver flask in order to enhance ethyl bromide boiling out of the reaction 
mixture. While maintaining this N2 stream, the temperature was raised to 100 °C and stirring was 
continued for 12 hours, after which 31P-NMR confirmed the total consumption of triethyl phosphite. 
Remaining traces of starting materials were then distilled out of the reaction mixture under vacuum, 
leaving pure 21 (6.70 g, quant.) as a colorless liquid. Analytical data were in accordance with 
previously reported data17. 
tert-Butyl 5-(diethoxyphosphoryl)-3-oxopentanoate (22). N-isopropylcyclohexylamine (1.74 mL, 
10.5 mmol) was dissolved in THF (5 mL) and cooled to -60 °C. nBuLi (4 mL of a 2.5 M solution in 
hexanes) was added, the solution was allowed to warm to room temperature and cooled again to 
-60 °C. tert-Butyl acetate (1.49 mL, 11 mmol) was added and the mixture was stirred for 20 minutes 
before it was cannulated  into a flask containing a solution of methyl 
3-(diethoxyphosphoryl)propanoate 21 (1.12 g, 5 mmol) in THF (10 mL) cooled to -60 °C. After 25 
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minutes of stirring the reaction was quenched by the addition of acetic acid (1 mL) and saturated 
aqueous NH4Cl, and extracted three times with ethyl acetate. The combined organic fractions were 
washed with saturated aqueous NaHCO3, brine and dried over anhydrous Na2SO4. Purification of the 
crude product by flash column chromatography (hexanes/ethyl acetate: 50/50 to 0/100) yielded 
998 mg (65 %) of pure 22 as a colorless oil. 1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.30 (t, J=7.03 
Hz, 6 H) 1.39 - 1.54 (m, 9 H) 1.87 - 2.14 (m, 3 H) 2.70 - 2.94 (m, 2 H) 3.36 (s, 2 H) 3.95 - 4.19 (m, 4 H); 
HRMS (ESI) m/z 309.1477 [(M+H)+, calcd for C13H26O6P+ 309,1462] 
tert-Butyl 5-(diethoxyphosphoryl)-3-hydroxypentanoate (23). To a stirred solution of 22 (100 
mg, 0.32 mmol) in methanol was added sodium borohydride (13 mg, 0.36 mmol) at 0 °C. After 30 
minutes, the reaction was quenched by the addition of saturated aqueous NH4Cl, and extracted three 
times with ethyl acetate. The combined organic fractions were washed with brine and dried over 
anhydrous Na2SO4. Purification of the crude product by flash column chromatography (hexanes/ethyl 
acetate: 75/25 to 50/50) yielded 94 mg (95 %) of 23 as a colorless oil. 1H NMR (300 MHz, acetone) δ 
ppm 1.27 (t, J=7.03 Hz, 6 H) 1.38 - 1.49 (m, 9 H) 1.59 - 1.99 (m, 4 H) 2.36 (dd, J=6.44, 1.76 Hz, 2 H) 
3.89 - 4.17 (m, 5 H); HRMS (ESI) m/z 311.1605 [(M+H)+, calcd for C13H28O6P+ 311,1618] 
5-(Diethoxyphosphoryl)-3-hydroxypentanoic acid (24). tert-Butyl 5-(diethoxyphosphoryl)-3-
hydroxypentanoate 23 (479 mg, 1.54 mmol) was dissolved in dichloromethane, followed by the 
addition of triethylsilane (0.62 mL, 3.86 mmol) and TFA (1.77 mL, 23 mmol) at 0 °C. The reaction 
mixture was stirred at room temperature for 1.5 hours, and all volatiles were removed in vacuo. 
Coevaporation with toluene afforded 568 mg (quantitative) of an off-white oil that was used as such 
in the next reaction. 
Diethyl (5-((benzyloxy)amino)-3-hydroxy-5-oxopentyl)phosphonate (25). 
5-(Diethoxyphosphoryl)-3-hydroxypentanoic acid 24 (391 mg, 1.54 mmol) and 
O-benzylhydroxylamine (free base, 284 mg, 2.31 mmol) were dissolved in THF (8 mL) and water 
(3 mL). EDC (442 mg, 2.31 mmol) was added and the reaction mixture was stirred overnight at room 
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temperature. Aqueous HCl (0.1 M) was added and the mixture was extracted three times with ethyl 
acetate. The combined organic fractions were washed with saturated aqueous K2CO3, brine and dried 
over anhydrous Na2SO4. Purification of the crude product by flash column chromatography 
(dichloromethane/methanol: 95/5) yielded 406 mg (73 %) of 25 as a colorless oil. 1H NMR (300 MHz, 
DMSO-d6) δ ppm 1.22 (t, J=7.18 Hz, 6 H) 1.33 - 1.53 (m, 1 H) 1.53 - 1.92 (m, 3 H) 2.07 (d, J=6.44 Hz, 2 
H) 3.69 - 3.89 (m, 1 H) 3.89 - 4.13 (m, 4 H) 4.78 (s, 2 H) 4.86 (d, J=5.56 Hz, 1 H) 7.19 - 7.53 (m, 5 H) 
10.96 (s, 1 H); HRMS (ESI) m/z 360.1575 [(M+H)+, calcd for C16H27NO6P+ 360,1571] 
Diethyl (2-(1-(benzyloxy)-4-oxoazetidin-2-yl)ethyl)phosphonate (26). Diethyl 
(5-((benzyloxy)amino)-3-hydroxy-5-oxopentyl)phosphonate 25 (377 mg, 1.05 mmol) and 
triphenylphosphine (304 mg, 1.16 mmol) were dissolved in THF (20 mL) and DIAD (0.23 mL, 
1.16 mmol) was added while stirring at room temperature. After 7 hours, all volatiles were removed 
in vacuo at 30 °C. The resulting crude was purified by two consecutive flash columns (I: 
dichloromethane/methanol: 95/5; II: hexanes/acetone: 50/50 to 0/100), giving 326 mg (91 %) of 26 
as a colourless oil. 1H NMR (300 MHz, DMSO-d6) δ ppm 1.22 (t, J=7.18 Hz, 6 H) 1.55 - 1.93 (m, 4 H) 
2.42 (dd, J=13.77, 2.34 Hz, 1 H) 2.71 (dd, J=13.77, 5.27 Hz, 1 H) 3.84 (dd, J=5.27, 2.34 Hz, 1 H) 3.89 - 
4.10 (m, 4 H) 4.77 - 5.00 (m, 2 H) 7.27 - 7.51 (m, 5 H); HRMS (ESI) m/z 342.1460 [(M+H)+, calcd for 
C16H25NO5P+ 342,1465] 
Diethyl (2-(1-hydroxy-4-oxoazetidin-2-yl)ethyl)phosphonate (27). Diethyl (2-(1-(benzyloxy)-4-
oxoazetidin-2-yl)ethyl)phosphonate 26 (287 mg, 0.84 mmol) was dissolved in methanol (9 mL), Pd 
(10% wt. on activated carbon) was added and the mixture was stirred under a hydrogen atmosphere 
at room temperature. After 1 hour, the reaction mixture was filtered over a celite pad and the filter 
was rinsed with ethyl acetate. The combined organic fractions were evaporated and the resulting oil 
was purified by flash column chromatography (dichloromethane/methanol: 95/5 to 90/10) to give 
195 mg (92 %) of 27 as a colourless oil. 1H NMR (300 MHz, DMSO-d6) δ ppm 1.09 - 1.32 (m, 6 H) 1.58 - 
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1.94 (m, 4 H) 2.36 (dd, J=13.47, 2.34 Hz, 1 H) 2.70 (dd, J=13.47, 4.98 Hz, 1 H) 3.64 - 3.83 (m, 1 H) 3.86 
- 4.14 (m, 4 H) 9.97 (s, 1 H); HRMS (ESI) m/z 252.1003 [(M+H)+, calcd for C9H19NO5P+ 252,0995] 
Methyl 3-(dibenzoxyphosphoryl)propanoate (34). To a cooled (0 °C) suspension of sodium 
hydride (1.53 g of a 60 % suspension in mineral oil, 38.3 mmol) in DMF (100 mL) was added dibenzyl 
phosphite (10.58 mL, 38.3 mmol) under vigorous stirring. The icebath was removed and the solution 
was allowed to warm to room temperature. Methyl 3-bromopropionate (2.87 mL, 25.5 mmol) was 
then added and the reaction mixture was stirred overnight at room temperature. The reaction was 
quenched by the addition of saturated aqueous NH4Cl, diluted with aqueous 0.1 M HCl and extracted 
three times with ethyl acetate. The combined organic fractions were washed with saturated aqueous 
NaHCO3, brine and dried over anhydrous MgSO4. Purification of the crude product by flash column 
chromatography (toluene/hexanes/ethyl acetate: 35/35/30 to 10/10/80) yielded 10.77 g (99 %) of 34 
as a colorless oil. 1H NMR (300 MHz, acetone) δ ppm 1.99 - 2.21 (m, 2 H) 2.54 (dt, J=13.11, 7.80 Hz, 2 
H) 3.59 (s, 3 H) 4.90 - 5.19 (m, 4 H) 7.08 - 7.48 (m, 10 H); HRMS (ESI) m/z 349.1203 [(M+H)+, calcd for 
C18H22O5P+ 349,1199] 
tert-Butyl 5-(dibenzoxyphosphoryl)-3-oxopentanoate (35). The title compound was synthesized 
from methyl 3-(dibenzoxyphosphoryl)propanoate 34 (10.08g, 28.9 mmol) using the same method as 
described for 22, giving 9.69 g (78%) of 35 as a colourless oil that was used in the next reaction 
without further purification. HRMS (ESI) m/z 433.1794 [(M+H)+, calcd for C23H30O6P+ 433,1775] 
tert-Butyl 5-(dibenzoxyphosphoryl)-3-hydroxypentanoate (36). The title compound was 
synthesized from tert-butyl 5-(dibenzoxyphosphoryl)-3-oxopentanoate 35 (8.65 g, 20.0 mmol) using 
the same method as described for 23, giving 6.13 g (71%) of 36 as a colourless oil. 1H NMR (300 MHz, 
acetone) δ ppm 1.30 - 1.50 (m, 9 H) 1.62 - 2.02 (m, 4 H) 2.23 - 2.40 (m, 2 H) 3.85 - 4.04 (m, 1 H) 4.07 
(br. s., 1 H) 5.04 (qd, J=12.16, 8.05 Hz, 4 H) 7.19 - 7.51 (m, 10 H); HRMS (ESI) m/z 435.1922 [(M+H)+, 
calcd for C23H32O6P+ 435,1931] 
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5-(Dibenzoxyphosphoryl)-3-hydroxypentanoic acid (37). The title compound was synthesized 
from tert-butyl 5-(dibenzoxyphosphoryl)-3-hydroxypentanoate 36 (1.21 g, 2.58 mmol) using the same 
method as described for 24, giving 1.18 g of crude 37 that was used as such in the next reaction. 
HRMS (ESI) m/z 377.1171 [(M-H+), calcd for C19H22O6P- 377,1159] 
Dibenzyl (5-((benzyloxy)amino)-3-hydroxy-5-oxopentyl)phosphonate (38). The title compound 
was synthesized from crude 5-(dibenzoxyphosphoryl)-3-hydroxypentanoic acid 37 (1.04 g, 
2.41 mmol) using the same method as described for 25, giving 780 mg of 38 (66 %) as a colorless oil. 
1H NMR (300 MHz, acetone) δ ppm 1.67 - 2.09 (m, 4 H) 2.14 - 2.29 (m, 2 H) 3.84 - 4.09 (m, 1 H) 4.87 
(m, 3 H) 4.91 - 5.29 (m, 4 H) 7.20 - 7.49 (m, 15 H) 10.27 (br. s., 1 H); HRMS (ESI) m/z 484.1892 [(M-H+), 
calcd for C26H31NO6P+ 484,1884] 
Dibenzyl (2-(1-(benzyloxy)-4-oxoazetidin-2-yl)ethyl)phosphonate (39). The title compound was 
synthesized from dibenzyl (5-((benzyloxy)amino)-3-hydroxy-5-oxopentyl)phosphonate 38 (776 mg, 
1.60 mmol) using the same method as described for 39, giving 588 mg of 39 (79 %) as a colorless oil. 
1H NMR (300 MHz, DMSO-d6) δ ppm 1.55 - 1.95 (m, 4 H) 2.36 (dd, J=13.77, 2.34 Hz, 1 H) 2.66 (dd, 
J=13.77, 5.27 Hz, 1 H) 3.70 - 3.91 (m, 1 H) 4.76 - 4.92 (m, 2 H) 4.92 - 5.11 (m, 4 H) 7.17 - 7.54 (m, 15 
H); HRMS (ESI) m/z 466.1782 [(M-H+), calcd for C26H29NO5P+ 466,1778] 
(2-(1-Hydroxy-4-oxoazetidin-2-yl)ethyl)phosphonic acid (3). Dibenzyl (2-(1-(benzyloxy)-4-
oxoazetidin-2-yl)ethyl)phosphonate 39 (48 mg, 0.103 mmol) was dissolved in methanol (1.5 mL), Pd 
(10% wt. on activated carbon) was added and the mixture was stirred under a hydrogen atmosphere 
at room temperature. After 3 hour, the reaction mixture was filtered over a 20 µm cellulose acetate 
syringe filter and the filter was rinsed with methanol. The combined organic fractions were 
evaporated in vacuo at 26 °C, giving 19 mg (99 %) of 3 as a clear colorless sticky gum. 1H NMR (300 
MHz, METHANOL-d4) δ ppm 1.67 - 1.99 (m, 3 H) 1.99 - 2.18 (m, 1 H) 2.32 - 2.44 (m, 1 H) 2.80 (dd, 
J=13.47, 4.98 Hz, 1 H) 3.81 - 3.96 (m, 1 H); 13C NMR (75 MHz, METHANOL-d4) δ ppm 23.93 (d, 
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J=140.15 Hz), 26.96 (d, J=4.15 Hz), 37.80, 59.93 (d, J=18.52 Hz) 166.17; 31P NMR (121 MHz, 
METHANOL-d4) δ ppm 29.07; HRMS (ESI) m/z 194.0177 [(M-H
+), calcd for C5H9NO5P- 194,0224] 
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V.Alpha-heteroatom Derivatized Analogues of FR900098 
V.A Introduction 
As described in the general introduction (Chapter I), derivatisation of the three-carbon spacer of 
fosmidomycin has afforded very promising antimalarials. Alkyl and aryl groups have been appended 
to the α- and the γ-position of the spacer, but substitution of the latter led to a detrimental loss in 
activity. Concerning the α-position, only α-aryl substituents gave an increase in antimalarial activity 
whereas α-(hydroxyl)alkyl and α-arylalkyl substituents were less favorable. All these modifications 
share a carbon-carbon bond between the substituent and the α-position of the spacer. Except for the 
α-halogenated analogues described in Chapter III, no fosmidomycin derivatives bearing a heteroatom 
in α-position have been described. 
Therefore, we decided to devise a series of FR900098 analogues starting from α-OH and α-NH2 
FR900098, in which a variety of substituents are linked via different O- or N-based functional groups 
to the α-carbon of the spacer. This strategy has several advantages such as: 
 Relative ease of synthesis of starting materials. The synthesis of (α-
hydroxy)alkylphosphonates is well documented. The most common methods rely on the 
addition of dialkyl or trialkyl phosphites to aldehydes or ketones (Pudovik resp. Abramov 
reaction). Also the synthesis of (α-amino)alkylphosphonates is a well described field, due 
to the importance of these molecules as amino acid analogues. The one-pot three 
component reaction between a phosphite, an amine and an aldehyde or a ketone 
leading to α-aminoalkylphosphonates is known as the Kabachnik-Fields reaction. 
 Relative ease of further derivatisation. The hydroxyl- and aminogroups in α-position 
serve as excellent handles for further derivatisation, allowing divergent synthesis from 
common precursors. 
Chapter V: Alpha-heteroatom derivatized analogues of FR900098 
V.2 
 
 Possibility of broad SAR ‘scanning’. A large variety of substituents can be linked to the α-
carbon via different functional groups based on OH (ether, ester) and NH (amide, urea, 
amine, sulfonamide, triazole,…) 
V.B Retrosynthesis 
As described above, both envisaged α-hydroxy and α-amino alkylphosphonates can be 
synthesized from a common aldehyde precursor (8, Figure V.1). Reaction of this aldehyde with a 
phosphite alone (Pudovik reaction) leads to α-OH FR900098 (6), whereas the same reaction in the 
presence of an ammonia source (Kabachnik-Fields reaction) may give α-NH2 FR900098 (7). The α-OH 
analogue can then be converted to different ether analogues, or serve as a starting material for the 
synthesis of α-azido FR900098 (2). The latter may be tested as such, but also serves as a starting 
material for the synthesis of triazole derivatives (1) by means of a copper catalyzed azide-alkyne 
cycloaddition reaction. α-NH2 FR900098 (7) on the other hand, can straightforwardly be transformed 
into α-amido, α-urea and α-sulfonamide derivatives. 
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Figure V.1: Retrosynthetic analysis toward α-heteroatom substituted analogues of FR900098 
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V.C Chemistry 
Aldehyde 8, already equipped with a protected retrohydroxamate moiety, served as a starting 
point for the synthesis of α-O-based analogues via a Pudovik reaction. Its synthesis started with the 
alkylation of N-Boc-O-benzylhydroxylamine (10) with bromobutene (9) in DMF1, (Scheme V.1) 
followed by a one-pot deprotection-acetylation2 to afford terminal alkene 12 that can be stored 
indefinitely. Oxidative cleavage of the double bond with periodate and osmate gave the desired 
aldehyde 8 in good yields. 
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Scheme V.1: Synthesis of the common aldehyde precursor 8 and α-OH based analogues 
 
For the synthesis of benzyl protected α-hydroxy-FR900098 6 we chose a base-assisted Pudovik 
reaction with dibenzyl phosphite at low temperature for it resulted in a cleaner reaction mixture and 
higher yields than when using ‘classical’ Pudovik conditions. Using benzyl protection for both the 
phosphonate and the retrohydroxamate allowed us for a convenient one-step final deprotection 
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under very gentle conditions. α-Hydroxy-FR900098 6 was converted into its methyl ether 13a by a 
Williamson reaction with iodomethane and silver oxide. Attempted synthesis of α-phenyl ether 13b 
under standard Mitsunobu conditions in THF proved unsuccessful. This was ascribed to a 
combination of the steric hindrance of the α-carbon by the phosphonate group and the sterical 
hindrance and/or too low acidity of phenol. Therefore, we switched to more forcing conditions as 
described by Lepore et al.3: using a high concentration of reactants in very little THF, resulting in a 
highly viscous reaction mixture that was mixed by sonication. This allowed us to synthesize 13b albeit 
the complex reaction mixture called for fractionating by flash chromatography followed by 
purification by preparative HPLC. 
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Scheme V.2: Synthesis of α-(1,2,3-triazolyl) analogues 
 
Starting from the tri-benzylated α-hydroxy-FR900098 6, α-azidophosphonate 14 was synthesized 
by means of a Mitsunobu reaction with hydrazoic acid as the pronucleophile4 (Scheme V.2) (Caution: 
HN3 is volatile, highly toxic and explosive!). Using ‘classical’ Mitsunobu conditions (2 equiv. of both 
triphenyl phosphine and diethylazodicarboxylate (DEAD), excess hydrazoic acid, submolar 
Chapter V: Alpha-heteroatom derivatized analogues of FR900098 
V.6 
 
concentrations in toluene) we were able to synthesize the desired α-azide in what appeared to be 
pure form according to TLC or HPLC. However, persistent ethyl signals were seen in the 1H-NMR 
spectrum of the product. Originally assigned to ethyl acetate trapped in the oily product, it later 
turned out that these signals arose from the α-ethylcarbonate formed by attack of α-hydroxy-
FR900098 6 on one of the carbonyl groups of DEAD. As this unwanted product co-elutes with α-
azidophosphonate 14 both on TLC and RP-HPLC it took us some time to identify it. This problem was 
circumvented by switching to the more sterically hindered diisopropylazodicarboxylate (DIAD) and 
mixing the reactants in a different order (precomplexing triphenylphosphine and DIAD, followed by 
adding the hydrazoic acid solution and finally the α-hydroxyphosphonate). The obtained benzyl-
protected α-azidophosphonate 14 subsequently served in the synthesis of α-1,4-triazole-substituted 
analogues by copper-catalyzed azide-alkyne cycloaddition (CuAAC) with two acetylene derivatives. To 
the best of our knowledge, no literature data on the CuAAC of α-azidophosphonates exists and only 
thermal, hence non-regiospecific, phosphonomethylazide-alkyne cycloadditions have been 
performed before.5 Attempted CuAAC using copper(II)sulfate and ascorbic acid with phenyl- or 
t-butylacetylene at room temperature or with conventional heating failed, but upon switching to 
microwave heating clean products were obtained in good yields. The unsubstituted triazole 15a was 
synthesized using the protocol of Hansen et al.6: heating azide 14 in vinyl acetate under microwave 
irradiation for several hours. 
We considered α-azido-FR900098 also of interest as a potential DXR inhibitor, but for obvious 
reasons total deprotection by reductive debenzylation could not be performed on precursor 14. As 
we also feared that debenzylation of 14 with boron trichloride would lead to an unresolvable 
complex mixture of very polar compounds, we chose to synthesize a different α-azido precursor with 
orthogonal protective groups, in casu a benzyl ether for the retrohydroxamate and ethyl esters for 
the phosphonate (Scheme V.3). Therefore, a Pudovik reaction analogous to the one described above 
was performed with diethyl phosphite, leading to diethyl α-hydroxyphosphonate 16, which was 
converted to the α-azide 17 as described above. The retrohydroxamate moiety of compound 17 was 
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first debenzylated with boron trichloride, followed by purification of 18 on deactivated silica gel, 
prior to removal of the phosphonate esters by trimethylsilyl bromide in acetonitrile and basic workup 
yielding α-azido-FR900098 2 as a bisammonium salt. 
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Scheme V.3: Synthesis of α-azido-FR900098 
 
Synthesis of the α-N based series of analogues (Scheme V.4) started with the synthesis of benzyl 
protected α-Boc-amino-FR900098 20 as described by Klepacz et al.7 in two steps: first aldehyde 8 was 
converted to sulfone 19 in a three-component reaction with t-butylcarbamate and sodium 
p-toluenesulfinate, followed by displacement of the sulfone with dibenzyl phosphite. The 
Boc-protecting group on the amine facilitated purification of 20 and was removed without 
subsequent purification before further reactions. Although numerous alternatives for the synthesis 
of α-aminophosphonates are known, such as a Kabachnik-Fields reaction with HMDS or ammonium 
carbonate (which only gave marginal results in our hands), or the evident Staudinger reduction of 
azide 16 (which would be a much less economic way of synthesizing amine 7), this method benefits 
from high yields and easy purification. Conversion of amine 7 into benzamide 21a and phenylurea 
21b was carried out under standard conditions as depicted in Scheme V.4. 
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Scheme V.4: Synthesis of α-N based analogues 
 
As stated before, the use of only benzyl protecting groups allowed mild final deprotection in one 
step upon hydrogenation on palladium on carbon. First attempts were made by bubbling hydrogen 
gas through methanolic solutions of the starting materials, and we noticed the importance of 
working ‘metal free’ here: apparently upon the use of standard metal hydrogenation needles the 
reaction was poisoned by metal ions coming off these needles. Therefore, hydrogen gas was bubbled 
into the reaction mixture through a glass capillary, resulting in clean deprotection for analogues 5a, 
5b and 1b. Other analogues showed acid-mediated breakdown of the retrohydroxamic acid moiety 
during deprotection, calling for the incorporation of a base in the reaction in order to neutralize the 
formed phosphonic acid. We found a solution to this problem in using catalytic transfer 
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hydrogenation with ammonium formate as the hydrogen donor, the ammonium acting as a base to 
neutralize the formed phosphonates. Excess ammonium formate was removed by lyophilization with 
mixed success, resulting in the end products as their monoammonium salts. 
Attempts were also made to synthesize α-phenylsulfonamide FR900098 (4a, Scheme V.5) by 
reacting α-amine 7 with phenylsulfonyl chloride. Although this yielded penultimate 
α-phenylsulfonamide 22 in an affordable yield, the subsequent debenzylation got stuck after the two 
phosphonate benzyl esters were removed. Applying more forcing conditions (Pd black, hydrogen 
pressure up to 50 bar) only resulted in breakdown of the molecule. 
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Scheme V.5: Attempted synthesis of α-phenylsulfonamide analogue 
We then decided to try a boron trichloride mediated debenzylation for this compound, 
analogous to the procedure followed for the α-azido analogue above. This implied synthesis of the 
diethyl phosphonate precursor 25 (Scheme V.6), for which we used a three-component reaction 
between diethyl phosphite, phenylsulfonamide and aldehyde 8 in acetyl chloride8. The use of acetyl 
chloride as a solvent seems a bit strange but probably it serves as a dehydrating agent. 
α-Phenylsulfonyl diethylphosphonate 25 was formed in excellent yield by this procedure. 
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Scheme V.6: Attempted synthesis of α-phenylsulfonamide analogue via the diethylphosphonate 
Before attempting the planned deprotection of the retrohydroxamate with boron trichloride, we 
decided to give reductive debenzylation another try on this analogue. To our delight, simple 
hydrogenation over palladium on carbon in ethyl acetate at room temperature quickly and cleanly 
debenzylated 25. Unfortunately, the resulting free retrohydroxamate spontaneously broke down 
upon flash column purification, probably under influence of the acidic sulfonamide. These stability 
issues made us stop the development of α-phenylsulfonamide FR900098 (4a). 
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V.D Biological Evaluation 
The title compounds were tested their capacity to inhibit EcDXR using a spectrophotometric 
assay, i.e. by monitoring the decrease in NADPH absorption at 340 nm. Inhibition rates for all 
analogues as well as references fosmidomycin, FR900098 and α-(3,4-dichlorophenyl)fosmidomycin, 
incubated at 100nM are shown in Table V.1. 
Table V.1: In vitro EcDXR inhibition and P. falciparum growth inhibition by α-heteroatom 
substituted FR900098 analogues. 
  EcDXR Enzyme Inhibition  In vitro 
growth 
inhibition 
(IC50 in µM) 
Compound 
α-substituent % inhibition at 
100 nM 
Ki 
(nM) 
IC50 
(nM) 
P. falciparum 
K1 
Fosmidomycin  75.57 - - 1.73 
FR900098  74.71 15.11 30.23 0.42 
α-(3,4-dichlorophenyl) 
fosmidomycin 
 
- - - 0.16 
      
3a -OH 48.86 - - 1.82 
3b -OMe 4.14 - - 4.00 
3c -OPh No Inhibition - - 13.02 
      
1a -triazol-1-yl 3.32 - - 8.96 
1b -4-tBu- triazol-1-yl 12.66 1918 3837 2.75 
1c -4-Ph- triazol-1-yl 1.15 207.3 414.7 7.76 
      
2 -N3 77.48 74.6 149 1.98 
      
5a -benzamide 1.42 - - 49.02 
5b -phenylurea 1.30 - - >64.00 
 
Remarkably, promising DXR inhibition is confined to analogues with the smallest substituents 
(azido and hydroxy) at the α-position. In light of the appreciable DXR affinity obtained with  
α-phenylpyridyl substituents9, it is surprising that none of the α-triazoles showed significant 
inhibitory activity. Possibly the triazole ring is too electron rich to form strong π-stacking with Trp 211 
described in this study. The activity seen with the α-azido derivative is encouraging, as this is the first 
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example of a DXR inhibitor equaling FR900098’s DXR inhibitory potency. Crystallography studies 
should give us more insight in the binding mode of this molecule and the interaction of the rigid 
linear azide moiety with DXR. 
All α-heteroatom analogues were subsequently tested for their inhibitory effect against 
intraerythrocytic forms of P. falciparum (K1 strain) using a microdilution assay (Table V.1). The same 
trends are noticeable here: both α-N based analogues 5a and 5b hardly showed antiplasmodial 
activity, and the same is true for both α-ether derivatives 3b and 3c. The three α-triazolyl analogues 
1a, 1b and 1c show encouraging activity and follow the same trend  as observed in the enzymatic 
assay: the t-butyl substituted triazole shows the highest activity, the phenyl substituted and the 
unsubstituted show a comparable lower activity. The best antiplasmodial activity in the cellular assay 
is seen with α-OH and α-azido FR900098 3a and 2. The latter surpassed the in vitro antiplasmodial 
potency of parent FR900098 and is a promising analogue for further in vivo testing and 
crystallographic investigation.  
All α-heteroatom analogues were also tested for their cytotoxicity against MRC-5 SV2 cells, 
human fetal lung fibroblast, where they showed IC50 values of more than 64 µM. Furthermore, the 
title compounds were screened for their activity against T. cruzei, L. infantum, T. brucei, T. 
rhodesiense, E. coli, S. aureus, C. albicans, T. rubrum and A. fumigatus. No activity (IC50 >64 µM) was 
seen for all analogues against any of these organisms, confirming their selectivity for Plasmodium 
species. 
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V.E Experimental Details 
 
General Methods and Materials. See section III.F. 
Spectrophotometric DXR inhibition assay. See section III.F. 
In vitro P. falciparum growth inhibition assay and microbial screening. See section III.F. 
Cytotoxicity. See section III.F. 
tert-Butyl N-(benzyloxy)-N-(but-3-enyl)carbamate (11). To a solution of t-butyl N-
benzyloxycarbamate (6300 mg, 28.22 mmol) in dry DMF (60mL) was added sodium hydride (1242 mg 
of a 60% dispersion in mineral oil, 31.04 mmol) in small portions under vigorous stirring at room 
temperature. After 30 minutes, neat 4-bromobut-1-ene (3.15 mL, 4190 mg, 31.04 mg) was added 
dropwise via syringe to the clear solution. The reaction mixture was stirred for 90 minutes, quenched 
by the addition of saturated aqueous NH4Cl and partitioned between aqueous 0.1N HCl and diethyl 
ether. The extraction with diethyl ether was repeated two times, the combined organic phases were 
washed with brine, dried over anhydrous Na2SO4 and evaporated in vacuo. The resulting crude 
mixture was purified by dry column vacuum chromatography (DCVC)10 with a gradient of ethyl 
acetate in hexanes to yield 6.81g (87 %) of 11 as a colourless oil. 1H NMR (300 MHz, CHLOROFORM-d) 
δ ppm 1.50 (s, 9 H) 2.20 - 2.50 (m, 2 H) 3.32 - 3.61 (m, 2 H) 4.83 (s, 2 H) 5.05 (ddt, J=3.84, 2.60, 1.32, 
1.32 Hz, 1H) 5.11 (q, J=1.46 Hz, 1 H) 5.77 (ddt, J=17.06, 10.25, 6.85, 6.85 Hz, 1 H) 7.27 - 7.51 (m, 5 H) 
13C NMR (75 MHz, CHLOROFORM-d) δ ppm 28.30 ((CH3)3 ) 31.44 (CH2) 49.23 (CH2N) 76.91 (OCH2) 
81.19 (C(CH3)3) 116.68 (=CH2) 128.39 (=CH- ) 128.44 (=CH-) 129.31 (=CH-) 135.27 (=CH-) 135.69 (Cq) 
156.54 (C=O); HRMS (ESI) m/z 278.1745 [(M+H)+, calcd for C16H24NO3
+ 278.1751]. 
N-(benzyloxy)-N-(but-3-enyl)acetamide (12). tert-Butyl N-(benzyloxy)-N-(but-3-enyl)carbamate 
11 (2774 mg, 10 mmol), NaI (2998 mg, 20 mmol) and methanol (dry, 0.81 mL, 20 mmol) were 
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dissolved in 40 mL of dry acetonitrile, resulting in a clear yellow solution. Acetyl chloride (2.85 mL, 40 
mmol) was added dropwise while stirring the reaction mixture at room temperature. After 60 
minutes the reaction mixture was cooled to 0° C in an icebath and Et3N (5.6 mL, 40 mmol) was added 
as well as DMAP (122 mg, 1 mmol). The icebath was removed after 5 minutes and the reaction 
mixture stirred at room temperature for another 60 minutes. The reaction mixture was then poured 
into a separating funnel containing 1M aqueous HCl and extracted 3 times with diethyl ether. The 
combined organic fractions were washed with aqueous NaHCO3, aqueous Na2S2O3 and brine and 
dried over anhydrous Na2SO4. Purification of the crude material by DCVC (hexanes/ethyl acetate) 
yielded 2.07g (94%) of 12 as a slightly yellow oil. 1H NMR (300 MHz, CHLOROFORM-d) δ ppm 2.07-
2.08 (2s (rotamers), 3 H) 2.28 - 2.53 (m, 2 H) 3.69 (t, J=7.03 Hz, 2 H) 4.81 (s, 2 H) 4.93 - 5.22 (m, 2 H) 
5.59 - 5.94 (m, 1 H) 7.28 - 7.51 (m, 5 H) 13C NMR (75 MHz, CHLOROFORM-d) δ ppm 20.57 (CH3) 31.26 
(CH2) 45.04 (NCH2) 76.28 (PhCH2) 116.97 (=CH2) 128.68 (=CH-) 128.90 (=CH-) 129.11 (=CH-) 134.57 
(=CH-) 134.93 (Cq) 172.48 (C=O); HRMS (ESI) m/z 220.1320 [(M+H)
+, calcd for C13H18NO2
+ 220.1332]. 
N-(benzyloxy)-N-(2-formylethyl)acetamide (8). To a solution of 12 (2200 mg, 10 mmol) in THF 
(50 mL) was added 40 mg K2OsO4.2H2O and a hot (50° C) solution of NaIO4 (10700 mg, 50 mmol) in 
50 mL water. The resulting off-white thick suspension was shielded from light and stirred for 4 hours, 
after which TLC (90:10 dichloromethane/methanol) confirmed the complete conversion of the 
starting material. The reaction mixture was then filtered over a glassfibre pad, the filter was rinsed 
with diethyl ether, the resulting biphasic filtrate was transferred to a separating funnel and aqueous 
Na2SO4 was added followed by threefold extraction with diethyl ether. The combined ether phases 
were washed with brine, dried over anhydrous Na2SO4 and evaporated in vacuo, yielding 1.85g (84%) 
of a brown oil that was used without further purification in the next reaction. 1H NMR (300 MHz, 
CHLOROFORM-d) δ ppm 2.05 (s, 3 H) 2.68 (td, J=6.59, 1.46 Hz, 2 H) 3.95 (t, J=6.59 Hz, 2 H) 4.80 (s, 
2 H) 7.22 - 7.50 (m, 5 H) 9.73 (t, J=1.46 Hz, 1 H) 13C NMR (75 MHz, CHLOROFORM-d) δ ppm 20.50 
(CH3) 39.54 (NCH2) 41.32 (CH2) 76.37 (PhCH2) 128.70 (=CH-) 129.01 (=CH-) 129.36 (=CH-) 134.20 (Cq) 
172.80 (C=O) 200.19 (HC=O); HRMS (ESI) m/z 222.1136 [(M+H)+, calcd for C12H16NO3
+ 222.1125]. 
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Dibenzyl 3-(N-(benzyloxy)acetamido)-1-hydroxypropylphosphonate (6). Dibenzyl phosphite 
(4330 mg, 16.5 mmol) was dissolved in THF (20 mL), the solution was cooled to -78°C and LiHMDS 
(15 mL of a 1M solution in THF) was slowly added. After 15 minutes a solution of aldehyde 8 (3320 
mg, 15 mmol) in 30 mL dry THF was added via syringe and the icebath was removed. After another 
15 minutes of stirring the reaction mixture had warmed up to room temperature at which point it 
was quenched by the addition of saturated aqueous NH4Cl and extracted three times with ethyl 
acetate.  The combined organic phases were washed with brine, dried over anhydrous Na2SO4 and 
evaporated in vacuo. The resulting crude mixture was purified by dry column vacuum 
chromatography (DCVC) with a gradient of ethyl acetate in toluene containing 0.1% formic acid to 
yield 5.22g (72 %) of 6 as an off-white solid. 1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.85 - 2.03 
(m, 1 H) 2.05 (s, 3 H) 2.07 - 2.25 (m, 1 H) 3.56 - 3.72 (m, 1 H) 3.83 - 3.96 (m, 1 H) 4.05 (br. s., 1 H) 4.57 
(br. s., 1 H) 4.71 - 4.85 (m, 2 H) 4.98 - 5.14 (m, 4 H) 7.11 - 7.42 (m, 15 H) 13C NMR (75 MHz, 
CHLOROFORM-d) δ ppm 20.32 (CH3) 29.21 (CH2) 42.09 (NCH2) 65.02 (d, 
1JC-P= 166.96Hz, P-CHOH) 
68.01 (d, 2JC-P= 5.80Hz, POCH2) 68.10 (d, 
2JC-P= 5.80Hz, POCH2) 76.43 (PhCH2) 127.92 (=CH-) 128.31 
(=CH-) 128.50 (=CH-) 128.70 (=CH-) 128.99 (=CH-) 129.19 (=CH-) 134.12 (Cq)136.22 (d, 
3JC-P= 2.21Hz, 
Cq) 136.3 (d, 
3JC-P= 2.21Hz, Cq) 173.12 (C=O) ; HRMS (ESI) m/z 484.1852 [(M+H)
+, calcd for 
C26H31NO6P
+ 484.1884]. 
Dibenzyl 3-(N-(benzyloxy)acetamido)-1-methoxypropylphosphonate (13a). Dibenzyl 3-(N-
(benzyloxy)acetamido)-1-hydroxypropylphosphonate (6) (488 mg, 1 mmol) was dissolved in DMF 
(4 mL) and Ag2O (348 mg, 1.5 mmol) was added under vigorous stirring. Neat iodomethane (0.62 mL, 
1419 mg, 10 mmol) was added via syringe, the reaction mixture was shielded from light and stirred 
overnight at room temperature. The reaction mixture was then filtered over a glassfibre pad, the 
filtrate was concentrated and filtered again, resulting in a clear solution that was evaporated in 
vacuo. The resulting crude material was purified by DCVC with a gradient of ethyl acetate in hexanes 
to yield 304 mg (61%) of 13a as a colourless oil. 1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.85 - 
2.02 (m, 1 H) 2.02 - 2.09 (m, 3 H) 2.09 - 2.29 (m, 1 H) 3.41 - 3.57 (m, 4 H) 3.59 - 3.76 (m, 1 H) 3.80 - 
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4.07 (m, 1 H) 4.63 - 4.86 (m, 2 H) 4.91 - 5.21 (m, 4 H) 7.14 - 7.45 (m, 15 H); HRMS (ESI) m/z 498.2035 
[(M+H)+, calcd for C27H33NO6P+  498,204]. 
Dibenzyl 3-(N-(benzyloxy)acetamido)-1-phenoxypropylphosphonate (13b). Dibenzyl 3-(N-
(benzyloxy)acetamido)-1-hydroxypropylphosphonate (6) (725 mg, 1.5 mmol), triphenylphosphine 
(393 mg, 1.5 mmol) and phenol (141 mg, 1.5 mmol) were dissolved in 0.5 mL THF under sonication at 
30° C to give a clear viscous jelly. To this mixture was added diisopropyl azodicarboxylate (0.30 mL, 
1.5 mmol) and sonication at 30°C was continued for one hour. Then another half equivalent of 
phenol (47 mg, 0.5 mmol), triphenylphosphine (131 mg, 0.5 mmol) and diisopropyl azodicarboxylate 
(0.10 mL, 0.5 mmol) dissolved in 0.250 mL THF were added and the mixture was sonicated at room 
temperature overnight. Subsequently, all volatiles were removed in vacuo and the crude material 
was fractionated by DCVC (hexanes/ethyl acetate). All fractions containing product were pooled and 
evaporated and the resulting material was purified by preparative HPLC (50/50 to 100/0 acetonitrile 
– water containing 0.2% formic acid) to give 224 mg (27%) of 13a as a colourless oil. 1H NMR (300 
MHz, CHLOROFORM-d) δ ppm 1.99 (s, 3 H) 2.10 - 2.45 (m, 2 H) 3.62 - 4.01 (m, 2 H) 4.46 - 4.81 (m, 3 
H) 4.82 - 5.15 (m, 4 H) 6.82 - 7.10 (m, 3 H) 7.12 - 7.50 (m, 17 H); HRMS (ESI) m/z 560.2203 [(M+H)+, 
calcd for C32H35NO6P+ 560,2197]. 
Dibenzyl 3-(N-(benzyloxy)acetamido)-1-azidopropylphosphonate (14). Hydrazoic acid solution 
(Caution: HN3 is volatile, highly toxic and explosive!): Sodium azide (4000 mg, 61.5 mmol) was 
dissolved in water (10 mL). Toluene (50 mL) was added and the resulting biphasic system was cooled 
on ice to 0°C. Under vigorous stirring, concentrated sulfuric acid (8 mL) was added dropwise. After 30 
min of stiring, the organic layer was separated and stored on anhydrous Na2SO4. 
Triphenylphosphine (5250 mg, 20 mmol) was dissolved in toluene (60 mL), cooled to 0°C and 
diisopropylazodicarboxylate (3.96 mL, 20 mmol) was added, followed by 10 mL of the freshly 
prepared hydrazoic acid stock solution. Then a solution of compound 6 (4880 mg, 10 mmol) in 
toluene (25 mL) was added and the icebath was removed. Stirring was continued for 2 hours during 
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which the appearance of the reaction mixture shifted from turbid and yellow to clear and almost 
colourless. The reaction mixture was concentrated in vacuo, the residue was taken up in diethyl 
ether and triphenylphosphine oxide was crystallized out by addition of heptane and seeding with 
triphenylphosphine oxide. The resulting crude product was then purified by DCVC (0 to 100% ethyl 
acetate in hexanes) to yield 3865 mg (76 %) of 14 as an oil. 1H NMR (300 MHz, CHLOROFORM-d) δ 
ppm 1.69 - 1.93 (m, 1 H) 2.00 - 2.09 (m, 3 H) 2.15 (ddt, J=14.50, 7.18, 3.81, 3.81 Hz, 1 H) 3.54 (td, 
J=11.42, 3.22 Hz, 1 H) 3.63 - 3.91 (m, 2 H) 4.77 (s, 2 H) 4.92 - 5.19 (m, 4 H) 7.17 - 7.54 (m, 15 H); 
HRMS (ESI) m/z 509.1952 [(M+H)+, calcd for C26H30N4O5P+ 509,1948]. 
Dibenzyl (3-(N-(benzyloxy)acetamido)-1-(1H-1,2,3-triazol-1-yl)propyl)phosphonate (15a). Azide 
14 (508 mg, 1.01 mmol) was dissolved in vinyl acetate (10 mL, 108 mmol) and the solution was 
heated in a microwave at 120° C for 6.5 hours, followed by removal of all volatiles in vacuo. The 
resulting crude was purified by DCVC (0 to 100% ethyl acetate in hexanes followed by 2% ethanol in 
ethyl acetate) to yield 370 mg (69 %) of 15a as an oil. 1H NMR (300 MHz, CHLOROFORM-d) δ ppm 
2.01 (s, 3 H) 2.36 - 2.68 (m, 2 H) 3.27 - 3.67 (m, 2 H) 4.55 - 4.72 (m, 2 H) 4.72 - 5.14 (m, 5 H) 7.09 - 
7.46 (m, 15 H) 7.58 - 7.80 (m, 2 H); HRMS (ESI) m/z 535.2098 [(M+H)+, calcd for C28H32N4O5P+ 
535,2105]. 
Dibenzyl (3-(N-(benzyloxy)acetamido)-1-(4-(tert-butyl)-1H-1,2,3-triazol-1-
yl)propyl)phosphonate (15b). To a solution of 14 (530 mg, 1.04 mmol) in DMF (10 mL) was added 
CuSO4 (0.1 mL of a 0.1M aqueous stock solution, 0.01 mmol), sodium ascorbate (0.5 mL of a freshly 
prepared 0.1M aqueous stock solution, 0.05 mmol) and 3,3-dimethylbut-1-yne (2 mL, 1340 mg, 16.3 
mmol). The reaction mixture was heated in a microwave oven for 30 minutes at 60° C. Assessment of 
the reaction mixture by TLC (25:75 toluene – ethyl acetate) showed the presence of unreacted azide, 
so another 0.5 mL of sodium ascorbate stock solution and 0.1 mL of CuSO4 stock solution were added 
and the reaction mixture was irradiated for another 45 minutes at 70° C. At that point all azide was 
converted and the reaction mixture was concentrated, followed by purification of the resulting crude 
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by DCVC (0 to 100% ethyl acetate in hexanes) to yield 594 mg (97 %) of 15b as a colourless oil. 1H 
NMR (300 MHz, CHLOROFORM-d) δ ppm 1.16 - 1.45 (m, 9 H) 2.01 (s, 3 H) 2.37 - 2.68 (m, 2 H) 3.35 - 
3.67 (m, 2 H) 4.57 - 4.74 (m, 2 H) 4.74 - 4.91 (m, 2 H) 4.91 - 5.11 (m, 3 H) 7.07 - 7.40 (m, 15 H) 7.44 (d, 
J=0.88 Hz, 1 H); HRMS (ESI) m/z 591.2731 [(M+H)+, calcd for C32H40N4O5P+ 591,2731]. 
Dibenzyl (3-(N-(benzyloxy)acetamido)-1-(4-phenyl-1H-1,2,3-triazol-1-yl)propyl)phosphonate 
(15c). To a solution of 14 (536 mg, 1.1 mmol) in DMF (10 mL) was added CuSO4 (0.5 mL of a 0.1M 
aqueous stock solution, 0.05 mmol), sodium ascorbate (1 mL of a freshly prepared 0.1M aqueous 
stock solution, 0.1 mmol) and phenylacetylene (3 mL, 2790 mg, 27.3 mmol). The reaction mixture 
was heated in a microwave oven for 1 hour at 80° C, followed by removal of all volatiles in vacuo. The 
resulting crude was purified by DCVC (0 to 95% ethyl acetate in hexanes) to yield 610 mg (95 %) of 
15c as an oil. 1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.89 - 2.14 (m, 3 H) 2.41 - 2.73 (m, 2 H) 
3.34 - 3.74 (m, 2 H) 4.51 - 4.74 (m, 2 H) 4.76 - 4.93 (m, 2 H) 4.93 - 5.16 (m, 3 H) 7.08 - 7.45 (m, 18 H) 
7.69 - 7.83 (m, 2 H) 7.83 - 7.91 (m, 1 H); HRMS (ESI) m/z 611.2417 [(M+H)+, calcd for C34H36N4O5P+ 
611,2418]. 
Diethyl 3-(N-(benzyloxy)acetamido)-1-hydroxypropylphosphonate (16). Diethyl phosphite 
(684 mg, 4.95 mmol) was dissolved in THF (5 mL), the solution was cooled to -78°C and LiHMDS 
(4.5 mL of a 1M solution in THF) was slowly added. After 30 minutes a solution of aldehyde 8 (996 
mg, 4.5 mmol) in 10 mL dry THF was added via syringe. After 20 minutes of stirring at -78°C the 
reaction was quenched by the addition of saturated aqueous NH4Cl and extracted three times with 
ethyl acetate.  The combined organic phases were washed with brine, dried over anhydrous Na2SO4 
and evaporated in vacuo. The resulting crude mixture was purified by DCVC (0 to 100 % acetone in 
toluene continued by 0 to 20 % methanol in acetone) to yield 1200 mg (74 %) of 16 as an oil. 1H NMR 
(300 MHz, CHLOROFORM-d) d ppm 1.26 - 1.41 (m, 6 H) 1.81 - 2.04 (m, 1 H) 2.09 (s, 3 H) 2.10 - 2.25 
(m, 1 H) 3.70 (dt, J=14.64, 4.83 Hz, 1 H) 3.86 (dddd, J=11.35, 8.57, 5.86, 2.93 Hz, 1 H) 3.94 - 4.28 (m, 5 
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H) 4.48 - 4.73 (m, 1 H) 4.74 - 4.96 (m, 2 H) 7.38 (s, 5 H); HRMS (ESI) m/z 360.1578 [(M+H)+, calcd for 
C16H27NO6P+ 360,1571]. 
Diethyl 3-(N-(benzyloxy)acetamido)-1-azidopropylphosphonate (17). Hydrazoic acid solution 
(Caution: HN3 is volatile, highly toxic and explosive!): Sodium azide (4000 mg, 61.5 mmol) was 
dissolved in water (10 mL). Toluene (50 mL) was added and the resulting biphasic system was cooled 
on ice to 0°C. Under vigorous stirring, concentrated sulfuric acid (8 mL) was added dropwise. After 30 
min of stiring, the organic layer was separated and stored on anhydrous Na2SO4. 
Triphenylphosphine (525 mg, 2.0 mmol) was dissolved in toluene (5 mL), cooled to 0°C and 
diisopropylazodicarboxylate (0.40 mL, 2.0 mmol) was added, followed by 5 mL of the freshly 
prepared hydrazoic acid stock solution, resulting in the formation of copious yellow precipitate. Then 
a solution of compound 16 (360 mg, 1.0 mmol) in toluene (5 mL) was added and the icebath was 
removed. Stirring was continued for 4 hours during which the appearance of the reaction mixture 
shifted to clear and almost colourless. The reaction mixture was concentrated in vacuo, the residue 
was taken up in diethyl ether and triphenylphosphine oxide was crystallized out by addition of 
heptane and seeding with triphenylphosphine oxide. The resulting crude product was then purified 
by DCVC (25 to 100 % ethyl acetate in toluene continued by 0 to 10 % methanol in ethyl acetate) to 
yield 336 mg (88 %) of 17 as an oil. 1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.34 (td, J=7.10, 0.73 
Hz, 6 H) 1.71 - 1.95 (m, 1 H) 2.10 (s, 3 H) 2.12 - 2.32 (m, 1 H) 3.56 (td, J=11.50, 3.37 Hz, 1 H) 3.68 - 
3.95 (m, 2 H) 4.08 - 4.29 (m, 4 H) 4.84 (s, 2 H) 7.38 (s, 5 H); HRMS (ESI) m/z 385.1628 [(M+H)+, calcd 
for C16H26N4O5P+ 385,1635]. 
Diethyl 3-(N-hydroxyacetamido)-1-azidopropylphosphonate (18). A solution of 17 (334 mg, 0.87 
mmol) in dichloromethane (8 mL) was cooled to -75°C and BCl3 (2.6 mL of a 1M solution in 
dichloromethane, 2.6 mmol) was added dropwise. After 45 minutes of stirring at -75°C the reaction 
mixture was poured into aqueous NaHCO3 and extracted 4 times with dichloromethane. The 
combined organic fractions were washed with brine, dried over anhydrous Na2SO4 and evaporated in 
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vacuo. The resulting crude mixture was purified by DCVC on a silica column that was previously 
‘deactivated’ by rinsing with 5% triethylamine in hexanes (0 to 20 % methanol in ethyl acetate 
containing 1% triethylamine) to yield 201 mg (79 %) of 18 as an oil. 1H NMR (300 MHz, METHANOL-
d4) δ ppm 1.22 - 1.49 (m, 6 H) 1.62 - 1.88 (m, 1 H) 1.98 - 2.25 (m, 4 H) 3.60 - 3.99 (m, 3 H) 4.08 - 4.32 
(m, 5 H); HRMS (ESI) m/z 295.1169 [(M+H)+, calcd for C9H20N4O5P+ 295,1166]. 
tert-Butyl 3-(N-(benzyloxy)acetamido)-1-tosylpropylcarbamate (19). A mixture of aldehyde 8 
(1106 mg, 5 mmol), tert-butyl carbamate (650 mg, 5.5 mmol), anhydrous sodium p-toluenesulfinate 
(980 mg, 5.5 mmol), water (5 ml), THF (2 ml), acetonitrile (5 mL) and formic acid (540 µL, 14 mmol) 
was stirred overnight at room temperature, forming a clear solution. As the reaction was not finished 
at this point according to TLC (25:75 toluene – ethyl acetate), the reaction mixture was stirred for 
another 6 hours at 50°C. After cooling to room temperature, aqueous NaHCO3 was added and the 
mixture was extracted three times with diethyl ether, the combined organic phases were washed 
with brine, dried over anhydrous Na2SO4 and evaporated in vacuo. The resulting crude mixture was 
purified by DCVC (0 to 50 % ethyl acetate in hexanes) to yield 1920 mg (81 %) of 19. 1H NMR (300 
MHz, CHLOROFORM-d) δ ppm 1.10 - 1.32 (m, 9 H) 1.88 - 2.22 (m, 4 H) 2.29 - 2.46 (m, 3 H) 2.46 - 2.69 
(m, 1 H) 3.66 - 3.96 (m, 2 H) 4.83 (s, 2 H) 4.90 (td, J=10.54, 4.10 Hz, 1 H) 5.41 (d, J=10.54 Hz, 1 H) 7.18 
- 7.35 (m, 2 H) 7.39 (s, 5 H) 7.61 - 7.88 (m, 2 H); HRMS (ESI) m/z 477.2058 [(M+H)+, calcd for 
C24H33N2O6S+ 477,2054]. 
tert-Butyl 1-((benzyloxy)phosphono)-3-(N-(benzyloxy)acetamido)propylcarbamate (20). To a 
solution of 19 (1920 mg, 4.03 mmol) in THF (15 mL) was added NaH (360 mg of a 60% dispersion in 
mineral oil, 8.06 mmol) in one batch while stirring at room temperature, resulting in a grey 
suspension. After 15 minutes, a solution of dibenzyl phosphite (1160 mg, 4.42 mmol) in THF (5 mL) 
was added dropwise and the reaction mixture was stirred for 1 hour at room temperature.  The 
reaction mixture was then cooled to 0°C, quenched with saturated aqueous NH4Cl and extracted 
three times with ethyl acetate.  The combined organic phases were washed with brine, dried over 
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anhydrous Na2SO4 and evaporated in vacuo. The resulting crude mixture was purified by DCVC (50 to 
100 % ethyl acetate in hexanes) to yield 2020 mg (86 %) of 20 as an oil. 1H NMR (300 MHz, 
CHLOROFORM-d) δ ppm 1.24 - 1.52 (m, 9 H) 1.84 (dt, J=9.15, 4.65 Hz, 1 H) 2.04 (s, 3 H) 2.24 (d, J=8.20 
Hz, 1 H) 3.54 - 3.89 (m, 2 H) 4.05 - 4.35 (m, 1 H) 4.68 - 4.82 (m, 2 H) 4.87 (d, J=10.25 Hz, 1 H) 4.92 - 
5.12 (m, 4 H) 7.11 - 7.51 (m, 15 H); HRMS (ESI) m/z 583.2568 [(M+H)+, calcd for C31H40N2O7P+ 
583,2568]. 
Dibenzyl 3-(N-(benzyloxy)acetamido)-1-aminopropylphosphonate (7). A solution of 20 
(1660 mg, 2.85 mmol) in dichloromethane (30 mL) was cooled to 0°C and TFA (11 mL, 142 mmol) was 
added dropwise. After 20 minutes of stirring at 0°C the reaction mixture was poured into aqueous 
K2CO3 and extracted 4 times with chloroform. The combined organic fractions were washed with 
brine, dried over anhydrous Na2SO4 and evaporated in vacuo which resulted in 1350 mg (98 %) of 
crude 7 that was used as such in the following reactions. HRMS (ESI) m/z 483.2050 [(M+H)+, calcd for 
C26H32N2O5P+ 483,2043] 
Dibenzyl 3-(N-(benzyloxy)acetamido)-1-(benzamido)propylphosphonate (21a). To a solution 
of 7 (241 mg, 0.5 mmol) in dichloromethane (2.5 mL) was added triethylamine (140 µL, 1 mmol), 
DMAP (6 mg, 0.05 mmol) and benzoylchloride (87µL, 0.75 mmol). The reaction mixture was stirred at 
room temperature for 3.5 hours, then poured into aqueous 0.2N HCl and extracted three times with 
ethyl acetate. The combined organic phases were washed with brine, dried over anhydrous Na2SO4 
and evaporated in vacuo. The resulting crude mixture was purified by DCVC (50 to 100 % ethyl 
acetate in hexanes continued by 0 to 10 % ethanol in ethyl acetate) to yield 261 mg (89 %) of 21a as 
an oil. 1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.87 (s, 3 H) 1.96 - 2.19 (m, 1 H) 2.21 - 2.44 (m, 1 
H) 3.83 (t, J=6.88 Hz, 2 H) 4.43 - 4.62 (m, 2 H) 4.62 - 4.80 (m, 1 H) 4.86 - 5.10 (m, 4 H) 6.98 (d, J=6.74 
Hz, 2 H) 7.07 - 7.47 (m, 16 H) 7.50 - 7.65 (m, 2 H); HRMS (ESI) m/z 587.2311 [(M+H)+, calcd for 
C33H36N2O6P+ 587,2305] 
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Dibenzyl 3-(N-(benzyloxy)acetamido)-1-(3-phenylureido)propylphosphonate (21b). To a 
solution of 7 (241 mg, 0.5 mmol) in dichloromethane (2.5 mL) was added triethylamine (70 µL, 
0.5 mmol), DMAP (6 mg, 0.05 mmol) and phenylisocyanate (65µL, 0.6 mmol). The reaction mixture 
was stirred at room temperature for 4 hours, then poured into aqueous 0.2N HCl and extracted three 
times with ethyl acetate. The combined organic phases were washed with brine, dried over 
anhydrous Na2SO4 and evaporated in vacuo. The resulting crude mixture was purified by DCVC (50 to 
100 % ethyl acetate in hexanes continued by 0 to 10 % ethanol in ethyl acetate) to yield 291 mg 
(97 %) of 21b as an oil. 1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.80 - 2.01 (m, 4 H) 2.27 (br. s., 1 
H) 3.46 - 3.85 (m, 2 H) 4.51 - 4.72 (m, 1 H) 4.72 - 4.87 (m, 2 H) 4.89 - 5.12 (m, 4 H) 6.73 (d, J=9.67 Hz, 
1 H) 6.90 - 7.09 (m, 1 H) 7.13 - 7.43 (m, 19 H) 7.49 (s, 1 H); HRMS (ESI) m/z 602.2410 [(M+H)+, calcd 
for C33H37N3O6P+ 602,2414] 
Phenyl 1-((benzyloxy)phosphono)-3-(N-(benzyloxy)acetamido)propylsulfonamide (22). A 
solution of 7 (436 mg, 0.90 mmol) and triethylamine (190 µL, 1.35 mmol) in dichloromethane (5 mL) 
was cooled to 0°C and phenylsulfonylchloride (120 µL, 0.9 mmol) was added dropwise. The icebath 
was removed and the reaction mixture was stirred overnight, gradually warming to room 
temperature. Saturated aqueous NH4Cl was then added to quench the reaction, the reaction mixture 
was partitioned between water and ethyl acetate and the aqueous phase was extracted three times 
with ethyl acetate. The combined organic phases were washed with brine, dried over anhydrous 
Na2SO4 and evaporated in vacuo. The resulting crude mixture was purified by DCVC (50 to 100 % 
ethyl acetate in hexanes continued by 0 to 10 % methanol in ethyl acetate) to yield 384 mg (69 %) of 
22 as a white solid. 1H NMR (300 MHz, CHLOROFORM-d) d ppm 1.72 - 1.97 (m, 4 H) 2.05 - 2.19 (m, 1 
H) 2.99 (br. s., 2 H) 4.41 - 4.70 (m, 1 H) 4.84 - 5.16 (m, 6 H) 6.46 - 6.76 (m, 1 H) 7.14 - 7.37 (m, 15 H) 
7.39 - 7.54 (m, 2 H) 7.54 - 7.64 (m, 1 H) 7.72 - 7.88 (m, 2 H); HRMS (ESI) m/z 623.1968 [(M+H)+, calcd 
for C32H36N2O7PS+ 623,1975] 
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Diethyl (3-(N-(benzyloxy)acetamido)-1-(phenylsulfonamido)propyl)phosphonate (25). 
Benzenesulfonamide (473 mg, 3 mmol) was suspended in acetyl chloride (20 mL), cooled to 0° C and 
diethyl phosphite (0.384 mL, 3 mmol) and aldehyde 8 (733 mg, 3.31 mmol) were added dropwise. 
After 20 minutes of stirring at 0° C the icebath was removed and stirring was continued overnight at 
room temperature. All volatiles were removed in vacuo and the resulting crude was purified by DCVC 
(50 to 100 % ethyl acetate in hexanes continued by 0 to 10 % methanol in ethyl acetate) to yield 1737 
mg (93 %) of 25 as a white solid. 1H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.08 - 1.43 (m, 6 H) 1.85 
- 2.24 (m, 5 H) 3.55 - 3.71 (m, 2 H) 3.71 - 3.87 (m, 1 H) 3.87 - 4.23 (m, 4 H) 4.73 (s, 2 H) 6.94 (d, J=8.20 
Hz, 1 H) 7.21 - 7.56 (m, 8 H) 7.79 - 8.02 (m, 2 H); HRMS (ESI) m/z 499.1668 [(M+H)+, calcd for 
C22H32N2O7PS+ 499,1662] 
3-(N-hydroxyacetamido)-1-azidopropylphosphonic acid, bisammonium salt (2). Compound 18 
(165 mg, 0.561 mmol) was coevaporated with toluene (3 × 10 mL), taken up in acetonitrile (5 mL) and 
BSTFA (600 µL, 2.24 mmol) was added. After 15 minutes of stirring at room temperature, an icebath 
was installed and TMSBr (2.5 mL, 19 mmol) was added. The icebath was removed after 10 minutes 
and the reaction was stirred further at room temperature until, after 2.5 hours, 31P-NMR confirmed 
that the starting phosphonate was completely deprotected (shift from δ = 23 ppm to 3 ppm). All 
volatiles were removed in vacuo, followed by coevaporation with toluene (3 × 10 mL). The resulting 
oil was taken up in acetonitrile, concentrated ammonia was added, the mixture was stirred at room 
temperature for 30 minutes and evaporated to give the crude material as a brown oil. This was 
dissolved in methanol, decolorized over activated carbon and lyophilized from water to give the 
product as a hygroscopic resin in quantitative yield. 1H NMR (300 MHz, METHANOL-d4) δ ppm 1.63 - 
1.87 (m, 1 H) 2.03 - 2.35 (m, 4 H) 3.18 - 3.37 (m, 1 H) 3.45 - 3.69 (m, 1 H) 3.88 - 4.11 (m, 1 H); 13C 
NMR (75 MHz, METHANOL-d4) δ ppm 20.57, 28.60,  46.73 (d, J=12.99 Hz), 59.09 (d, J=143.47 Hz), 
173.94; 31P NMR (121 MHz, METHANOL-d4) δ ppm 16.45; HRMS (ESI) m/z 237.0423 [(M-H+), calcd 
for C5H10N4O5P- 237,0394].  
Chapter V: Alpha-heteroatom derivatized analogues of FR900098 
V.24 
 
3-(N-hydroxyacetamido)-1-(benzamido)propylphosphonic acid (5a). To a solution of 21a 
(309 mg, 0.53 mmol) in a mixture of methanol – water – tert-butanol (10 mL) was added 10% Pd/C. 
Hydrogen gas was bubbled through via a glass capillary at atmospheric pressure for 3.5 hours after 
which the reaction mixture was filtered and concentrated in vacuo. The residue was taken up in 
tert-butanol, frozen and lyophilized to give the product as a white foam in quantitative yield. 1H NMR 
(300 MHz, METHANOL-d4) δ ppm 1.72 - 2.11 (m, 3 H) 2.42 (ddd, J=14.21, 6.59, 3.22 Hz, 1 H) 3.52 - 
3.79 (m, 1 H) 3.90 (d, J=4.69 Hz, 1 H) 4.34 (t, J=12.59 Hz, 1 H) 7.23 - 7.51 (m, 5 H) 7.61 (d, J=7.03 Hz, 1 
H) ); 13C NMR (75 MHz, METHANOL-d4) δ ppm 21.53, 26.55, 30.04,  44.60 (d, J=155.91 Hz), 129.90, 
128.12, 130.33, 134.59, 172.20; 31P NMR (121 MHz, METHANOL-d4) δ ppm 22.53; HRMS (ESI) m/z 
315.0767 [(M-H+), calcd for C12H16N2O6P- 315,0751]. 
3-(N-hydroxyacetamido)-1-(3-phenylureido)propylphosphonic acid (5b). To a solution of 21b 
(321 mg, 0.53 mmol) in a mixture of methanol – water – tert-butanol (10 mL) was added 10% Pd/C. 
Hydrogen gas was bubbled through via a glass capillary at atmospheric pressure for 3 hours after 
which the reaction mixture was filtered and concentrated in vacuo. The residue was taken up in a 
mixture of water and tert-butanol, frozen and lyophilized to give the product as a white foam in 
quantitative yield. 1H NMR (300 MHz, DMSO-d6) d ppm 1.58 - 1.82 (m, 1 H) 1.82 - 1.91 (m, 3 H) 1.96 - 
2.17 (m, 1 H) 3.29 - 3.58 (m, 2 H) 4.04 (ddd, J=16.69, 10.84, 3.81 Hz, 1 H) 6.82 - 7.06 (m, 1 H) 7.14 - 
7.34 (m, 2 H) 7.50 - 7.72 (m, 2 H); 13C NMR (75 MHz, DMSO-d6) d ppm 22.51, 22.56, 27.10, 44.25 (d, 
J=153.70 Hz), 47.52 (d, J=14.93 Hz), 119.19, (s, 1 C) 119.30, (s, 1 C) 122.16, 128.39, 139.37, 157.39, 
169.03; 31P NMR (121 MHz, DMSO-d6) δ ppm 21.12; HRMS (ESI) m/z 330.0901 [(M-H+), calcd for 
C12H17N3O6P- 330,0860]. 
3-(N-hydroxyacetamido)-1-(4-tert-butyl-1H-1,2,3-triazol-1-yl)propylphosphonic acid (1b). To a 
solution of 15b (84 mg, 0.14 mmol) in a mixture of methanol – water – tert-butanol (10 mL) was 
added 10% Pd/C. Hydrogen gas was bubbled through via a glass capillary at atmospheric pressure for 
4 hours after which the reaction mixture was filtered and concentrated in vacuo. The residue was 
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taken up in tert-butanol, frozen and lyophilized to give the product as a white foam in quantitative 
yield. 1H NMR (300 MHz, METHANOL-d4) d ppm 1.37 (s, 9 H) 2.06 (s, 3 H) 2.41 - 2.79 (m, 2 H) 3.35 - 
3.51 (m, 1 H) 3.61 (dd, J=14.35, 7.32 Hz, 1 H) 4.76 - 4.99 (m, 1 H) 7.91 (s, 1 H); 13C NMR (75 MHz, 
METHANOL-d4) δ ppm 20.20, 28.34, 30.49, 31.73, 44.49 (d, J=12.72 Hz), 57.82 (d, J=148.17 Hz),  
122.30, 157.58, 174.002; 31P NMR (121 MHz, METHANOL-d4) δ ppm 14.83; HRMS (ESI) m/z 
319.1200 [(M-H+), calcd for C11H20N4O5P- 319,1177]. 
3-(N-hydroxyacetamido)-1-hydroxypropylphosphonic acid, ammonium salt (3a). A mixture of 
compound 6 (261 mg, 0,54 mmol), ammonium formate (520 mg, 8.10 mmol) and 10% Pd/C in 
methanol (10 mL) was heated at reflux for 20 minutes, followed by filtration over a glass microfiber 
pad. The filter was rinsed with methanol and water and the filtrate was concentrated in vacuo. The 
resulting residue was lyophilized from a mixture of water and tert-butanol to give the product as an 
extremely hygroscopic resinous solid in quantitative yield. 1H NMR (300 MHz, METHANOL-d4) δ ppm 
1.67 - 1.98 (m, 1 H) 2.13 (s, 4 H) 3.46 - 3.80 (m, 2 H) 3.80 - 4.12 (m, 1 H); 13C NMR (75 MHz, 
METHANOL-d4) d ppm 20.64, 30.98, 46.70 (d, J=14.93 Hz), 67.99 (d, J=157.84 Hz); 31P NMR (121 
MHz, METHANOL-d4) δ ppm 19.86; HRMS (ESI) m/z 212.0351 [(M-H+), calcd for C5H11NO6P- 
212,0329]. 
3-(N-hydroxyacetamido)-1-methoxypropylphosphonic acid (3b). Was prepared according to the 
same procedure as 3a yielding an off-white hygroscopic solid (quant.). 1H NMR (300 MHz, 
METHANOL-d4) δ ppm 1.83 (dquin, J=14.33, 7.47, 7.47, 7.47, 7.47 Hz, 1 H) 2.05 - 2.29 (m, 4 H) 3.16 - 
3.28 (m, 1 H) 3.43 - 3.64 (m, 4 H) 3.88 - 4.08 (m, 1 H); 13C NMR (75 MHz, METHANOL-d4) δ ppm 20.56, 
29.50, 29.52 (d, J=3.59 Hz), 46.02 (d, J=12.99 Hz) 60.24, 78.15 (d, J=158.40 Hz) 173.70; 31P NMR (121 
MHz, METHANOL-d4) δ ppm 18.83; HRMS (ESI) m/z 226.0520 [(M-H+), calcd for C6H13NO6P-
226,0486]. 
3-(N-hydroxyacetamido)-1-phenoxypropylphosphonic acid (3c). Was prepared according to the 
same procedure as 3a yielding a white hygroscopic solid (quant.). 1H NMR (300 MHz, METHANOL-d4) 
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δ ppm 1.92 - 2.22 (m, 4 H) 2.22 - 2.54 (m, 1 H) 3.58 - 3.97 (m, 2 H) 4.29 - 4.59 (m, 1 H) 6.89 (t, J=7.18 
Hz, 1 H) 7.05 (d, J=7.91 Hz, 2 H) 7.23 (t, J=7.91 Hz, 2 H) 8.52 (s, 1 H); 13C NMR (75 MHz, METHANOL-d4) 
δ ppm 20.36, 29.64, 46.27 (d, J=8.85 Hz), 75.05 (d, J= 158.67Hz), 117.31, 121.93, 130.331, 160.70 (d, 
J=6.63 Hz) 173.46; 31P NMR (121 MHz, METHANOL-d4) δ ppm 16.52; HRMS (ESI) m/z 288.0633 [(M-
H+), calcd for C11H15NO6P- 288,0642]. 
3-(N-hydroxyacetamido)-1-(1H-1,2,3-triazol-1-yl)propylphosphonic acid (1a). Was prepared 
according to the same procedure as 3a yielding a white solid (quant.).
 1H NMR (300 MHz, 
METHANOL-d4) δ ppm 2.07 (s, 3 H) 2.22 - 2.49 (m, 1 H) 2.51 - 2.76 (m, 1 H) 3.18 - 3.43 (m, 2 H) 3.64 
(dt, J=14.28, 7.36 Hz, 1 H) 4.55 - 4.91 (m, 1 H) 7.72 (s, 1 H) 8.08 (s, 1 H); 13C NMR (75 MHz, 
METHANOL-d4) δ ppm 20.57, 29.98, 46.28 (d, J= 12.72 Hz), 59.92 (d, J= 136.56 Hz), 125.93, 134.15, 
173.89; 31P NMR (121 MHz, METHANOL-d4) δ ppm 11.88; HRMS (ESI) m/z 263.0589 [(M-H+), calcd 
for C7H12N4O5P- 263,0551]. 
3-(N-(benzyloxy)acetamido)-1-(4-phenyl-1H-1,2,3-triazol-1-yl)propylphosphonic acid (1c). Was 
prepared according to the same procedure as 3a yielding a white solid (quant.). 1H NMR (300 MHz, 
METHANOL-d4) δ ppm 2.07 (s, 3 H) 2.32 - 2.56 (m, 1 H) 2.56 - 2.81 (m, 1 H) 3.33 - 3.52 (m, 1 H) 3.72 
(dt, J=14.06, 7.32 Hz, 1 H) 4.59 - 4.86 (m, 1 H) 7.23 - 7.51 (m, 3 H) 7.73 - 7.95 (m, 2 H) 8.39 (s, 1 H); 
31P NMR (121 MHz, METHANOL-d4) δ ppm 12.27; HRMS (ESI) m/z 339.0839 [(M-H+), calcd for 
C13H16N4O5P- 339,0864]. 
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VI.Summary  
The current worldwide malaria burden, combined with the issue of resistance and the difficulties 
associated with the development of a vaccine form the major motivation for the development of 
new antimalarial drugs. The non-mevalonate pathway for isoprenoid biosynthesis, which is vital for 
the malaria causing Plasmodium parasite and absent in humans forms an interesting and validated 
target for the development of new antimalarials. Fosmidomycin and its acetyl congener FR900098 
inhibit DXR, the second enzyme of the non-mevalonate pathway, and the former was found to be a 
safe and effective antimalarial when combined with clindamycin or artesunate in Phase III clinical 
trials. The major drawbacks of fosmidomycin are its high polarity and moderate potency, thus 
creating the necessity for high daily doses to cure malaria. In an effort to unravel the mode of action 
of fosmidomycin-based DXR inhibitors and to design more potent antimalarials, many analogues of 
fosmidomycin have been synthesized and published over the past decade. An overview is given in 
Chapter I, together with an attempt to derive structure-activity relationships. This thesis describes 
our efforts toward the synthesis of novel fosmidomycin analogues expected to show potent DXR 
inhibition based on this SAR. Toward this end, three major modifications of fosmidomycin/FR900098 
were proposed: 
 First, we explored α-halogenation of FR900098 so as to increase the acidity of the phosphonate 
and to obtain a better phosphate mimic, thereby leading to enhanced DXR inhibition (Chapter III). 
Based on a literature procedure for electrophilic α-halogenation of alkylphosphonates, diethyl 
butenylphosphonate 1 was converted to versatile α-chloro and α-fluoro butenylphosphonate 
building blocks 2a and 2b (Figure VI.1). These were further transformed into the α-monochloro and 
the α-monofluoro FR900098 analogues 3a and 3b, as well as the α-monofluoro reversed 
hydroxamate 4.  
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Figure VI.1: Development of α-halogenated analogues of FR900098 
 Many efforts were undertaken to synthesize α,α-difluoro FR900098 (8), but final deprotection of 
7 always caused rapid hydrolysis of  the retrohydroxamate functionality, probably mediated by the 
(increased) acidity of the α,α-difluorophosphonate moiety.  
The expected pKa2 decrease in the monohalogenated analogues was assessed by a 
31P-NMR 
monitored acid-base titration. Biological testing of the three halogenated free phosphonates 
revealed enhanced DXR inhibition and a stronger antiplasmodial effect compared to parent 
fosmidomycin. Following these good results, a synthetic strategy towards two prodrugs of α-fluoro 
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FR900098 (5, 6) was optimized, resulting in the bis-POM (5) and the bis-carbonate (6) prodrugs. 
These two compounds showed the highest in vitro antiplasmodial activity so far for fosmidomycin 
based DXR inhibitors. Upscaling of these prodrugs to allow in vivo evaluation would be desirable. 
The retrohydroxamate moiety of fosmidomycin/FR900098 makes an important contribution to 
the overall binding affinity for DXR and modifications of this functionality generally led to detrimental 
losses in DXR inhibition. Nevertheless, we inferred that incorporation of the (retro)hydroxamate in a 
four-membered ring structure (an N-hydroxyazetidinone, NHA) might lock it in its active (metal 
chelating) conformation and thus increase the potency of such an analogue, while the steric 
implications of such a modification should be limited. In Chapter IV we describe the development of 
a straightforward synthetic route toward the 4-(ω-phosphonoethyl)-NHA (or ‘retrohydroxamate N-
hydroxybetalactam’) analogue, featuring one final deprotection under mild conditions (Figure VI.2).  
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Figure VI.2: Development of a conformationally restricted FR900098 analogue 
Unfortunately, 11 proved very sensitive to hydrolysis. The low potency observed in vitro is 
probably due to fast hydrolytic breakdown under testing conditions. On the other hand, good 
interaction with DXR may be impeded by sterical hindrance, as γ-methyl fosmidomycin was 
previously shown to be inactive. Because of the inherent sensitivity of the NHA structure toward 
hydrolysis, the 3-(ω-phosphonoethyl)-NHA (or ‘hydroxamate N-hydroxybetalactam’) was not 
pursued. 
In the third major part of this work, described in Chapter V, we tried to extend the successful 
series of α-substituted fosmidomycin analogues. By introducing a hydroxyl or an amine group on the 
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α-carbon of FR900098, divergent α-substitution became possible. All envisaged analogues were 
synthesized in few steps and usually good yields from common aldehyde building block 12 (Figure 
VI.3). A high yield straightforward synthesis towards this aldehyde was also developed.  
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Figure VI.3: Development of α-heteroatom substituted analogues of FR900098 
Four major analogues/groups of analogues were synthesized and biologically tested: 
1. The α-benzamide 15a and α-phenylurea 15b failed to inhibit EcDXR or P. falciparum 
growth. 
2. The α-hydroxy analogue of FR900098 (16a) showed considerable EcDXR inhibition as well 
as P. falciparum growth inhibition, while its methyl and phenyl ether (16b, 16c)were 
virtually inactive. 
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3. Surprisingly, none of  α-triazolyl analogues 1a, 1b and 1c suppressed P. falciparum 
growth to a significant extent and only t-butylated triazole 1b showed EcDXR inhibition 
(albeit rather weak). Probably the triazole moiety in these molecules is too electron rich 
in order to obtain the π-π-stacking interaction with Trp211 of the enzyme that 
consolidates the binding of the aforementioned α-aryl fosmidomycins. 
4. The α-Azido FR900098 (18) showed the highest activity in this series, surpassing both 
parent compounds (fosmidomycin and FR900098) in EcDXR inhibition and almost 
equaling fosmidomycin in inhibiting P. falciparum growth. It is also the first 
fosmidomycin analogue bearing a rigid, linear, heteroatom-based α-substituent. Perhaps 
its enhanced potency is due to the halogen-mimicking effect of the azide, increasing the 
acidity of the phosphonate moiety but other, new interactions with the enzyme are also 
possible. X-ray studies could provide more insight in this matter. The unique reactivity of 
the azide group in this potent DXR inhibitor also opens the way for a target-guided, in 
situ click chemistry approach as already successfully employed for discovering 
acetylcholinesterase (AChE) inhibitors by incubating the DXR/azide 3 combination with a 
variety of acetylene reagents in an effort to identify new binding partners for the flexible 
loop of DXR, e.g., for interaction with other residues, neighboring Trp211. 
In summary, new and potent inhibitors of DXR were developed during this doctoral research, 
which may lead to novel antimalarials. The introduction of a halogen or an azide group in 
α-position of the phosphonate of FR900098 led to the most interesting DXR inhibitors and 
the formulation of prodrugs robustly enhanced the antimalarial potency of α-fluoro 
FR900098. Further research into such phosphonate prodrugs, as well as the binding mode of 
the α-azido analogue are warranted. 
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VII.Samenvatting  
De huidige wereldwijde dreiging van malaria, gecombineerd met de resistentieproblematiek en 
de moeizame vordering in de ontwikkeling van een vaccin vormen een sterke motivatie voor de 
ontwikkeling van nieuwe antimalariamiddelen. De non-mevalonaat pathway voor de biosynthese van 
isoprenoiden, welke levensbelangrijk is voor de pathogene Plasmodium parasiet maar afwezig in de 
mens, is een interessant en gevalideerd doel voor de ontwikkeling van nieuwe antimalariamiddelen. 
Fosmidomycine en zijn acetyl-analoog FR900098 inhiberen DXR, het tweede enzym in de non-
mevalonaat pathway en fosmidomycine bleek reeds een veilig en effectief antimalariamiddel in 
combinatie met clindamycine of artesunaat in Fase III klinische studies. De voornaamste nadelen van 
fosmidomycine zijn zijn hoge polariteit en matige sterkte, die hoge dagelijkse dosissen nodig maken 
in de behandeling van malaria. Gedurende de voorbije tien jaar is een veelvoud aan fosmidomycine-
gebaseerd DXR-inhibitoren gesynthetiseerd en gepubliceerd, met het oog op de studie van het 
mechanisme van DXR en het ontwikkelen van krachtiger antimalariamiddelen. Een overzicht hiervan 
wordt gegeven in Hoofdstuk I, samen met een poging structuur-activiteitsrelaties bloot te leggen. In 
dit doctoraatswerk wordt de synthese beschreven van fosmidomycine-analogen waarvan, gebaseerd 
op deze gegevens, een sterke DXR inhibitie wordt verwacht. Hiertoe werden drie 
modificatiestrategieën van fosmidomycine/FR900098 uitgetest: 
Eerst werd de α-halogenering van FR900098 verkend als strategie om de zuursterkte van de 
fosfonaatgroep te verhogen en een beter fosfaat-analoog te bekomen, wat moet leiden tot een 
sterkere inhibitie van DXR (Hoofdstuk III). Diëthyl butenylfosfonaat 1 werd daartoe omgezet in de 
veelzijdige bouwstenen 2a en 2b (Figuur VII.1) door middel van een literatuurgebaseerde procedure 
voor de elektrofiele α-halogenering van alkylfosfonaten. Deze bouwstenen dienden voor de synthese 
van α-monochloro en α-monofluoro FR900098 analogen 3a en 3b, en ook voor synthese van 
α-monofluoro omgekeerd hydroxamaat 4. 
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Figuur VI.1: Ontwikkeling van α-gehalogeneerde analogen van FR900098 
 Veel aandacht werd besteed aan de synthese van α,α-difluoro FR900098 (8), maar finale 
ontscherming van precursor 7 leidde steevast tot snelle hydrolyse van de 
retrohydroxamaatfunctionaliteit, mogelijks onder invloed van (of versneld door) de zure 
α,α-difluorofosfonaatgroep. 
De veronderstelde daling in pKa2 van de fosfonaatgroep in de α-monogehalogeneerde analogen 
werd aangetoond met behulp van een zuur-base titratie opgevolgd mbv 31P-NMR . In biologische 
Chapter VII: Samenvatting  
VII.3 
 
testen vertoonden alledrie de gehalogeneerde vrije fosfonzuren een verhoogde DXR inhibitie en een 
sterker antimalaria effect dan moedermolecule fosmidomycine. Gevolg gevend aan deze hoopvolle 
resultaten werd een synthesestrategie op punt gesteld voor twee prodrugs van α-fluoro FR900098 
(3b): de bis-POM ester (5) en bis-carbonaat 6. Deze moleculen vertoonden de sterkste in vitro 
antimalaria activiteit totnogtoe voor fosmidomycine-gebaseerde DXR inhibitoren. Opschaling van 
deze analogen voor in vivo tests is nu zeer wenselijk. 
De retrohydroxamaatgroep van fosmidomycine/FR900098 draagt in belangrijke mate bij tot de 
algemene bindingsaffiniteit voor DXR, en modificatie van deze functionaliteit leidde totnogtoe in 
quasi alle gevallen tot grote verliezen in DXR inhibitie. Nochtans zou het incorporeren van de 
(retro)hydroxamaatgroep in een vierledige ringstructuur (een N-hydroxyazetidinon, NHA) ervoor 
zorgen dat het (retro)hydroxamaat wordt vastgezet in zijn actieve (metaalbindende) conformatie. Dit 
zou moeten leiden tot een hogere activiteit voor zulk analoog terwijl de sterische hinder veroorzaakt 
door de modificatie eerder beperkt is. In Hoofdstuk IV wordt de ontwikkeling beschreven van een 
syntheseroute voor het 4-(ω-fosfonoethyl)-NHA (of ‘retrohydroxamaat N-hydroxybetalactam’) 
analoog, gekenmerkt door één finale ontschermingsstap onder milde condities (Figuur VII.2). 
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Figuur VII.2: Ontwikkeling van een conformationeel verstard FR900098 analoog 
Helaas bleek 11 bijzonder hydrolysegevoelig te zijn. De lage activiteit die in vitro werd 
waargenomen is mogelijk het gevolg van een snelle hydrolytische afbraak tijdens de test. Anderzijds 
is het ook mogelijk dat een goede interactie van 11 met DXR wordt belet door sterische hinder, 
aangezien eerder werd aangetoond dat γ-methylfosmidomycine geen DXR inhiberende activiteit 
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bezit. Gezien de inherente, hoge hydrolysegevoeligheid van de NHA-structuur werd besloten de 
synthese van het 3-(ω-fosfonoethyl)-NHA (of ‘hydroxamaat N-hydroxybetalactam’) te staken. 
Het derde grote deel van dit werk, beschreven in Hoofdstuk V, omvat een poging tot uitbreiding 
van de succesvolle reeks van α-arylfosmidomycines. Divergente α-substitutie werd hier mogelijk 
gemaakt door invoeren van een hydroxyl- of aminegroep op de α-koolstof van FR900098. Alle 
voorziene analogen werden gesynthetiseerd in slechts enkele stappen en in goede rendementen 
uitgaande van gemeenschappelijk aldehyde bouwsteen 12 (Figuur VII.3). Een snelle methode voor de 
synthese van dit aldehyde in hoog rendement werd eveneens ontwikkeld. 
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Figuur VII.3: Ontwikkeling van α-heteroatoom gebaseerde analogen van FR900098 
De gesynthetiseerde en geteste analogen kunnen worden ingedeeld in vier grote klassen: 
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1. Het α-benzamide 15a en α-phenylureumderivaat 15b bleken noch EcDXR te inhiberen, 
noch de groei van P. falciparum te remmen. 
2. Het α-hydroxy analoog van FR900098 (16a) vertoonde behoorlijke EcDXR inhibitie en 
P. falciparum groei-inhibitie, terwijl de corresponderende methyl en fenyl ethers (16b, 
16c) nagenoeg inactief bleken. 
3. Tot onze verbazing onderdrukte geen enkele van de α-triazolyl analogen 17a, 17b en 17c 
de groei van P. falciparum en vertoonde enkel t-butyl triazol 17b inhibitie van EcDXR (zij 
het eerder zwak). Waarschijnlijk is de triazolfunctionaliteit in deze moleculen te 
elektronenrijk om de π-π-stapelingsinteractie met Trp211 van het enzym aan te gaan die 
de binding van voornoemde α-arylanaloga versterkt . 
4. Het α-azido FR900098 (18) vertoonde de hoogste activiteit in deze reeks analogen: het 
verslaat zowel fosmidomycine als FR900098 in EcDXR inhibitie en is bijna even sterk als 
fosmidomycine in het afremmen van de groei van P. falciparum. Daarenboven is dit het 
eerste fosmidomycine-analoog dat een rigiede, lineaire, heteroatoom-gebaseerde 
α-substituent draagt. Mogelijks dankt het zijn verhoogde activiteit aan het halogeen-
nabootsend effect van het azide, nl. de verhoging van de zuursterkte van de 
fosfonaatgroep. Nieuwe interacties met het enzym zijn evenwel niet uit te sluiten, en 
X-straal onderzoek zouden hier meer inzicht kunnen verschaffen. De unieke reactiviteit 
van de azidogroep in deze sterke DXR-inhibitor opent verder ook de deur naar target-
guided, in situ click-chemie voor het identificeren van nieuwe bindingspartners voor de 
flexibele lus van DXR, bv voor interactie met zijketens van de aminozuren naast Trp211. 
Deze aanpak bestaat erin het DXR/3 complex te incuberen met een reeks 
acetyleenreagentia en werd reeds met succes toegepast in de ontdekking van 
acetylcholinesterase (AChE) inhbitoren. 
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Als besluit kan worden gesteld dat tijdens dit doctoraatswerk nieuwe en potente inhibitoren 
van DXR werden ontwikkeld die kunnen leiden tot nieuwe antimalariamiddelen. Het 
invoeren van een halogeen of een azidegroep in α-positie van het fosfonaat van FR900098 
leidde tot de meest interessante DXR inhibitoren, en het formuleren van prodrugs versterkte 
het antimalaria effect van α-fluor FR900098 in belangrijke mate. Verder onderzoek naar 
zulke fosfonaatprodrugs en de binding van het α-azide analoog aan DXR is wenselijk. 
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